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 Methyl-CpG binding protein 2 (MeCP2) was discovered as a protein binding 
to methylated DNA more than 20 years ago. It is very abundant in the brain and was 
shown to be able to repress transcription. The mutations in MeCP2 cause Rett 
syndrome, an autism-spectrum neurological disorder affecting girls. Yet, the exact 
role of MeCP2 in Rett disease, its function and mechanism of action are not fully 
elucidated. In order to shed some light on its role in the disease the aim of this 
project was to identify proteins interacting with MeCP2. Affinity purification of 
MeCP2 from mouse brains and mass spectrometry analysis revealed new interactions 
between MeCP2 and protein complexes. Detailed analysis confirmed the findings 
and narrowed down the top interactions to distinct regions of MeCP2. One of the 
domains interacts with identified NCoR/SMRT co-repressor complex and is mutated 
in many patients with Rett syndrome. In vitro assays proved that these mutations 
abolish the putative transcriptional repressor function of MeCP2. We propose a 
model in which Rett syndrome is caused by two types of mutations: either disrupting 
the interaction with DNA or affecting the interaction with the identified complex, 
which has an effect on the global state of chromatin. The presented findings can help 
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Chapter 1: Introduction 
 
1.1 Modifications of DNA 
 
 The genetic information in all cellular organisms is encoded in 
deoxyribonucleic acid (DNA). It is build of only four nucleotides: adenine, guanine, 
thymine and cytosine, with backbones made of sugars and phosphate groups. In the 
DNA double helix adenine complementarily pairs with thymine and guanine with 
cytosine, allowing faithful replication of the genome and its inheritance through cell 
divisions (Watson and Crick, 1953). The four building blocks of DNA are sufficient 
to encode the information needed to build any protein from twenty standard amino 
acids by usage of codons consisting of nucleotide triplets. Despite the redundancy of 
such a genetic code, the DNA bases are additionally found to be modified by 
chemical addition of covalently bound moieties, expanding the regulatory capacity of 
the genome. For example, in prokaryotes adenine is frequently methylated on 
nitrogen-6 and cytosine exists in methylated states on carbon-5 and nitrogen-4 
(Ehrlich et al., 1987). Bacterial DNA methylation serves three purposes: (1) it allows 
distinguishing between self and intruder DNA, permitting the defence mechanism by 
methyl-sensitive restriction digestion degrading only the non-host genome (reviewed 
in: Wilson and Murray, 1991); (2) it ensures fidelity of the genome replication by 
DNA mismatch repair machinery operating on non-methylated newly synthesised 
strand (Laengle-Rouault et al., 1986); and (3) it regulates transcription of genes 
(reviewed in: Palmer and Marinus, 1994).  
 
1.1.1 DNA methylation and hydroxymethylation in eukaryotes 
 
 In eukaryotes the DNA modifications are found exclusively on cytosine in the 
form of 5-methylcytosine and its derivative 5-hydroxymethylcytosine (Fig. 1.1). Two 
additional forms of cytosine detected in mouse cells are 5-formylcytosine and 
5-carboxylcytosine (Ito et al., 2011), but as yet they were studied to a much lower 






Figure 1.1. Chemical structure of cytosine nucleotide and its modified forms. 
 
 The occurrence, distribution and function of methylcytosine and its 
derivatives vary between the organisms, and are not always correlated with the 
course of evolution.  
 The lower eukaryotes such as budding and fission yeast Sacharomyces 
cerevisae and Schizosaccharomyces pombe contain no detectable DNA 
modifications (Antequera et al., 1984; Proffitt et al., 1984). In other fungi, 
Sporotrichum dimorphosporum, Phycomyces blakesleeanus or Neurospora crassa 
5-methylcytosine was found at levels ranging from 0.2% up to 3% of all cytosines 
(Antequera et al., 1984; Selker et al., 2003). 
 Invertebrates also show variable amounts of DNA methylation: from 
undetectable in nematode Caenorhabditis elegans, through trace levels in fruit fly 
Drosophila melanogaster to long stretches of methylated cytosines in sea urchin 
Echinus esculentus and sea squirt Ciona intestinalis (Bird et al., 1979; Antequera 
et al., 1984; Simmen et al., 1999; Lyko et al., 2000).  
 With no exceptions found to date, the genomes of all vertebrates are globally 
methylated (Bird and Taggart, 1980; Tweedie and Charlton, 1997). The 
5-methylcytosine mark occurs almost exclusively symmetrically in the context of a 
palindromic dinucleotide, CpG. CpGs are broadly distributed in the genome and are 
methylated in 60-90% (Tweedie and Charlton, 1997). Low levels of non-CpG 
methylation (CpA, CpT and CpC) were found in embryonic stem (ES) cells and 
induced pluripotent stem cells (iPSC) but are nearly absent in somatic cells 
(Ramsahoye et al., 2000; Imamura et al., 2005; Lister et al., 2009; Ziller et al., 2011).  
       cytosine                       5-methylcytosine     5-hydroxymethylcytosine 
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 Interestingly, in the vertebrate bulk genome the CpG sequences are present at 
only one-fifth of the expected frequency (Bird, 1980). There are, however, regions of 
the genome rich in guanine and cytosine where the CpG dinucleotides are much 
more frequent. These ~1 kb long DNA stretches constitute less than 2% of the mouse 
genome, are predominantly unmethylated and were named CpG islands (CGIs; 
Bird et al., 1985). Based on genome-wide sequencing the numbers of CGIs in mouse 
and human genomes were estimated to be approximately 23 000 and 25 500, 
respectively (Illingworth et al., 2008, 2010). About 60% of CGIs are associated with 
promoters of known genes. Moreover, the remaining CGIs have also been linked to 
active transcription (Illingworth et al., 2010; Maunakea et al., 2010). These facts 
suggest possible mechanism of the origin of CpG islands. 5-methylcytosine is a 
potential mutagen as it can spontaneously deaminate to thymine. A resulting T:G 
mismatch with the other DNA strand can not be efficiently repaired (reviewed in: 
Bird, 1986). That led to under-representation of CpGs in the bulk genome. However, 
when the active fragments of genome were devoid of cytosine methylation, the CpG 
sequences were preserved during evolution at expected frequency. It also suggests 
that the DNA methylation in vertebrates may be associated with transcriptional 
repression. 
 In plants the genome contains relatively high levels of methylation, between 
5-25% of all cytosines depending on species (reviewed in: Rangwala and Richards, 
2004). The methyl mark occurs in the CpG context, as well as CpNpG and 
asymmetric CpHpH, where N is any nucleotide and H is any nucleotide but guanine. 
Genome-wide studies in Arabidopsis thaliana revealed that methylated cytosine is 
excluded from gene promoters, covers transposons and silent heterochromatin, but 
unlike in mammals, only 20% of the gene bodies are methylated (Zilberman et al., 
2007). 
 Another DNA modification, 5-hydroxymethylcytosine (Fig. 1.1) has gained a 
vast scientific attention in the last years. Although it was known for more than a half 
a century in bacteriophages and viruses (Wyatt and Cohen, 1952, 1953) only recently 
it has been discovered to be naturally present in Purkinje and embryonic stem cells in 
mice, at the level up to 0.6% of all nucleotides (Kriaucionis and Heintz, 2009; 
Tahiliani et al., 2009). It arises from 5-methylcytosine by conversion catalysed by 
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ten-eleven translocation (TET) proteins. It has been proposed to be an intermediate 
product of DNA de-methylation (both in passive or the putative active process), but 
may as well play a role on its own (Tahiliani et al., 2009). Using various techniques 
for genome-wide mapping of the 5-hydroxymethylcytosine mark it has been found to 
be associated with gene enhancers, transcriptional start sites, as well as with gene 
bodies (Pastor et al., 2011; Stroud et al., 2011; Williams et al., 2011). Its proposed 
roles in gene expression regulation or DNA demethylation are still awaiting 
confirmation and detailed analysis. 
 Because of the high abundance of 5-methylcytosine in mammals and the 
various functions associated with it (described below), it is sometimes called ‘the 
fifth base’. Whether 5-hydroxymethylcytosine should be referred to as ‘the sixth 
base’ is still uncertain. The recent and coming years of increased research on this 
form of cytosine give hope for obtaining an answer to this question in the near future. 
 
1.1.2 Processing of DNA modifications 
 
 The mechanism of deposition of the methylation mark on cytosines is known 
and has been well studied. In mammals de novo DNA methylation is catalysed by 
DNA methyltransferase enzymes, DNMT3a and DNMT3b (Okano et al., 1999). In 
somatic cells methylation patterns are relatively stable and are heritable through cell 
divisions. During DNA replication in the S-phase of cell cycle, the 5-methylcytosine 
mark is copied onto the newly synthesised strand by a so-called maintenance DNA 
methyltransferase, DNMT1 (for a comprehensive review see: Goll and Bestor, 2005). 
Conversely, how the genomic methylation is removed is still not known. 
Demethylation occurs globally twice during development – in primordial germ cells 
and in the preimplantation embryos (reviewed in: Reik et al., 2001). According to 
one theory it may be a passive mechanism, when during replication the mark is not 
copied then in subsequent cell divisions the methylated cytosines are simply diluted 
away. Another possibility is that 5-methylcytosine is converted back to cytosine in an 
active process. The rapid demethylation of paternal genome in mouse zygote has 
been observed, however the mechanism and the enzymes involved in this pathway 
have not been found (Oswald et al., 2000; Santos et al., 2002). There is some 
indication that TET proteins may perform that role by converting 5-methylcytosine 
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to its hydroxylated form. 5-hydroxymethylcytosine can be subsequently processed to 
5-hydroxyuracil by AID/APOBEC (activation-induced deaminase / apolipoprotein B 
mRNA-editing enzyme complex) and removed by base excision repair mechanism 
(Guo et al., 2011). However, the ability of AID/APOBEC to perform this convertion 
has been recently questioned (Nabel et al., 2012). Another hypothetical model of 
active de-methylation came with discovery that 5-hydroxymethylcytosine can be 
processed by TET enzymes to 5-formylcytosine and 5-carboxylcytosine (Ito et al., 
2011). These forms of cytosine can be removed by thymine DNA glycosylase, 
allowing the base excision repair mechanism to fill in the missing cytosine (Maiti 
and Drohat, 2011). However, the genome-wide generation of nucleotide excisions 
does not seem like a feasible mechanism for de-methylation as it is burdened with 
risk of introducing mutations. Moreover, the immunofluorescent staining of 
5-hydroxymethylcytosine in early stage zygote revealed that it is gradually reduced 
during cell divisions supporting the dilution hypothesis (Inoue and Zhang, 2011). 
The search for the exact de-methylation mechanism continues. 
 
1.1.3 The roles of DNA methylation 
  
 The loss-of-function mutation of Dnmt1 in mice, as well as double deletion of 
Dnmt3a and Dnmt3b, were embryonic lethal, suggesting that the establishment and 
maintenance of DNA methylation are crucial for the mouse development (Li et al., 
1992; Okano et al., 1999). 
 The most studied function of DNA methylation is repression of transcription. 
It has been observed that when cells were treated with 5-azacytidine, a nucleoside 
analogue causing hypomethylation of newly synthesised DNA (Jones and Taylor, 
1980), the expression of many genes was activated (Mohandas et al., 1981; Venolia 
et al., 1982). Other evidence for methylation-mediated transcriptional silencing was 
provided by introducing the adenine phosphoribosyltransferase (aprt) gene into aprt
-
 
mouse cells. When the transgene was in vitro methylated, it was not expressed and 
could not rescue the cells phenotype in contrast to its unmethylated version (Stein 
et al., 1982). There were many further reports based on methylated reporter genes 
and supporting the idea of CpG methylation leading to gene repression (Buschhausen 
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et al., 1985; Boyes and Bird, 1991; Siegfried et al., 1999). More recent studies 
employing genome-wide sequencing techniques also support this notion (Weber 
et al., 2007; Illingworth et al., 2008). 
 Another well-studied process involving DNA methylation is X chromosome 
inactivation. In mammals female genome contains two X chromosomes, whereas 
male only one. To compensate the dosage of X-linked genes between genders, one 
copy of female X has to be silenced (Lyon, 1961). The chromosome to be inactivated 
(Xi) is chosen randomly in each cell during embryogenesis and this choice is 
propagated through cell divisions. Silencing is mediated by coating the Xi
 
by 
non-coding RNA Xist (reviewed in: Brockdorff, 2011). Methylation of CpG islands 
of gene promoters on Xi  stabilises the inactive state and allows its heritability (Heard 
and Disteche, 2006). The early experiments with 5-azacytidine reactivating genes on 
the inactive X chromosome also supported the idea of the role of DNA methylation 
in dosage compensation in mammals (Mohandas et al., 1981; Venolia et al., 1982). 
 DNA methylation also has a function in genomic imprinting, where genes are 
expressed from only one allele determined by parental origin. The genomic sites 
exhibiting parent-specific methylation are called differentially methylated regions 
(DMR) and control the silencing of the locus (reviewed in: Edwards and Ferguson-
Smith, 2007). Loss of DNA methylation at DMRs leads to activation of normally 
silent, imprinted loci (Li et al., 1993). 
 DNA methylation additionally plays an important role in cancer 
development. Although cancer cells are generally hypomethylated, the CGI 
promoters of many tumour suppressor genes gain methylation (Ehrlich, 2009). In this 
way genes involved in various cellular processes, such as DNA repair (hMLH1, 
MGMT, BRCA1), cell cycle (p16INK4b, Rb), cell adherence (E-cadherin), 
signalling (RASSFIA, APC) or apoptosis (TMS1), are silenced and this contributes 
to tumour progression (reviewed in: Esteller, 2007). 
 The mammalian genome consists of more than 35% repetitive sequences, 
such as L1 and Alu retrotransposons, which are relics of intragenomic parasites 
(Yoder et al., 1997). As the bulk genome is largely methylated the modified CpGs 
have been found in these sequences too. It has been proposed that the main function 
of DNA methylation is to protect the genome from retrotransposition events by 
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repressing transcription of these transposable elements (Yoder et al., 1997). 
However, there is not much evidence to support these arguments. In particular, in 
germ cells and during embryogenesis the genome, including retrotransposons, is 
demethylated. Moreover, genome-wide studies did not find the transposable elements 
as particularly targeted for CpG methylation in Ciona intestinalis (Suzuki et al., 
2007) and in mammals (Rabinowicz et al., 2003). 
 Another possible function of the CpG methylation comes from the 
complexity of the mammalian genome. The methylation of bulk genome could 
reduce the ‘transcriptional noise’ from irrelevant, cryptic promoters, which could 
otherwise interfere with expression of important genes (Bird, 1995). 
 
 How exactly DNA methylation mediates the ascribed functions is still a topic 
of a debate. Theoretically, it is possible that the methyl residue on cytosine causes 
exclusion of DNA binding proteins which have affinity for the unmethylated 
sequence. It was shown to be the case for many proteins, such as c-Myc (Prendergast 
et al., 1991), Cfp1 (Thomson et al., 2010), or CTCF (Hark et al., 2000). Another 
possibility is that there are specialised proteins recognising and binding to DNA 
containing methylated CpGs. This notion was supported by observed protection of 
methylated DNA from restriction digestion in mammalian nuclei (Antequera et al., 
1989). 
 
1.2 Methyl-CpG binding proteins 
 
 The first search for proteins binding to methylated DNA revealed an activity 
named methyl-CpG binding protein 1 (MeCP1; Meehan et al., 1989). The protein 
identities of this large complex remained unknown for several years. Its discovery 
was however followed by identification of another methyl-CpG binding activity, 
named MeCP2, which was proven to be different from MeCP1 by size, DNA binding 
preference, biochemical properties and abundance in cells (Lewis et al., 1992; 
Meehan et al., 1992). It has been sequenced as one protein and the Mecp2 gene was 
cloned from rat brain (Lewis et al., 1992). As MeCP2 protein is the main focus of 
this thesis and it is described in detail in section 1.3.  
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1.2.1 MBD proteins 
 
 Deletion analysis of MeCP2 allowed identification of the minimal domain 
responsible for interaction with methylated cytosines, which was named methyl-CpG 
binding domain (MBD; Nan et al., 1993). The search for similar sequences in the 
expressed sequence tags database (dbEST) resulted in identification of a protein 
containing MBD domain 1 (PCM1; Cross et al., 1997), later re-named MBD1. 
Similar searches in mouse EST database found other genes: Mbd1, Mbd2, Mbd3 and 
Mbd4 (Hendrich and Bird, 1998), which were subsequently cloned and mapped 
(Hendrich et al., 1999a). All of the identified MBD proteins, with the exception of 
MBD3, were able to bind to methylated DNA in vitro and localised in the 
pericentromeric heterochromatin (PCH) foci in vivo (Hendrich and Bird, 1998). The 
PCH in mice consists of major satellite repeats, which are known to be rich in 
methylated sequences (Miller et al., 1974; Hörz et al., 1981). 
 Interestingly, even in cells with a mutated Dnmt1 gene and in consequence 
>95% reduced levels of methylation, MBD1 was still localised in the PCH (Hendrich 
and Bird, 1998; Jørgensen et al., 2004). The non-methyl CpG binding was confirmed 
in vitro and was attributed to one of the three cystein-rich CxxC domains present in 
the MBD1 structure (Fig. 1.2A). MBD1 also contains a transcriptional repression 
domain (TRD) and was shown to repress transcription of both methylated and 
non-methylated reporter genes (Fujita et al., 1999; Ng et al., 2000; Jørgensen et al., 
2004). 
 MBD2 binds to a single methylated CpG without other sequence specificity 
(Ng et al., 1999; Klose et al., 2005). It has been found to be always associated with 
the nucleosome remodelling and histone deacetylase (NuRD) co-repressor complex 
(Le Guezennec et al., 2006). This complex was identified as a previously described 
methyl-CpG binding activity, MeCP1. It is able to repress transcription in a 
histone-deacetylase dependent manner (Ng et al., 1999). 
 Although mammalian MBD3 is closely related to MBD2 with 70% of their 
sequences identical (Hendrich and Tweedie, 2003), it is not capable of binding to 
methylated DNA due to a missense mutation in the MBD domain (Hendrich and 
Bird, 1998; Fraga, 2003). Its function is unknown, but it has been reported to be a 
part of NuRD repressor complex distinct from MBD2/NuRD (Le Guezennec et al., 
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2006).  There is also a  preliminary indication that its role depends on binding to 
5-hydroxymethylcytosine (Yildirim et al., 2011).  
 MBD4 was demonstrated to bind preferentially to methyl-CpG : TpG 
mismatches and to remove thymine or uracil in vitro (Hendrich et al., 1999b). The 
glycosylase domain responsible for this activity has been mapped to the C-terminus 
of the protein and is unique to MBD4 in the MBD protein family (Fig. 1.2A). As the 
CT transitions are the primary product of deamination of 5-methylcytosine, it was 
suggested that MBD4 plays a role in repairing such mutations. MBD4 was 
additionally shown to be able to repress transcription of reporter genes through 
interaction with Sin3A and histone deacetylase HDAC1 (Kondo et al., 2005). 
 By less stringent bioinformatic sequence similarity searches two additional 
proteins containing a homologue of methyl-CpG binding domain have been 
discovered and named MBD5 and MBD6 (Hendrich and Tweedie, 2003; Roloff et 
al., 2003; Laget et al., 2010). Their MBD domains, however, include a 9-amino acid 
deletion at the region conserved between other MBDs. MBD5 contains also a 
proline-tryptophan-tryptohan-proline core domain (PWWP) that may bind to 
histones (Fig. 1.2A; Laget et al., 2010). The properties and function of these new 
MBD family members have not been extensively studied, but it was reported that, 
although they localise in the heterochromatic foci in cells, both MBD5 and MBD6 
are incapable of binding to methylated DNA in vitro (Laget et al., 2010). 
 
1.2.2 Kaiso and other proteins binding to methylated DNA 
 
 There is another family of proteins that binds preferentially to methylated 
DNA, but lacks sequence similarity to MBD proteins (Fig. 1.2B). The founder 
member of the family, Kaiso, was shown to interact specifically with doubly 
methylated sequence CGCG, through the conserved zinc fingers present in its 
structure (Prokhortchouk et al., 2001; Daniel et al., 2002; Buck-Koehntop et al., 
2012). It is also able to repress transcription by interacting with the nuclear receptor 
co-repressor (NCoR) complex (Yoon et al., 2003). Two other members of the family, 
Kaiso-like proteins ZBTB4 and ZBTB38 require only a single methylated CpG to 





Figure 1.2. Methyl-CpG binding proteins. Schematic representation of proteins belonging 
to (A) MBD and (B) KAISO protein families. Where multiple isoforms of a protein exist, the 
longest version of human protein was depicted, with size in amino acid stated on the right. 
The domain coordinates were retrieved from PROSITE database (Sigrist et al., 2010) or taken 
from the literature. MBD – methyl-CpG binding domain, TRD – transcriptional repression 
domain, C – CxxC domain, GR – Glycine/Arginine repeats, PWWP – Proline-Tryptophan-




 There are additional proteins postulated to recognize and bind to methylated 
DNA, but have not been studied in details. UHRF1 (ubiquitin-like, containing PHD 
and RING finger domains 1; also known as nuclear protein 95, NP95) may play a 
role in maintenance of DNA methylation as it binds to hemimethylated DNA and is 
able to recruit DNMT1 (Bostick et al., 2007; Sharif et al., 2007). Interesting 
approach based on SILAC method (stable isotope labelling by amino acid in cell 
culture) and aimed at identification proteins binding to methylated CpGs identified 
most of the proteins described above and additionally detected RBP-J (Bartels et al., 
2011). Its binding to methylated DNA was shown to be sequence-specific but its 
functional consequence has not been investigated (Bartels et al., 2011).  
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1.2.3 Mouse models depleted of methyl-CpG binding proteins 
 
 The best method of assessing the role and importance of a gene is to generate 
knock-out animals and evaluate their phenotype (Jackson, 2001). The importance of 
DNA methylation for mouse development was demonstrated by embryonic lethality 
of mice with mutated Dnmt1 or Dnmt3a and Dnmt3b (Li et al., 1992; Okano et al., 
1999). Interestingly, deletion of different methyl-CpG binding proteins gave mixed 
outcomes suggesting their, at least partial, redundancy or a role of DNA methylation 
independent of proteins binding to it. The most severe effects come from deletion of 
Mecp2, leading to a neurological disorder resembling closely Rett syndrome in 
humans (Chen et al., 2001; Guy et al., 2001; see section 1.4). A much weaker 
phenotype was exhibited by Mbd1-null animals, with mild deficits in neurogenesis, 
memory formation, long-term potentiation and symptoms of autism-like behaviour 
(Zhao et al., 2003; Allan et al., 2008).  
 Mbd2 knock-out mice are viable and fertile and have normal appearance with 
only mild phenotypes. The Mbd2
-/-
 mothers fail to properly nurture their pups, who 
in consequence are significantly smaller (Hendrich et al., 2001). Deficiency of 
MBD2 also leads to subtle differences in gene expression patterns, as tested in 
T-helper cells (Hutchins et al., 2002) and in the colon (Berger et al., 2007). 
 The knock-out of Mbd3 was embryonic lethal (Hendrich et al., 2001). The 
function of the protein is unknown, but it was shown to play a role in ES cell 
differentiation by down-regulation of pluripotency markers (Kaji et al., 2007).  
 Mbd4
-/-
 mice showed 3.3-fold increase in frequency of CG  TA transitions 
at CpG sites (Millar et al., 2002). Moreover, when crossed with cancer-susceptible 
Apc
min/+ 
mice, accelerated tumour formation and reduced animal survival have been 
observed (Millar et al., 2002). The results implicate a role of MBD4 in suppressing 
the mutability of methylated CpG loci.  
 Deletion of Kaiso in Xenopus resulted in severe developmental problems 
(Ruzov et al., 2004), but surprisingly caused no overt phenotype in mice 
(Prokhortchouk et al., 2006). Interestingly, the effect of crossing Kaiso-null with 
Apc
min/+
 mice was a delayed onset of tumour formation (Prokhortchouk et al., 2006). 
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 The reason for existence of so many proteins able to bind to the same 
methylated sequences and repress transcription is unknown. The unique domains on 
each of the proteins suggest that they may have distinct interaction partners and 
therefore perform non-redundant functions. As different proteins exhibit variable 
expression levels across the organs it is possible that each of them is essential in 
different tissue. This notion, however, is not supported by the mutational analysis of 
MBD and Kaiso proteins in mice described above. Double and triple knock-outs of 
Mbd2, MeCP2 and Kaiso suggested that these proteins play non-overlapping roles in 
mouse development, but may be redundant to some extent in mature animals and 
neurons (Martín Caballero et al., 2009). There is also an indication that the sequence 
specificity of some of the MBD proteins is non-redundant and MeCP2, MBD1 and 
Kaiso possess their distinctive binding sites in the genome (Daniel et al., 2002; Klose 
et al., 2005; Clouaire et al., 2010). This idea remains to be confirmed in vivo, 
however some preliminary chromatin immunoprecipitation followed by high 
throughput sequencing (ChIP-seq) has been performed for MeCP2. Its global binding 
profile in the brain suggests that it interacts with any methylated CpG it can 
encounter (Skene et al., 2010). Additionally, the relationship between MBD and 
Kaiso-like proteins and the 5-hydroxymethylcytosine mark is not well established 
yet. The coming years of greatly enhanced research in this field should provide us 
with more understanding of the complex system of DNA methylation, 




1.3.1 Gene and protein 
 
 Methyl-CpG binding protein 2 was discovered and described as a protein 
with affinity to methylated DNA in 1992 (Lewis et al. 1992; Meehan et al. 1992). In 
humans it is encoded by a single gene on the X chromosome in locus Xq28 
(D’Esposito et al., 1996). MeCP2 protein was found to be expressed ubiquitously in 
human and mouse tissues, but is particularly abundant in brain, especially in neurons 
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(LaSalle et al., 2001; Shahbazian et al., 2002b). The quantification of MeCP2 
expression in neuronal nuclei sorted from adult mouse brains revealed that there are 
approximately 16 × 10
6
 molecules, compared to 2 × 10
6
 in glial cells and 0.5 × 10
6
 in 
liver (Skene et al., 2010). Such a high abundance, almost reaching the number of 
nucleosomes (estimated to be 30 × 10
6
) suggests the fundamental role of MeCP2 in 
neurons.  
 MeCP2 occurs in two splicing variants that differ at the N-terminal end of the 
protein (Kriaucionis and Bird, 2004; Mnatzakanian et al., 2004). The mRNA of 
human MeCP2 variant e2 (also known as isoform 1, MeCP2A and MeCP2β) consists 
of 4 exons, with the translational start site located in exon 2, giving a protein of 486 
amino acids (aa) and a predicted molecular weight of 52.4 kDa (Fig. 1.3). The 
second splicing variant, named MeCP2_e1 (also known as isoform 2, MeCP2B and 
MeCP2α) starts in exon 1 and omits exon 2, consists of 498 aa (53.5 kDa) and it was 
reported to be the most abundant isoform in mouse and human brains (Kriaucionis 
and Bird, 2004; Mnatzakanian et al., 2004). Both isoforms were expressed in all 
tested tissues and seem to function in the same way. They localise in the same 
regions of chromatin (Kriaucionis and Bird, 2004) and exhibit identical dynamics 
and mobility (Kumar et al., 2008). One isoform can successfully substitute the other 
in the Xenopus laevis embryo without any noticeable effects on its development 
(Stancheva et al., 2003). Also a very recent study showed that the phenotype of 
Mecp2-null mice is rescued by transgenic expression of MeCP2_e1 as well as 
MeCP2_e2 (Kerr et al., 2012). 
 
 Both isoforms contain two well-studied functional domains (Fig. 1.3). The 
methyl-CpG binding domain (MBD) is responsible for the interactions with 
methylated DNA (Nan et al., 1993) and transcriptional repression domain (TRD) is 
able to repress transcription (Nan et al., 1997). Alignment of MeCP2 sequence from 
Danio rerio, Xenopus laevis, Rattus norvegicus, Mus musculus, Macaca fascicularis 
and Homo sapiens revealed that MeCP2 is highly conserved from fish to humans, 
especially within the MBD and TRD regions (Thambirajah et al., 2009). Interestingly, 
multiple polyadenylation sites give rise to transcripts of various lengths, including an 
unusually long (10.2 kb) 3’ untranslated region (3’ UTR; Singh et al., 2008). Several 
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regions of this UTR are conserved between human and mouse and were suggested to 
be involved in the regulation of expression levels of MeCP2 (Coy et al., 1999). The 
exact mechanism of this regulation is unknown, however two microRNAs, miR-132 
and miR-212 were reported to bind 3’ UTR of MeCP2 and post-transcriptionally 




Figure 1.3. MeCP2 splicing variants. White rectangles depict the non-coding regions of 
MECP2 exons. Translated protein is marked in grey. Conserved domains are highlighted in 
red and green and their function is described in subsequent sections. MBD – methyl-CpG 
binding domain, TRD – transcriptional repression domain. The sizes of proteins in amino 




 Importantly, mutations in the MECP2 gene in humans cause Rett syndrome 
(RTT), a neurological disease, which is described in detail in section 1.4 of this 
chapter. Mecp2 gene was knocked-out in mice giving phenotype similar to RTT, 
which is described later. 
 
 Despite its calculated mass MeCP2 migrates on an electrophoretic gel with an 
apparent size of about 80 kDa. In gel filtration studies it eluted with an apparent mass 
of 400-500 kDa (Klose and Bird, 2004). Analytical centrifugation revealed that these 
discrepancies were not due to self-association of MeCP2, nor because of interactions 
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with nucleic acids or other proteins (Klose and Bird, 2004). The explanation 
suggested by authors was that MeCP2 monomers exhibit elongated rod-like shape 
and this was later confirmed by predictions from small angle X-ray scattering 
(SAXS) studies (Yang et al., 2011). Another contribution to the unusual behaviour in 
biochemical assays may have come from the fact that, as assessed by circular 
dichroism, MeCP2 demonstrates intrinsic disorder and 60% of the protein is 
unstructured (Adams et al., 2007). These may also be the reasons why the crystal 
structure of the full length MeCP2 has not been solved yet.  
 
 
1.3.2 Post-translational modifications of MeCP2 
 
 One of the ways to regulate protein activity involves post-translational 
modifications (PTM). There is a plethora of chemical marks than can be added to the 
protein and they can have various effects. For example polyubiquitination tags a 
protein for degradation, phosphorylation can change the interaction with other 
proteins and SUMOylation can affect intracellular localisation. The search for PTMs 
in MeCP2 revealed that it can be modified on many residues. The first identified 
modification was phosphorylation upon neuronal membrane depolarization (Chen 
et al., 2003). The calcium influx-induced phosphorylation of MeCP2 caused 
dissociation from brain-derived neurotrophic factor (Bdnf) promoter III in rat cortical 
neurons. It was later shown that this activity-dependent brain-specific 
phosphorylation of MeCP2 occurs on serine 421 (Zhou et al., 2006). In neuronal cell 
cultures the S421 phosphorylation correlated with Bdnf expression activation and 
dendritic spine maturation.  
  More phosphorylation sites have been identified by mass-spectrometric 
analysis of immunoprecipitated MeCP2 from normal and epileptic mouse and rat 
brains (Tao et al., 2009). The phosphorylation on serine 80 was present 
constitutively, whereas S421 and newly identified S424 were phosphorylated only 
upon seizure induction. Disappointingly, generated mice with mutated S80, S421 and 
S421/S424 residues exhibited rather mild phenotypes suggesting that 
phosphorylation of these residues is not crucial for the function of MeCP2 (Tao 
et al., 2009; Cohen et al., 2011).  
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 Bioinformatic analysis of the MeCP2 sequence revealed two PEST domains, 
enriched in proline, glutamate, serine and threonine (Thambirajah et al., 2009). These 
domains usually have lysine residues at their flanking regions and are likely to be 
SUMOylated and ubiquitinated, which can regulate protein activity or degradation 
(Rogers et al., 1986; Rechsteiner and Rogers, 1996; Melchior, 2000). Indeed, both 
marks have been found on MeCP2. The SUMO molecules were seen very weakly on 
Western blots and without mapping their positions (Miyake and Nagai, 2007). A 
more recent comprehensive mass spectrometry analysis of MeCP2 PTMs did not find 
SUMO modifications, but instead identified ten ubiquitinated lysines, some 
overlapping with predicted ends of the PEST domains (Gonzales et al., 2012). The 
authors additionally detected new phosphorylation sites in MeCP2 including those 
already reported. The effect of these modifications on MeCP2 function is still 
unknown. 
 
1.3.3 MeCP2 binding to methylated DNA 
 
 Since its discovery, MeCP2 was considered as a protein capable of 
preferential binding to methylated CpG dinucleotides in DNA. There is ample 
evidence based on various techniques supporting this notion. Using Southwestern 
assays it was shown that MeCP2 binds to DNA containing a single symmetrically 
methylated CpG and does not bind the hemimethylated substrate or when cytosines 
are methylated in non-CpG context (Lewis et al., 1992; Meehan et al., 1992). Also, 
in these experiments MeCP2 did not interact with unmethylated DNA in the presence 
of a DNA competitor. Furthermore, purified MeCP2 binds preferentially to 
methylated DNA in electromobility shift assays (Meehan et al., 1992; Jones et al., 
1998; Kaludov and Wolffe, 2000; Klose and Bird, 2004). The fragment of MeCP2 
responsible for methyl-specific DNA binding has been mapped to the 78 – 162 aa 
region of the rat protein and was named as the methyl-CpG binding domain (MBD; 
Nan et al., 1993). Identification of this domain allowed the discovery of other 
proteins binding to methylated CpGs via MBDs (Cross et al., 1997; Hendrich and 
Bird, 1998; see section 1.2). The MBD domain is the only part of MeCP2 for which 
structural studies have been successful thus far. Nuclear magnetic resonance (NMR) 
analysis suggested that it has a wedge-like shape, lacking the internal symmetry, 
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despite the symmetry of its binding substrate, methylated-CpG (Wakefield et al., 
1999). The interaction with DNA was thought to be due to van der Waals contacts 
between methyl groups on cytosines and a hydrophobic pocket in the MBD. 
However, X-ray crystallography of the MBD domain associated with methylated 
DNA fragment gave a similar overall structure of the domain, but revealed a 
surprising hydrophilic DNA-binding surface and structural water molecules 
facilitating the interaction between methyl-CpGs and MeCP2 (Ho et al., 2008).  
 The minimal size of DNA sufficient for binding of MeCP2 was estimated to 
be 11 base pairs (Nan et al., 1993; Nikitina et al., 2007a; Ghosh et al., 2010a). 
Analysis of binding preference of the MBD of MeCP2 using methyl-SELEX assay 
(systematic evolution of ligands by exponential enrichment) revealed that the binding 
to DNA was increased when methylated CpG was neighboured by a run of 4 or more 
adenines or thymines (Klose et al., 2005). This sequence requirement was observed 
only for the MBD of MeCP2 and was not necessary for the MBD domain from 
MBD2 protein. The increased in vitro binding affinity with increased occurrence of 
methylated CpG-[A/T]≥4 motifs was also observed by sedimentation equilibrium 
analyses (Ghosh et al., 2010a). The X-ray crystal structure of the DNA fragment 
bound by the MBD of MeCP2 also supports the need of an AT-run to bend 
methylated DNA in order to accommodate its interaction with the ‘Asx-ST’ motif of 
MeCP2 (Ho et al., 2008). This motif is not present in methyl-CpG binding domains 
of other MBD proteins. 
 MeCP2 was also tested for interactions with chromatin and was shown to 
selectively bind only to methylated version of the in vitro chromatinised plasmid 
(Nan et al., 1997). The same authors suggested that MeCP2 binds to the linker DNA 
between nucleosomes. This notion was confirmed later by band-shift assays with 
reconstituted mononucleosomes and MeCP2 bound methylated nucleosome entry-
exit sites better than when it was not methylated (Nikitina et al., 2007a; Ishibashi 
et al., 2008). DNase I footprinting analysis revealed that MeCP2 binds preferentially 
to methyl-CpGs exposed in the major groove of DNA on the nucleosome surface and 
linker DNA (Chandler et al., 1999). Another line of evidence comes from structural 
studies employing SAXS, where MeCP2 was able to bind to partially unpeeled 
nucleosomal DNA, but exhibited high preference to linker DNA (Yang et al., 2011). 
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 Immunofluorescent staining of MeCP2 showed that it localises in the nucleus 
at the characteristic foci of pericentromeric heterochromatin (Lewis et al., 1992), 
which in mouse is known to be rich in methylated microsatellite sequences (Miller 
et al., 1974; Hörz et al., 1981). In mouse cells with 95% lower levels of DNA 
methylation due to a mutation in DNA methyltransferase gene,  MeCP2 was not 
localised in these foci (Nan et al., 1996). Additionally, treatment of cells with the 
demethylating agent, 5-azadeoxycytidine, resulting in globally reduced DNA 
methylation, caused depletion of MeCP2 from heterochromatin (Ghosh et al., 
2010a). In cells of species lacking the pericentromeric heterochromatin (rat, human, 
monkey) MeCP2 coated whole chromosomes (Lewis et al., 1992; Nan et al., 1997) in 
agreement with the fact that the majority of the mammalian genome is methylated 
(Illingworth and Bird, 2009). 
 There is also ample evidence for MeCP2 binding preferentially to methylated 
DNA in vivo, coming from ChIP experiments on imprinted genes or differentially 
methylated chromatin (El-Osta and Wolffe, 2001; Gregory et al., 2001; Lorincz et 
al., 2001; Nguyen et al., 2001; El-Osta et al., 2002; Rietveld et al., 2002; Matarazzo 
et al., 2007; Muotri et al., 2010). Furthermore, a detailed study from our laboratory 
showed MeCP2 binding across the Xist locus and peaking over its methylated CpG 
island in male mouse brain (Skene et al., 2010). In females, who have two copies of 
the gene, one is methylated, whereas the other allele remains unmethylated to 
facilitate X chromosome inactivation (Beard et al., 1995; McDonald et al., 1998). 
Binding of MeCP2 over the Xist CpG island in female mouse brains was reduced 
2-fold when compared to the male binding profile, while in the flanking regions the 
profiles were indistinguishable. Bisulphite sequencing of female input DNA 
confirmed methylation of 50% of clones, but the analysis of material 
immunoprecipitated with MeCP2 revealed that almost 90% of MeCP2-bound 
chromatin was methylated (Skene et al., 2010). 
 
1.3.4 MeCP2 binding to unmethylated DNA 
 
 Contrary to the publications presented above, some researchers postulate that 
MeCP2 can also bind strongly to unmethylated DNA. The evidence for this comes 
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mostly from in vitro studies. The interaction with nucleosomal arrays regardless of 
their cytosine methylation status was ascribed to the regions of MeCP2 outside of the 
MBD domain, mainly in the C-terminal part of the protein (Georgel et al., 2003; 
Nikitina et al., 2007b; Ghosh et al., 2010b). Considering the strong basic character of 
MeCP2, the interaction with any negatively charged DNA is not surprising, 
especially given that in these studies no DNA competitor (Georgel et al., 2003), or 
only 2 – 3 - fold excess over the tested probe (Nikitina et al., 2007b; Ghosh et al., 
2010b) were used. In another in vitro study MeCP2 was shown to interact with 
unmethylated 4-way junction DNA via its MBD domain, even in the presence of a 
large excess of competitor (Galvão and Thomas, 2005). Although the nature of this 
binding has not been determined, it was suggested that MeCP2 is able to recognise 
the cruciform structure of the junction DNA and has higher affinity to it over DNA in 
linear form.  
 There is, however, a remaining question of how relevant these types of 
interactions are in vivo. The binding of MeCP2 to unmethylated active genes has 
been reported in human neuronal cell line SH-SY5Y (Yasui et al., 2007). Notably, 
the antibody used in the ChIP-microarray analyses in this study showed low 
enrichment of MeCP2-bound material in wild-type over Mecp2-null brains, thus 
questioning the validity of authors’ conclusions. Two other studies using ChIP at 
specific chromatin regions revealed that MeCP2 can bind to the unmethylated 
maternal H19 imprinting control region (Kernohan et al., 2010) and to the non-
methylated CpG island promoter of Slc6a2 gene (Harikrishnan et al., 2010). 
However in both cases MeCP2 was associated with large proteins: ATRX and 
cohesin (Kernohan et al., 2010), and the Smarca2 complex (Harikrishnan et al., 
2010), which could influence the binding specificity of MeCP2. 
 The rapid development of high-throughput sequencing methods as well as 
chromatin conformation capture strategies should help in gaining a better 
understanding of MeCP2 binding specificity and distribution in vivo. In fact, quite 
recently MeCP2 was immunoprecipitated from mouse brains and the fragments of 
chromatin bound by it were subjected to the next generation sequencing (Skene et al., 
2010). The depth of sequencing in this study allowed only low-resolution mapping of 
MeCP2 distribution; nevertheless it indicated that the binding profile of MeCP2 
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tracks the profile of methylated cytosine within the genome. Interestingly, even in 
chromatin regions known to be unmethylated (such as CpG islands of active genes) 
the binding of MeCP2 was always higher than the non-specific antibody binding in 
the control MeCP2 knock-out brains (Skene et al., 2010). These residual interactions 
with non-methylated DNA may be explained by the high abundance of MeCP2 in 
neurons causing it to bind non-specifically. Additionally, a search of the obtained 
ChIP-seq data for presence or absence of the CpG-[A/T]≥4 motif in DNA fragments 
bound by MeCP2 revealed no preference for such sequences (Skene, unpublished). It 
is possible, however, that the limitations of ChIP-seq technique masked the 
identification of specific MeCP2 binding sites. The immunoprecipitated fragments 
were ~500 bp long and contained more than one CpG per fragment, therefore even if 
MeCP2 was binding only to CpG-[A/T]≥4 motifs, the sequencing of the whole 
fragment would not reveal this binding sequence requirement. Use of ChIP-exo 
technique in the future could overcome this potential problem (Rhee and Pugh, 
2011). Further experiments aimed at unravelling the genome-wide binding 
specificity of MeCP2 are ongoing in ours and other laboratories. 
 
1.3.5 MeCP2 as a transcriptional repressor 
 
 Methylation of DNA at CpG dinucleotides is considered as a mark of a 
transcriptionally silent chromatin state (Stein et al., 1982). The discovery of 
methyl-CpG binding proteins led to an outburst of research suggesting their role in 
the transcriptional repression (Kass et al., 1997). MeCP2 was not different and 
although initial studies did not demonstrate its methyl-specific silencing character 
(Meehan et al., 1992), an improved set of experiments later revealed that MeCP2 acts 
as a transcriptional repressor (Nan et al., 1997). The minimal fragment of MeCP2 
able to repress transcription of a reporter gene has been mapped to the 207-310 aa 
region of the rat protein and named as the transcriptional repression domain (TRD; 
Nan et al., 1997). MeCP2 was able to repress transcription not only when binding to 
the promoter of reporter gene, but also from a distance up to 2 kb from the 
transcriptional start site (Nan et al., 1997; Kaludov and Wolffe, 2000).   
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 The mechanism of function of MeCP2 as a repressor of transcription was 
proposed based on the discovery that MeCP2 interacts with co-repressor complex 
Sin3A in HeLa cells and rat brains (Nan et al., 1998) as well as in Xenopus oocytes 
(Jones et al., 1998). The Sin3A complex contains histone deacetylases and in line 
with this fact were observations in both studies that the repression of reporter genes 
was relieved by treatment with trichostatin A (TSA), an HDAC inhibitor (Yoshida 
et al., 2007). Notably, the region of MeCP2 mapped to interact with Sin3A was not 
entirely overlapping with the functionally mapped transcriptional repression domain 
and the interaction is relatively weak (M. Lyst, personal communication) and not 
stable in biochemical assays (Klose and Bird, 2004). There were also other 
mechanisms proposed, based on the detection of binding of MeCP2 to various 
repressor proteins, such as Ski, NCoR (Kokura et al., 2001); SMRT (Stancheva et al., 
2003); CoREST, SUV39H1 (Lunyak et al., 2002); Brahma (Smarca2) (Harikrishnan 
et al., 2005, 2010) and YY1 (Forlani et al., 2010). Additionally, repression of 
transcription mediated by MeCP2 binding the transcription factor IIB (Kaludov and 
Wolffe, 2000) and in an HDAC-independent manner (Yu et al., 2000) have been 
observed, however both studies used artificial in vitro systems and the relevance of 
these discoveries in vivo is not known. Surprisingly, none of the aforementioned 
interactions of MeCP2 has been followed in detail in subsequent studies. The validity 
of the MeCP2 binding to Brahma has been questioned as it could not be confirmed 
by other laboratories (Harikrishnan et al., 2006; Hu et al., 2006). Therefore, up to 
now the mechanism of MeCP2-mediated transcriptional repression was generally 
believed to be due to its interaction with the Sin3A co-repressor (Klose and Bird, 
2006; Chahrour et al., 2008).  
 The functional link between two domains of MeCP2 has been demonstrated 
by means of methylated reporter assays. In these experiments transcription of a 
reporter gene with methylated CpGs is compared to the transcription of the same 
gene in the unmethylated state. As mammalian differentiated cells express various 
methyl-CpG binding proteins the transcription of luciferase reporter transfected into 
mouse tail fibroblasts was repressed by its methylation. Genetic knock-out of two 
genes coding MBD-containing proteins, MeCP2 and MBD2, resulted in an almost 
30-fold increase of normalised luciferase activity (Guy et al., 2001). Co-transfection 
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of these cells with a construct expressing MeCP2 reduced reporter gene activity to 
the normalised level of wild-type cells, suggesting that MeCP2 binds to the 
methylated reporter and represses its transcription (Guy et al., 2001). Similar 
experiments performed in HeLa cells confirmed that the repression of methylated 
reporter gene by MeCP2 is mediated by its TRD domain (Drewell et al., 2002). The 
repression was alleviated by TSA treatment, again suggesting the involvement of 
histone deacetylases in the process. 
1.3.6 Genes regulated by MeCP2 
 
 Availability of Mecp2 knock-out mice and the rapid development of 
molecular tools to globally investigate transcriptomes have allowed the search for 
putative MeCP2 target genes. Microarray studies comparing transcripts in wild-type 
mouse brains and in Mecp2-null mouse found only a handful of subtle differences 
(Tudor et al., 2002). Subsequent extensive searches employing various detection 
platforms have managed to identify several genes mis-regulated in Mecp2-null mice, 
but there was no consensus between the studies (Nuber et al., 2005; Kriaucionis 
et al., 2006; Deng et al., 2007; Jordan et al., 2007; Chahrour et al., 2008; Urdinguio 
et al., 2008; Ben-Shachar et al., 2009). Moreover, one study compared the 
transcriptomes of two different mouse models of RTT at different timepoints and the 
overlap was minimal (Jordan et al., 2007). Similar searches were performed in 
human samples from patients suffering from Rett syndrome. Analysis of gene 
expression in post-mortem brains (Colantuoni et al., 2001), lymphocytes (Delgado 
et al., 2006), lymphoblastoid cells (Traynor et al., 2002; Ballestar et al., 2005) and 
fibroblasts (Traynor et al., 2002; Nectoux et al., 2010) again did not provide any 
obvious or overlapping MeCP2 target genes.  
 
 Despite numerous trials using various approaches the data obtained was 
surprisingly inconclusive and failed to determine a reliable set of genes regulated by 
MeCP2. The relatively small changes in expression levels of tested genes between 
wild-type and KO brains may be due to the fact that brain is a mixture of different 
cell types and even neurons of the same type are not activated simultaneously. That 
could mask the effect of MeCP2 deletion if its role is to regulate transcription of 
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genes only upon activation of neurons. The candidate gene approach focusing on 
genes involved in neuronal function was somewhat more successful. One gene in 
particular, brain-derived neurotrophic factor (Bdnf), has been reported by several 
groups as mis-regulated in MeCP2 deficient cells (Chen et al., 2003; Martinowich 
et al., 2003; Chang et al., 2006; Chahrour et al., 2008; Larimore et al., 2009). BDNF 
is a protein with complex functions, involved in many processes in the brain such as 
neuronal development, survival and plasticity (reviewed in: Cohen-Cory et al., 
2010). Transcription of Bdnf gene is regulated by 8 alternative promoters and shows 
activity dependence and cell-type specificity (Aid et al., 2007). MeCP2 has been 
found to bind to the Bdnf promoter at exon III in rat cortical neurons (Chen et al., 
2003), and to a corresponding promoter in the mouse, at exon IV (Martinowich et al., 
2003) and repress the basal transcription. Upon neuronal membrane depolarisation 
the MeCP2 dissociates from the promoter, probably due to phosphorylation at S421 
(Chen et al., 2003; Zhou et al., 2006).  
 Due to the high abundance of MeCP2 and its binding motif, methyl-CpG, it is 
distributed broadly across the neuronal chromatin (Lewis et al., 1992; Skene et al., 
2010; Cohen et al., 2011). This genome-wide binding profile and the fact that 
MeCP2 can act as a transcriptional repressor in in vitro reporter gene assays suggest 
that it may work globally rather than on a specific subset of genes. The idea of 
MeCP2 serving as a general ‘dampener’ of spurious transcription was supported by 
detection of increased transcription from the repetitive elements in nuclei from 
Mecp2–null brains (Skene et al., 2010). Additionally, the global levels of histone H3 
acetylation were increased in the sorted neuronal nuclei of Mecp2 KO mouse (Skene 
et al., 2010) and in various brain structures of Mecp2
308/y
 mutant mouse (Shahbazian 
et al., 2002a) implicating its global function through histone deacetylases.  
 The functional consequence of such a global transcriptional noise from 
genomic regions not coding proteins is unknown. The intronic, intergenic and 
repetitive sequences quite often contain retrotransposons or regulatory elements such 
as microRNAs or long non-coding RNAs, which when expressed may affect other 
proteins and various cellular processes. The role of MeCP2 in regulation of 
expression of microRNAs was tested, but yet again a consensus has not been found 
between the different studies (Szulwach et al., 2010; Urdinguio et al., 2010; 
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Wu et al., 2010). Future experiments using unbiased high-throughput RNA 
sequencing should help in identifying the effect of MeCP2 on global and local 
transcription. 
1.3.7 MeCP2 as a transcriptional activator 
 
 Surprisingly, it has been noticed that in the hypothalamus of Mecp2 
knock-out mice more genes are mildly downregulated than upregulated, suggesting 
that MeCP2 may act like a transcriptional activator rather than repressor (Chahrour 
et al., 2008). This study was further supported by analysis of gene expression in 
hypothalamus of mice over-expressing MeCP2 two-fold (MeCP2
Tg1
; Collins et al., 
2004). In these animals the majority of downregulated genes in Mecp2-null mice 
showed reciprocal changes of expression and were upregulated and vice versa 
(Chahrour et al., 2008). Another study from the same laboratory focused on a 
different brain region, the cerebellum and the findings were comparable and a subset 
of identified genes activated by MeCP2 overlapped (Ben-Shachar et al., 2009). The 
mechanism of this transcriptional activation by MeCP2 was proposed based on the 
putative interaction of MeCP2 with CREB1 (cyclic-AMP responsive element binding 
protein 1), though it was only weakly detected by mass spectrometry (Chahrour 
et al., 2008). Bisulphite sequencing and limited ChIP-PCR analysis revealed that in 
wild-type brain MeCP2 was bound to the unmethylated promoters of the genes 
upregulated upon its deletion. ChIP-on-chip experiments in the human neuronal cell 
line SH-SY5Y revealed that MeCP2 binds to unmethylated promoters of active genes 
(Yasui et al., 2007). Surprisingly, the MeCP2 binding profile frequently overlapped 
with distribution of RNA polymerase II.  
 The whole effect of decreased transcription of some genes upon deletion of 
Mecp2 may well be indirect. It is possible to imagine wild-type situation when 
MeCP2 is engaging the transcriptional repression machinery throughout the bulk 
methylated genome to repress spurious transcription. In consequence, the genes 
coding the functional proteins are not repressed and are transcribed at their 
physiological level. In the case of depletion of MeCP2 the co-repressors normally 
bound to methylated DNA by MeCP2 are released and may then act on the 
promoters of functional genes, resulting in their decreased transcription. This would 
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be detected by microarrays in Mecp2 KO brains suggesting the role of MeCP2 as a 
transcriptional activator. This speculative hypothesis remains to be tested. 
 
1.3.8 Other functions of MeCP2 
 
Assembly of higher-order chromatin structures 
 
 Apart from the best studied MeCP2 function as a transcriptional regulator it 
has been also implicated in many other processes. The binding to methylated and 
unmethylated DNA through different domains has suggested a possible role in 
chromatin organisation. Indeed, electron microscopy of artificial chromosomes 
revealed that MeCP2 is able to condense chromatin to higher-order structures 
(Georgel et al., 2003; Nikitina et al., 2007a, 2007b). The DNA loops created by 
single MeCP2 molecules bridging distant fragments of naked DNA were also 
observed in vitro using atomic force microscopy (Ghosh et al., 2010a). The only 
study in vivo presenting MeCP2-mediated forming of chromatin loops employed the 
chromatin conformation capture method. Horike and co-workers showed that MeCP2 
facilitated forming of an 11 kb-long loop at the Dlx5-Dlx6 locus and in consequence 
silencing the imprinted allele (Horike et al., 2005). The findings of these authors, 
however, were later challenged (Schüle et al., 2007). 
 
Replacement of histone H1 
 
 MeCP2 has also been shown to be able to displace histone H1 from in vitro 
chromatinised methylated plasmid (Nan et al., 1997). Interestingly, DNase I 
footprinting analysis of H1 and MeCP2 binding to an in vitro reconstituted 
nucleosome revealed that these two proteins have distinct binding pattern (Chandler 
et al., 1999). However, this observation is based only on one DNA sequence tested 
(5S rRNA gene) and may not be true globally. 
 Analysis of changes in fluorescent anisotropy of labelled MeCP2 or H1 upon 
incubation with unlabelled protein showed that MeCP2 is more potent in displacing 
H1 than vice versa (Ghosh et al., 2010a). These experiments suggested that both 
proteins share the same binding sites and can not co-exist on the same nucleosomal 
linker DNA. These observations were confirmed in vivo by recording changes in 
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fluorescence recovery after photobleaching (FRAP) kinetics of H1-GFP when 
challenged by microinjection of MeCP2 into the nucleus and vice versa (Ghosh et al., 
2010a).  
 A potential link between the function of MeCP2 and H1 comes from the fact 
that although histone H1 is present at approximate stoichiometry of one molecule per 
nucleosome in most tissues (Woodcock, 2006), its abundance in neurons is reduced 
two-fold (Pearson et al., 1984). The number of MeCP2 molecules in neurons was 
estimated at approximately one per two nucleosome (Skene et al., 2010) as if 
matching the missing number of H1 molecules. Interestingly, the expression of 
histone H1 in neurons of Mecp2 knock-out mice was doubled when compared to the 
wild-type levels, probably compensating the lack of MeCP2 on the nucleosomal 
linkers (Skene et al., 2010).  
 All these findings suggest the possibility that, at least partially, MeCP2 and 
H1 have similar functions in the maintaining the structure of chromatin. 
 
Prevention of retrotransposition 
 
 Two laboratories reported a relationship between MeCP2 and long 
interspersed nuclear elements-1 (LINE-1), retrotranspons abundantly distributed in 
the genome (Yu et al., 2001; Muotri et al., 2010). MeCP2, but not MBD1 or MBD2, 
was able to repress transcription of a reporter gene with the methylated promoter of 
the L1 retrotransposon. Moreover, the retrotransposition assay revealed that 
expression of MeCP2 in HeLa cells reduced the frequency of retrotransposition 
events of the methylated construct (Yu et al., 2001). A well designed set of 
experiments performed in Gage laboratory confirmed these results and demonstrated 
increased retrotransposition of LINE-1 elements in MeCP2-deficient cultured 
neurons and mouse brains (Muotri et al., 2010). Additionally, the authors tested the 
effect of MeCP2 on LINE-1 retrotransposition in neuronal progenitor cells derived 
from induced pluripotent stem cells generated from fibroblasts of RTT patients. 
Again, more retrotransposition events were detected in MeCP2 deficient cells and it 
was also found to be true in post-mortem brain samples, but not in matched cardiac 
tissue from the same patients. The role of LINE-1 retrotransposition on the scale of 
the whole organism and their relevance to the Rett syndrome are not known. These 
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studies, however, add another layer of complexity towards understanding the 
function of MeCP2.  
 
Regulation of alternative pre-mRNA splicing 
 
 Another potential role of MeCP2 was proposed upon discovery of its 
interaction with Y-box binding protein 1 (YB-1; Young et al., 2005). YB-1 is a 
protein involved in many cellular processes including regulation of transcription, 
translation, DNA repair and RNA splicing (Kohno et al., 2003). The MeCP2-YB-1 
interaction was shown to be independent of binding to methylated DNA and was 
mapped to the TRD domain and C-terminal end of MeCP2. Interestingly it was 
abolished by RNAse treatment, suggesting the involvement of RNA in the binding. 
MeCP2 has been also reported to interact with RNA before (Jeffery and Nakielny, 
2004). Young and co-authors suggested that MeCP2 together with YB-1 may 
regulate alternative splicing and supported their hypothesis using reporter minigenes. 
Additionally, a comparison of mRNAs from mouse brains expressing wild-type and 
a truncated form of MeCP2 (Mecp2
308/y
) on a custom-made splicing microarray 
revealed a number of genes spliced differently. The fact that another mutated form of 
MeCP2 (R106W) that is unable to bind to methylated DNA still interacts with RNA 
and can regulate its splicing (Jeffery and Nakielny, 2004; Young et al., 2005) argues 
against the relevance of these discoveries for a global picture of MeCP2 function. 
Two other proteins potentially involved in alternative splicing have been identified to 
interact with MeCP2, formin-binding protein 11 (FBP11), a splicing factor 
containing the WW domain (Bedford et al., 1997) and huntingtin-interacting protein 
C (HYPC; Buschdorf and Strätling, 2004). It allowed a discovery of a WW-domain 
binding region on MeCP2 at its C-terminus, responsible for these interactions and 
possibly binding other splicing factors (Buschdorf and Strätling, 2004). However, the 
significance of these interactions in vivo is not known. 
 In summary, MeCP2 appears as a complex protein interacting with DNA and 
various other proteins. There are numerous potential functions ascribed to it but it is 
not known which of them are the most relevant in vivo. The insights for deciphering 
the key mechanism of action of MeCP2 should come from studying its association 
with Rett syndrome. 
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1.4 Rett syndrome 
 
1.4.1 Rett syndrome in humans 
 
 Rett syndrome (RTT) was described for the first time by Austrian 
paediatrician and neurologist Andreas Rett in 1966, but was not published in English 
until 1983 (Hagberg et al., 1983). This neurological disorder occurs approximately 
1 : 12 500 births and affects mostly girls, who develop normally for 6-18 months 
when they start exhibiting a range of symptoms and lose acquired skills, such as 
speech and walking (Cheval et al., 2012). The classical Rett patients suffer from 
stereotypic hand movements, seizures, gait difficulties, ataxia, breathing 
abnormalities, mental retardation and autism-like social interactions (Hagberg et al., 
1983). It was reported that the syndrome is an X-linked disease and it was mapped to 
Xq28 region (Sirianni et al., 1998; Xiang et al., 1998). The candidate gene approach 
allowed the identification of a gene mutated in the Rett syndrome patients, which 
turned out to be MECP2 (Amir et al., 1999). More than 90% of sporadic cases of 
classical RTT in females are as a result of mutations in the MECP2 gene (Bienvenu 
and Chelly, 2006). All of the genetic alterations identified in RTT patients were 
compiled in RettBASE database (Christodoulou et al., 2003). The general 
understanding is that disease-causing mutations can occur throughout the whole 
length of protein (Kriaucionis and Bird, 2003; Adkins and Georgel, 2011; Chao and 
Zoghbi, 2012). The search for a correlation between MECP2 mutation and Rett 
syndrome symptoms severity failed to find any clear links (Temudo et al., 2011) 
suggesting that all regions of MeCP2 are important for its function. Such a global 
view of all types of mutations does not provide specific information about MeCP2, 
because the nonsense and frameshift mutations disrupt large part of the protein 
having effect on its various aspects, such as folding, stability, localisation or multiple 
interactions. However, focusing only on missense mutations allows precise 
identification of the functional sites on MeCP2 that are key to Rett syndrome, 
because unlike other mutations, they surgically affect just one residue. Moreover, in 
some cases of RTT the parents of patients were not tested for mutations in their 
MECP2 gene and therefore the reported mutations could simply be polymorphisms 
not related to a disease. Careful analysis of the database regarding only the de novo 
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missense mutations revealed two clusters of mutational hotspots (Fig. 1.4). One of 
the large regions commonly mutated in RTT is restricted to the MBD domain and 
plausibly affects MeCP2 binding to methylated DNA. Both deletion and missense 
mutations in this domain cause disruption of binding to DNA as assessed by 
Southwestern (Ballestar et al., 2000; Yusufzai and Wolffe, 2000) and band-shift 
assays (Ballestar et al., 2000; Nikitina et al., 2007a, 2007b; Ho et al., 2008). The 
characteristic localisation of MeCP2 in heterochromatic foci was more diffuse when 
the protein was mutated in the MBD, as observed by immunofluorescent microscopy 
in fixed cells (Kudo et al., 2001, 2003; Schmiedeberg et al., 2009). Interestingly, 
live-cell imaging of cells expressing mutated versions of MeCP2 showed their 
wild-type-like localisation (Schmiedeberg et al., 2009) and it was suggested that the 
differences lie rather in their binding dynamics (Kumar et al., 2008; Schmiedeberg, 
unpublished). 
 The other cluster of RTT-causing missense mutations is localised at the 
C-terminus of the TRD domain and we hypothesise that these mutations could affect 







Figure 1.4. RTT missense mutations cluster in the functional domains of MeCP2.  
De novo missense mutations causing Rett syndrome were collected from RettBASE 
(Christodoulou et al., 2003) and depicted on the human MeCP2 isoform e2 sequence. 
MBD - methyl-CpG binding domain, TRD - transcriptional repression domain. 
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1.4.2 Mouse models of Rett syndrome 
 
 The first knock-out the Mecp2 gene in mice was performed before the link 
between MeCP2 protein and the Rett syndrome was known. The substitution of 
Mecp2 with lacZ gene in embryonic stem (ES) cells did not affect their morphology 
and differentiation potential. However, creation of Mecp2-null mouse from these 
cells was not successful due to embryonic lethality (Tate et al., 1996) suggesting its 
critical role in development. After the discovery of the genetic cause of RTT (Amir 
et al., 1999), two groups decided independently to delete Mecp2 using Cre-loxP 
conditional knock-out approach (Chen et al., 2001b; Guy et al., 2001). The resulting 
mice recapitulated most of the human Rett syndrome phenotypes as the apparently 
normal development of mouse was followed by a delayed onset of neurological 
symptoms including tremors, uncoordinated gait, abnormal breathing, and reduced 
brain size. Null animals started exhibiting symptoms between 3-8 weeks and died on 
average on day 54 after birth (Guy et al., 2001). The onset of symptoms in female 
heterozygous mice was delayed to 3-9 months and they were fertile and exhibited 
normal lifespans. Both homo- and heterozygotes for MeCP2 deletion are valid mouse 
models of Rett syndrome, however most subsequent studies were performed on male 
null mice as the phenotype appears faster and more uniformly. 
 Conditional deletion of Mecp2 in whole brain by Nestin-Cre gave rise to a 
phenotype comparable with the full body knock-out (Chen et al., 2001b; Guy et al., 
2001). However, CamKII-Cre-mediated Mecp2 deletion in post-mitotic neurons of 
forebrain, hippocampus and brainstem, but not in cerebellum and glial cells resulted 
in delayed and less severe phenotype (Chen et al., 2001b). Other region- and cell-
type specific Mecp2 deletions in brain recapitulated some of the RTT phenotypes to 
various extents (Reviewed in: Gadalla et al., 2011 and Guy et al., 2011). MECP2 
gene knocked in the Tau locus of Mecp2 null mice was able to rescue the RTT 
phenotype (Luikenhuis et al., 2004) suggesting the role of MeCP2 in the post-mitotic 
neurons. Interestingly, the function of MeCP2 in glial cells have also been recently 
reported (Lioy et al., 2011; Derecki et al., 2012). 
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 The remaining question with tremendous consequences for potential RTT 
therapies was whether MeCP2 deletions affect neuronal development, cause their 
irreversible degeneration or just impair their function. The answer came from very 
neat experiments when RTT mice were produced by inserting the floxed STOP-Neo 
cassette before exon 3 of Mecp2 and crossing it with a mouse inducibly expressing 
Cre recombinase upon treatment with tamoxifen (Guy et al., 2007). The mice were 
allowed to develop RTT symptoms and subsequent tamoxifen injections caused Cre 
to be expressed and excise the STOP cassette allowing full-length MeCP2 to be 
produced. Spectacular reversal of the advanced neuronal phenotypes has been 
observed (Guy et al., 2007). This suggested that MeCP2 is crucial for the proper 
neuronal function, but lack of it does not impair them irreversibly. This discovery has 
tremendous importance for the search of potential treatments for Rett syndrome. 
 
 The precise regulation of MeCP2 levels in cells is critical as too much and 
too little of the protein is detrimental. Humans with duplication of a locus containing 
MECP2 gene exhibit neurological symptoms, severe mental retardation, limited or 
absent speech, spasticity, facial hypotonia and locomotor problems (Van Esch et al., 
2005). Transgenic mice expressing twice as much MeCP2 as wild-type levels 
(MeCP2
Tg1
) also demonstrate a spectrum of neurological and behavioural problems 
and premature death (Collins et al., 2004). Moreover, in mice with three-fold MeCP2 
expression (MeCP2
Tg3
) the phenotypic severity is increased. On the other hand, 
reducing the level of MeCP2 by 50% results in mild, but statistically significant 
differences in mice behaviour and performance (Samaco et al., 2008). 
 Because of the necessity of keeping the expression of MeCP2 at wild-type 
levels, the potential gene therapy aimed at replacing the faulty MECP2 gene in Rett 
syndrome patients may be difficult (Reviewed in: Gadalla et al., 2011). The fact that 
in RTT females approximately half of the neurons are expressing normal levels of 
MeCP2 presents a real hurdle in the design and/or proper targeting the gene therapy 
only to the defective cells. Therefore, despite the initial trials in mice serving rather 
as a proof of principle, the prospective therapy based on gene delivery is still far 
away from clinics. 
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 A very recent study gives some hope to prevent Rett syndrome. Experiments 
in Mecp2 null mice showed that a bone marrow transplant from wild-type animal can 
prevent the occurrence of RTT-like pathology (Derecki et al., 2012). The proposed 
mechanism relies on migration of transplanted microglial cells in blood, crossing the 
blood-brain barrier and serving as phagocytes removing cell debris in the brain. The 
drawback of this approach is that it was only successful in arresting the symptoms 
occurrence in pre-symptomatic mice. To apply it to humans, every newborn child 
should be screened for RTT mutations and given a bone marrow transplant before it 
can be diagnosed with the syndrome based on the symptoms. It sounds unrealistic at 
the moment, but rapidly dropping prices and increasing speed of genome sequencing 





Aims of the thesis 
 
 
 Despite more than 20 years of research on MeCP2, its molecular function and 
the role it plays in Rett syndrome are still not fully known. Many putative 
mechanisms of action have been ascribed to MeCP2, however it is important to 
distinguish between the functions which may be true when tested in in vitro assays, 
and the functions found and proved in vivo. In my opinion the most interesting and 
relevant are the MeCP2 activities which are disrupted in Rett syndrome. Therefore, 
in this study we decided to re-address the issue of deciphering the function of 
MeCP2, focussing on its association with RTT. 
 
The aims of this thesis were: 
(1) To search for interacting partners of MeCP2 and identify new proteins 
(2) To map the confirmed interactions onto the MeCP2 sequence 
(3) To investigate the functionality of these interactions with regard to Rett 




Chapter 2: Materials and methods 
2.1 Materials 
 
 All standard chemicals and reagents used in this study were provided by 
Sigma-Aldrich and all tissue culture media and chemicals were supplied from Gibco, 
unless stated otherwise. 
 
2.1.1 Standard buffers 
 
DNA sequencing buffer (2.5×): 
20 mM Tris-HCl, 5 mM MgCl2, pH 8.0 
 
Orange G DNA loading buffer (5×): 
0.198% orange G, 12% Ficoll, 120 mM EDTA, 4.2% SDS, pH 8.0 
 
PBS (phosphate buffered saline): 
137 mM NaCl, 2.7 mM KCl, 2 mM KH2PO4, 10 mM Na2HPO4 · 2H2O, pH 7.4 
 
SDS-PAGE sample buffer (2×): 
125 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 300 mM β-mercaptoethanol, 
0.2% bromophenol blue 
 
SDS-PAGE running buffer: 
25 mM Tris, 250 mM glycine, 0.1% SDS 
 
Transfer buffer: 
25 mM Tris, 192 mM glycine 
 
TAE (Tris-acetate EDTA): 
40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8.0 
 
TBS (Tris-buffered saline): 
50 mM Tris-HCl, 150 mM NaCl, pH 8.0 
 
TBS-T (TBS-Tween): 





 All primary antibodies used in this study are listed in the Table 2.1.2A and 
the secondary antibodies in the Table 2.1.2B. 
 
Table 2.1.2A Primary antibodies used in this study. The symbols for applications are as 
follows: WB – Western blot, IHC – immunohistochemistry, IP – immunoprecipitation. 
Antibody Species 
Source,  





    
anti-CamKIIα mouse Abcam, ab22609, 1 mg/ml WB (1:1000) 
anti-CK2α rabbit Abcam, ab10466, 1 mg/ml WB (1:1000) 
anti-FLAG mouse Sigma, F3165, 2 mg/ml WB (1:2000) 
anti-GAL4-DBD mouse Santa Cruz, Sc-510, 0.2mg/ml WB (1:500-1:1000) 
anti-GAPDH mouse Abcam, ab9484, 1 mg/ml WB (1:1000) 
anti-GFAP mouse Sigma, G3893, 2 mg/ml IHC (1:200) 
anti-H2B rabbit Abcam, ab1790, 0.5 mg/ml WB (1:2000) 
anti-H3 rabbit Abcam, ab1791, 1 mg/ml WB (1:5000) 
anti-H3 acetyl rabbit Millipore, 06-599, 1 mg/ml WB (1:1000) 
anti-HDAC3 rabbit Abcam, ab7030, 1 mg/ml IHC (1:100) 
anti-KPNA3 goat Abcam, ab6038, 0.5 mg/ml WB (1:1000) 
IHC (1:100) 
 
anti-KPNA4 rabbit Abcam, ab81451, 1 mg/ml WB (1:1000) 
IHC (1:100) 
 
anti-KPNA4 rabbit Bethyl, A301-627A, 0.2 mg/ml  WB (1:1000) 
anti-KPNA4 rabbit Bethyl, IHC-00321, 0.2 mg/ml IHC (1:100) 
anti-MAP1B mouse Abcam, ab3095, 0.2 mg/ml WB (1:1000) 
anti-MAP2 rabbit Millipore, AB5622, 1 mg/ml IHC (1:200) 
anti-MeCP2 mouse Sigma, M6818, 2 mg/ml WB (1:1000) 
anti-MeCP2 rabbit Millipore, 07-013, 1 mg/ml IHC (1:100) 
anti-NeuN mouse Millipore, MAB377, 1 mg/ml WB (1:1000) 
IHC (1:400) 
 
anti-Tuj1 mouse Covance, MMS-435P, 1mg/ml IHC (1:400) 
anti-WBP11 rabbit Abcam, ab85563, 1 mg/ml WB (1:1000) 




mouse Sigma, A2220 IP (1:200) 
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Table 2.1.2B Secondary antibodies used in this study. The abbreviations used here are as 
follows: WB – Western blot, ECL – enhanced chemiluminescence, HRP – horseradish 








anti-mouse-HRP GE Healthcare, NA931V WB-ECL (1:8 000) 
anti-rabbit-HRP GE Healthcare, NA934V WB-ECL (1:8 000) 
anti-goat-HRP Abcam, ab6885  WB-ECL (1:5 000) 
anti-mouse IRDye 800CW Odyssey, 926-32212 WB-Licor (1:10 000) 
anti-rabbit IRDye 700LT Odyssey, 926-32223 WB-Licor (1:10 000) 
anti-rabbit IRDye 800CW Odyssey, 926-32213 WB-Licor (1:10 000) 
anti-goat IRDye 800CW Odyssey, 926-32214 WB-Licor (1:10 000) 
anti-mouse-594 (goat) Molecular probes, A11032 IHC (1:500) 
anti-mouse-633 (goat) Molecular probes, A21071 IHC (1:500) 
anti-rabbit-594 (donkey) Molecular probes, A21207 IHC (1:500) 
anti-goat-594 (donkey) Molecular probes, A11058 IHC (1:500) 
 
2.1.3 Mice  
All mice used in this study were bred and maintained at the University of Edinburgh 
animal facilities under standard conditions and all procedures were carried out by 
staff licensed by UK Home Office and according to the Animals and Scientific 
Procedures Act 1986. The genotypes of mice used in different experiments are listed 
in the Table 2.1.3. All animals were 6-9 weeks old and wherever possible the 
matching littermates were used. 
 
Table 2.1.3 Mice used in this study. The mouse genotypes used in each type of experiment. 
Type of experiment Mouse genotypes 
 
Genetic background 
♂ wild-type C57BL/6 
♂ Mecp2-GFP C57BL/6 segregating 
Immunoprecipitations 
♂ H2B-GFP (Jiang et al., 2008) 
   
Immunohistochemistry ♀ Mecp2-GFP+/- mixed (outbred) 
   
Analysis of protein 
and mRNA levels  





2.1.4 Cell lines 
The wild-type mouse ES cell line used was E14 TG2α. The Mecp2-GFP, 
Mecp2-GFP [T158M] and Mecp2-GFP [R306C] lines were generated as described 
elsewhere (Thomson et al., 2010). The Mecp2-null ES cells were produced from cells 
described in (Guy et al., 2001), by deletion of floxed segment by in vitro Cre 
transfection (performed by J. Guy). Other cell lines used were HeLa and NIH-3T3, 
cultured as described below. 
 
2.1.5 PCR primers 
  
All primers have been synthesised by Sigma-Aldrich, resuspended in H2O to a 
concentration of 100 µM and stored at -20 °C as a stock solution. The sequences of 
primers are listed at each method where they were used. 
 
2.2 Methods 
The methods are listed in order of their appearance in the results chapters 3-6. 
 
2.2.1 Isolation of nuclei from mouse brains 
 
Three brains from 6-9 weeks old male Mecp2-GFP knock-in mice or age-matching 
wild-type (C57BL/6 strain) or CamKII-H2B-GFP mice were collected, snap-frozen 
in liquid nitrogen and stored at -80 °C. Brains thawed on ice were homogenised in 9 
ml of ice-cold buffer A (10 mM HEPES pH 7.9, 25 mM KCl, 1 mM EDTA, 0.5 mM 
EGTA, 2 M sucrose, 10% glycerol, 0.15 mM spermine, 0.5 mM spermidine and 
complete protease inhibitors [Roche]) in a 15 ml glass dounce using Potter S 
motorised homogeniser (Braun) at 1100 rpm for seven strokes. The homogenates 
were layered onto 3 ml cushion of buffer A in 
9
/16" × 3¾" polyallomer tubes 
(Beckman) and centrifuged at 24 000 rpm at 4 °C for 40 min on SW-40Ti rotor in 
Beckman Coulter XL-100 ultracentrifuge. The supernatant was decanted and pelleted 
nuclei were left in the inverted tubes on ice to drain briefly before being used in 
subsequent applications. 
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2.2.2 Nuclear protein isolation 
 
The nuclei were resuspended in 1 ml of cold NE-1 buffer (20 mM HEPES pH 7.5, 
10 mM KCl, 1mM MgCl2, 0.1% Triton X-100, complete protease inhibitors [Roche] 
and 14.3 mM β-mercaptoethanol) and transferred to cold eppendorf tubes. After 
5 min centrifugation at 600 g at 4 °C the supernatant was discarded and white nuclear 
pellets resuspended in 100 µl NE-1. 3 µl (250 units) of benzonase nuclease was 
added and the tubes were incubated for 10 min. at room temperature. Subsequently, 
volume was increased to 700 µl with NE-1 buffer and then 300 µl of NE-2 buffer 
(NE-1 supplemented with 500 mM NaCl) was added in a drop-wise fashion with 
mixing in order to uniformly reach 150 mM final concentration of NaCl. The nuclei 
were incubated 30 min on a rotating wheel at 4 °C. After centrifugation at 16 000 g 
for 20 min at 4 °C, the supernatant was transferred to new eppendorf tubes as a 
nuclear extract. 
 
2.2.3 Protein electrophoresis 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on 
home-made gels containing 0.1% SDS, 10-15% acylamide:bis-acrylamide (29:1; 
Bio-rad) in 375 mM Tris pH 8.8 (separating gel) or 4.3% acylamide:bisacrylamide in 
125 mM Tris pH 6.8 (stacking gel), polymerised with ammonium persulphate and 
TEMED in Mini Protean-3 apparatus (Bio-rad). Protein samples were boiled in SDS 
PAGE sample buffer for 5 min and loaded on the gel alongside the PageRuler 
Prestained protein ladder (Thermo scientific). The electrophoresis was performed in 
SDS PAGE running buffer for 1 h at 180 V. 
2.2.4 Western blotting 
 
In order to transfer the proteins separated on the SDS-PAGE to nitrocellulose 
membrane, the wet transfer in Mini trans-blot cell system (Bio-rad) was used 
according to manufacturer’s instructions. Briefly, the transfer cassette was assembled 
with sponge, 2 layers of Whatman paper, gel, membrane, 2 layers of Whatman paper 
and another sponge, all soaked in the protein transfer buffer. The transfer was 
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performed for 2 hours at 250 mA at 4 °C. The membrane was then blocked with 
5% milk in TBS-T buffer (blocking solution) for at least 1 hour at room temperature, 
and incubated with primary antibodies diluted as in Table 2.1.2A in the blocking 
buffer at 4 °C overnight. Three washes for 10 min with TBS-T were followed by 
2 hour incubation with secondary antibodies (Table 2.1.2B) diluted in blocking 
solution. Three washes as previously were followed by signal detection. 
 
ECL detection 
To visualise the proteins, membranes were incubated for 1 min in developing 
solution (0.1 M Tris-HCl pH 8.8, 0.01% H2O2, 1.5 mM luminol, 0.25 mM 
p-coumaric acid), drained and exposed to an X-ray film for 10 s – 30 min depending 
on the strength of the signal. The films were developed in SRX-101A film processor 
(Konica Minolta). 
 
Ultra-sensitive ECL detection 
In order to detect very low abundant proteins by Western blotting, the primary 
antibodies were used at higher than usually concentration (1:500 dilution), secondary 
antibodies were kept for longer (up to 4 hours) and to develop the signal a 
commercial SuperSignal WestFemto Chemiluminescent substrate (Thermo 
scientific) was used according to the manufacturer’s protocol. Exposition onto the 
ultra-sensitive X-ray film (Hyperfilm ECL High Performance; Amersham) for 5 – 60 
min was followed by film development as in classical ECL detection. 
 
Quantitative infrared detection 
To be able to quantitatively measure the intensity of Western blot bands the LiCOR 
infrared system was used. The membranes were processed with primary antibodies 
as in normal ECL detection, but were incubated with secondary antibodies coupled 
with fluorescent dyes (1:10 000 dilution) in the dark. The scanning of the signal and 
subsequent image analysis were performed on Oddysey scanner and Odyssey 3.0 
software using the average background subtraction method. 
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2.2.5 Silver staining 
 
Protein samples were resolved on the 10% polyacrylamide gel and stained with 
SilverQuest silver staining kit (Invitrogen) according to the manufacturer’s 
instructions.  
 
2.2.6 GFP immunoprecipitation 
 
After nuclear protein extraction, 25 µl of the extract was mixed with 25 µl protein 
loading buffer, boiled for 5 min and stored at -20 °C as an input fraction. The 
remaining extract was mixed with 30 µl of GFP-Trap_A agarose beads (Chromotek), 
which have been previously equilibrated in NE-1 buffer supplemented with 150 mM 
NaCl  (4 washes with 1 ml buffer, centrifugations performed for 1 min at 2 000 g). 
The extract was incubated with beads for 30 min on a rotating wheel in at 4 °C. The 
beads were pelleted by centrifugation (1 min, 2 000 g, 4 °C) and washed four times 
with 750 µl of buffer NE-1 supplemented with 150 mM NaCl, discarding the 
supernatants. The pelleted and washed beads were mixed with 60 µl protein loading 
buffer, boiled for 5 min and stored at -20 °C as the IP (immunoprecipitated) fraction 
for subsequent mass spectrometry or Western blot analyses. 
 
2.2.7 Mass spectrometry 
 
50 µl of IP samples were loaded onto NuPAGE pre-cast 4-12% Bis-Tris protein gels 
(Invitrogen). The electophoresis was run at 200V until the dye front migrated 1 cm 
into the gel. The gel was then washed 3 × 5 min with H2O and stained for 1 h with 
the Imperial Protein coomassie stain (Thermo scientific), washed once with water 
and stored at 4 °C. Subsequent mass spectrometry analysis was performed by Flavia 
de Lima Alves in the laboratory of Juri Rappsilber. The bands of coomassie-stained 
proteins on the gel were excised and the proteins were digested with trypsin as 
described elsewhere (Shevchenko et al., 1996). In brief, proteins were reduced in 10 
mM DTT for 30 min at 37 °C, alkylated in 55 mM iodoacetamide for 20 min at room 
temperature in the dark, and digested overnight at 37 °C with 13 ng/µl trypsin 
(Proteomics Grade, Sigma). The digestion media was then acidified to 0.1% of TFA 
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and spun onto StageTips as described in the literature (Rappsilber et al., 2003). 
Peptides were eluted in 20 µl of 80% acetonitrile in 0.1% TFA and were 
concentrated to 4 µl (Concentrator 5301, Eppendorf AG). The peptides sample was 
then diluted to 5 µl by 0.1% TFA for LC-MS/MS analysis. An LTQ-Orbitrap mass 
spectrometer (Thermofisher Scientific) was coupled on-line to an Agilent 1100 
binary nanopump and an HTC PAL autosampler (CTC). The peptides were separated 
using an analytical column with a self-assembled particle frit (as described in: 
Ishihama et al., 2002) and C18 material (ReproSil-Pur C18-AQ 3 µm; Dr. Maisch 
GmbH) was packed into a spray emitter (100 µm ID, 8 µm opening, 80 mm length; 
New Objective) using an air-pressure pump (Proxeon Biosystems). Mobile phase A 
consisted of water, 5% acetonitrile, and 0.5% acetic acid; mobile phase B consisted 
of acetonitrile and 0.5% acetic acid. The gradient used was 98 min. The peptides 
were loaded onto the column at a flow rate of 0.7 µl/min and eluted at a flow rate of 
0.3 µl/min according to the gradient. 0% to 5% buffer B in 5 min, 5% to 20% 
buffer B in 80 min and then to 80% buffer B in 13 min. FTMS spectra were recorded 
at 30,000 resolution and the six most intense peaks of the MS scan were selected in 
the ion trap for MS2 (normal scan, wideband activation, filling 7.5×10
5
 ions for MS 
scan, 1.5×10
4
 ions for MS2, maximum fill time 150 msec, dynamic exclusion for 
150 sec). Identified peptides were searched against the mouse IPI protein library 
database (Kersey et al., 2004) and unique identifiers were assigned. 
2.2.8 Mammalian cell culture 
 
HeLa and NIH-3T3 cells were grown in DMEM medium supplemented with 10% 
foetal bovine serum (FBS; Hyclone), 100 U/ml penicillin and 100 µg/ml 
streptomycin. Cells were cultured in 75 cm
2
 flasks (Corning) in 12 ml of complete 
medium at 37 °C, 5% CO2 in standard cell culture incubator. When cells reached 
approximately 90% confluency they were washed with PBS, trypsinised with 
1 ml TrypLE express trypsin and seeded at 1:10 dilution. For luciferase reporter gene 
assays and immunocytofluorescence cells were counted in haemocytometer and 
seeded at desired density. 
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2.2.9 Production of MeCP2 truncation mutants 
 
In order to map the protein-MeCP2 interactions a series of FLAG-tagged truncation 
mutants of MeCP2 had to be produced. The primers containing NotI and BglII 
restriction enzyme sites were designed to amplify a desired region of human 
MeCP2_e2 and are available on request. The PCR reactions were performed in 25 µl 
final volume, using 50 ng pFS-MeCP2 plasmid as a template (a gift from M. Lyst), 
2.5 µl 10× Pfu buffer (Promega), 200 µM dNTPs, 250 nM forward and reverse 
primers and 0.6 units of Pfu DNA polymerase (Promega). The reaction conditions 
were as follows: DNA denaturation at 95 °C for 1 min, then 30 cycles of 95 °C for 
30 s; 60 °C for 30 s and 72 °C for 2 min, followed by final incubation at 72 °C for 10 
min. The PCR product was purified on PCR purification column (Qiagen) according 
to manufacturer’s protocol and eluted with 30 µl H2O. The sample was 
double-digested with NotI and BglII restriction enzymes (in 40 µl total volume with 
4 µl 10x buffer 2 [NEB], 1 mg/ml BSA, 1 µl NotI-HF and 2.5 µl BglII) for 2 hours at 
37 °C. 5 µg of 3xFLAG-CMV-10 plasmid (Sigma) was digested in the same way. 
Both reaction solutions were mixed with Orange G DNA loading dye, separated on 
1% agarose DNA gel with 0.5 µg/ml ethidium bromide in TAE buffer and the bands 
corresponding to digested vector and PCR product were excised with a scalpel under 
the UV light. The DNA was extracted from the gel with Gel extraction kit (Qiagen) 
and eluted with 30 µl H2O. The ∆NLS2 mutant devoid of 255-269 aa fragment was 
produced from pFS-MeCP2 plasmid, using QuikChange II XL site directed 
mutagenesis kit (Stratagene) according to the manufacturer’s instructions. 
 
2.2.10 DNA ligation and plasmid amplification 
 
The concentration of purified DNA was measured on Nanodrop spectrophotometer 
and 100 ng of vector was ligated with insert DNA at 1:3 molar ratio, using T4 DNA 
ligase (NEB) according to manufacturer’s protocol. DH5α E. Coli bacteria were 
transformed with 10 µl ligation mixture by a standard heat shock method (Froger and 
Hall, 2007). The DNA from resulting colonies was extracted by Mini-prep method 
(Qiagen) and verified by diagnostic restriction digestion and sequencing to confirm 
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the correct length of desired truncation and lack of mutations. Plasmids were then 
amplified by Maxi-prep method (Qiagen), aliquoted and stored at -20 °C. Some of 
the MeCP2 truncation mutants were designed and produced by Matt Lyst.  
2.2.11 DNA sequencing 
 
Sequencing reactions were performed in 10 µl total volume, containing 2 µl BigDye 
Terminator v3.1 (Applied Biosystems), 4 µl 2.5 x DNA sequencing buffer, 5 pmol of 
sequencing primer and ~200 ng DNA. The reaction conditions were as follows: DNA 
denaturation at 96°C for 3 min, then 24 cycles of 96 °C for 30 s; 50 °C for 20 s and 
60 °C for 4 min. Sequencing reactions were cleaned up and run on a ABI 3730 
capillary sequencer by the GenePool sequencing facility (University of Edinburgh). 
Obtained sequences were analysed using BioEdit (Hall, 1999) and Lasergene v.10 
software (DNAStar). 
 
2.2.12 HeLa cell transfections for FLAG immunoprecipitation 
 
For FLAG-immunoprecipitation experiments, ~5 × 10
6
 HeLa cells were seeded on 
15 cm dishes (Corning) in 22 ml of complete medium. 24 h after plating the cells 
were transfected with 20 µg of a plasmid harbouring the produced FLAG-tagged 
truncation mutant of MeCP2 or eGFP-C1 plasmid as a control, using JetPEI 
(Polyplus transfection) according to the manufacturer’s protocol. The cells were 
harvested 24 h after transfection by trypsinisation, washed in PBS and stored at 
-80 °C. 
 
2.2.13 FLAG immunoprecipitation 
 
Harvested HeLa cells were defrosted on ice and homogenized in 1.5 ml cold NE-1 
buffer in a 3 ml glass dounce. The nuclei were pelleted by centrifugation (5 min, 
800 g, 4 °C) and the nuclear protein extraction was performed as in method 2.2.2. 
The FLAG immunoprecipitation was performed as in method 2.2.6, with the 
exception that 5 µl of washed anti-FLAG affinity agarose was used instead of 
GFP-Trap_A. After four washes of the beads the bound proteins were eluted with 
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20 µl of 1 mg/ml 3 × FLAG peptide (Sigma, F4799) for 3 hours on a rotating wheel 
in the cold room. Subsequently the beads were pelleted by 1 min centrifugation at 
1000 g and the supernatants were mixed with 20 µl protein loading buffer, boiled for 
5 min and stored at -20 °C as the IP (immunoprecipitated) fraction for subsequent 
Western blot analysis. 
 
2.2.14 Cloning of CamKIIα gene 
 
The primers were designed to amplify mouse CamKIIα gene (NCBI Reference 
Sequence: NM_177407.4) from mouse brain cDNA. Additionally, forward primer 
contained SalI restriction site and the reverse primer BamHI site and two linker 
nucleotides so the resulting product could be cloned in frame with GFP fusion 
protein in pEGFP-N1 plasmid (Clontech). 
 




enzyme Primer sequence 5’-3’ 
CamKII_FWD SalI ATTGTCGACATGGCTACCATCACCTGCACC 
CamKII_REV BamHI TATGGATCCCCTCCATGCGGCAGGACG 
 
Mouse brain cDNA was a gift from Pete Skene. The PCR reaction was performed 
and purified as in the method 2.2.9. Cloning to eGFP-N1 plasmid (Clonetech) was 
performed as in the method 2.2.10. For FLAG immunoprecipitations in HeLa cells 
10 µg of the plasmid coding CamKIIα-GFP was co-transfected with 10 µg MeCP2 
truncations and the IPs were performed as above. 
 
2.2.15 Live cell imaging 
 
Microscopic analysis and photography of live cells was performed on Nikon Eclipse 
TS100 inverted microscope in bright field and using mercury lamp and FITC filter 
for fluorescent images. The transfected ES cell-derived neurons were observed live 
under Zeiss Axiovert 25 inverted microscope fitted with mercury lamp and Filter sets 
20 and 38. 
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 NIH-3T3 cells were seeded on each of the chambers of 8-chamber glass slide 
(BD Falcon) and transfected with 0.5 µg of GFP-MeCP2 or GFP-MeCP2 [255X] 
plasmids (gifts from L. Schmiedeberg) using JetPEI (Polyplus transfection) 
according to manufacturer’s protocol. 24 h post-transfection the cells were washed 
2 × 5 min with PBS, fixed 15 min with 4% paraformaldehyde (pH 7.4) in PBS, 
washed 3 × 5 min with PBS, permeabilised for 10 min with 0.1% Triton X-100 in 
PBS and washed as previously. Cells were then blocked with blocking solution 
(1.5% serum of the species where secondary antibodies were produced in PBS) for 
30 min and incubated with primary antibodies (diluted in the blocking solution as 
listed in the Table 2.1.2A) for 2 h at room temperature. The 3 × 5 min washes with 
PBS were followed by incubation with secondary antibodies (Table 2.1.2B) for 1 h at 
room temperature in dark. Subsequently cells were washed 4 × 5 min with PBS and 
4',6-diamidino-2-phenylindole (DAPI) was added to second wash (at 1 µg/ml final 
concentration). The coverslip was mounted with Prolong Gold (Invitrogen), corners 
were painted with nail varnish and slides were incubated at 4 °C overnight and stored 
at -20 °C. 
 




 mouse was perfused with 4% paraformaldehyde (pH 7.4) in PBS 
(performed by H. Cheval and J. Selfridge) and the brain was removed, soaked in 
4% paraformaldehyde overnight at 4 °C and in 30% sucrose for next 24 hours at 
4 °C. Subsequently the brain was washed once with PBS, drained on paper, snap-
frozen in isopentene on dry ice, moved to new container and stored at -80 °C. The 
brain slices were cut on CM1900 cryostat (Leica) at 14 µm thickness, placed on 
microscopic slides and frozen at -80 °C. The fluorescent immunostaining was 
performed as in method 2.2.16 from permeabilisation step, using coplin jars. 
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2.2.18 Picture analysis 
 
The confocal microscopy was performed on Leica TCS SP5 microscope. The 
pictures were analyzed and processed in ImageJ v. 1.46r with LOCI tools plug-in 
(Schneider et al., 2012). 
2.2.19 Biochemical fractionation of cytoplasmic and nuclear 
proteins 
 
A single mouse brain was homogenised in 3 ml NE-1 buffer in 5 ml glass dounce by 
hand. After 15 min incubation on ice, 25 µl of the homogenate was boiled with equal 
amount of protein loading buffer and stored at -20 °C as a total brain protein extract. 
The rest of the homogenate was centrifuged for 10 min at 850 g at 4 °C. Supernatant 
was saved as cytoplasmic fraction and the pellets were washed twice with 1 ml NE-1 
buffer (centrifuging as previously). The pellets was resuspended in 160 µl NE-1 
buffer, 1 µl of benzonase nuclease was added and incubated at room temperature for 
10 min. Subsequently, 240 µl NE-2 buffer was added to a 300 mM final NaCl 
concentration, vortexed and incubated 30 min on a rotating wheel at 4°C. After 
centrifugation at 16 000 g for 20 min at 4°C the supernatant was transferred to new 
tubes as a nuclear fraction. 
 
2.2.20 Reverse-transcription quantitative PCR 
 
The primers for gene expression analysis were designed in neighbouring exons of 
each gene, so the specific product of ~200 kb should be produced only from the 
cDNA, and possible contamination with genomic DNA would not give a product 
because of the presence of introns. Mouse brain cDNA used as a template in 
RT-qPCR was a gift from Pete Skene. Each reaction contained 10 µl 2x SensiMix 
SYBR & Fluorescein MasterMix (Bioline), 0.25 µM FWD primer, 0.25 µM REV 
primer, 5 µl of cDNA template and H2O to 20 µl. The reactions were performed 
according to the following programme: initial denaturation at 95 °C for 10 min, 45 
cycles of 95 °C for 10 s; 60 °C for 10 s 72 °C for 15 s (with an acquisition taken at 
the end of this step) in LightCycler 480 (Roche) and analysed in LightCyler480 
Software 1.5.0.  
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 Table 2.2.20 Primers for qPCR analysis of gene expression. 
Primer Sequence 5’-3’ 
Kpna3 FWD AGTTGAGTGCTGTGCAGGCAGC 
Kpna3 REV TGTTTCCCAAAGCCCACACCGC 
Kpna4 FWD CCACAAAGACCCACCACCACC 
Kpna4 REV TGGTGGCTGAGTAGCGGAACC 
Kpna6 FWD AGCCGCGATGGAGACCATGG 
Kpna6 REV CCGGAATTTCTGCGTGGTTGC 
Gapdh FWD TACCCCCAATGTGTCCGTCG 
Gapdh REV CCTGCTTCACCACCTTCTTG 
 




 of HeLa or NIH-3T3 cells per well were seeded on 24-well plates. In the 
initial experiments cells were co-transfected with JetPEI reagent with following 
amounts of plasmids: 1 µg GAL4 DBD-MeCP2 (C-terminal half, wild-type or 
R306C), 1 µg TK-Firefly (containing 5 GAL4 UAS sites) and 100 ng pRL-TK 
(control Renilla luciferase). We found that the use of limiting amounts of MeCP2 
was critical to reveal the failure of repression by RTT mutants. Therefore, the 
optimised amounts of plasmids used in all subsequent assays were: 
10 ng GAL4 DBD-MeCP2, 1 µg pEGFP-C1, 1 µg TK-Firefly, 100 ng pRL-TK. 
Where indicated, 50 ng/ml of TSA (Sigma) was added to the medium at the moment 
of transfection. Each combination of plasmids was repeated in 2 - 4 wells. 48 hours 
post-transfection the cells were harvested and reporter gene expression was 
quantified using the Dual-luciferase reporter assay system (Promega) and TD-20/20 
Luminometer. Transfection efficiencies were normalised by dividing the Firefly 
luciferase signal by Renilla luciferase levels. Fold repression of the Firefly luciferase 
reporter was calculated relative to a sample without MeCP2 or sample transfected 
with N-terminal half of MeCP2. The combined fold-repression was calculated by 
averaging fold repression of 2-6 biological replicates and the statistical significance 
of differences of repression by wild-type MeCP2 or mutated MeCP2 was assessed by 
unpaired two-sample Student’s t-test assuming unequal variances. 
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2.2.22 ES cell culture 
 
Mouse embryonic stem cells (section 2.1.4) were cultured in undifferentiated state in 
Glasgow MEM medium supplemented with 15% FBS, 1% sodium pyruvate, 
1% non-essential amino acids, 0.1% β-mercaptoethanol, 100 U/ml penicillin, 
100 µg/ml streptomycin and leukaemia inhibitory factor (LIF; gift from J. Guy) on 
gelatinised tissue culture plasticware. Cells were split by trypsinisation at 1:8 dilution 
every two days.  
2.2.23 Neuronal differentiation system 
 
The neuronal differentiation was performed as follows: 4 × 10
6
 ES cells were plated 
on 10 cm Petri dish and cultured in 15 ml of ES medium with 10% FBS and without 
LIF. The media was changed every 2 days and 5 µM retinoic acid was added after 4 
days. After 8 days the resulting embryoid bodies were treated with trypsin and cells 
were then resuspended in DMEM/F-12 medium with N2 supplement (Invitrogen) 
and passed through a 40 µm cell strainer (Falcon). 3 × 10
6
 cells were plated on 6 cm 
dishes coated with poly-DL-ornithine hydrobromide (Sigma) and laminin (Roche) as 
described in (Bibel et al., 2004). After 24 hours the medium was replaced with a 
50:50 mixture of N2 medium and Neurobasal medium with B27 supplement 
(Invitrogen). Every 3 days half of the medium was removed and replaced with 
Neurobasal/B27 medium. 6 days after plating cells were transfected for methylated 
luciferase assay or harvested for protein extraction. For immunocytochemistry the 
round 22 mm cover slips were put in the culture dishes. 6 days after plating the 
neuronal progenitors the cover slips were transferred to a 6-well plate and 
immunofluorescent staining was performed as in the method 2.2.16. 
 
2.2.24 Transfection of ES cell-derived neurons 
 
Test transfection of ES cell-derived neurons was performed in 24-well format to find 
the best gene delivery method. 1 µg of mCherry plasmid was transfected to each well 
containing 3 × 10
5 
neurons. Five transfection reagents were tested using two volumes 
of reagent per well as follows: JetPEI (Polyplus transfection): 2 µl and 4 µl; 
Lipofectamine Plus (Invitrogen): 2 µl and 4 µl, both with 1 µl Plus reagent; X-treme 
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gene HP (Roche): 1 µl and 3 µl, X-treme gene 9 (Roche): 3 µl and 6 µl; 1 M 
Ca3(PO4)2 : pH 7.0 and pH 7.1 (homemade), 6.2 µl; all according to the 
manufacturers’ protocols. The best transfection method was chosen by live cell 
imaging, assessing the number of cells fluorescing red in each well. 
 
2.2.25 Methylation of DNA 
 
Methylation of 50 µg pRL-SV40 plasmid (Promega) was performed in 500 µl total 
reaction volume, containing 20 units of M. SssI CpG methyltransferase (NEB),  50 µl 
buffer 2 (NEB) and 2.5 µl S-adenosylmethionine (NEB). After 3 hours incubation at 
37 °C, 2.5 µl of fresh S-adenosylmethionine was added and reactions were incubated 
for further 3 hours. As an unmethylated control the reactions were performed in the 
same way but without addition of the enzyme. The DNA was purified on PCR 
purification columns (Qiagen) and the efficiency of methylation was assessed by 
digestion of 200 ng DNA with methyl-sensitive restriction enzymes HpaII and 
HinP1I or methyl-insensitive enzyme MspI as a control for restriction reaction. The 
digestions were performed in 20 µl final volume with 1 µl of each enzyme and 2 µl 
of appropriate 10 × reaction buffer (NEB) for 2 hours at 37 °C. DNA was mixed with 
Orange G DNA loading buffer, separated on a 2% agarose gel. 
 
2.2.26 Methylated reporter assay in neurons 
 
The ES cell-derived neurons on 6 cm dishes were co-transfected with 1 µg of 
methylated or unmethylated pRL-SV40 plasmid, 1 µg pGL3 control plasmid 
(Promega) and 3 µg mCherry plasmid, using 15 µl X-treme gene 9 transfection 
reagent (Roche), according to the manufacturer’s protocol. 48 hours after 
transfection the cells were harvested by scraping in 300 µl passive lysis buffer 
(Promega) and the reporter genes activities were quantified by three separate 
measurements using the Dual-luciferase reporter assay system (Promega) and 
TD-20/20 Luminometer. Transfection efficiencies were normalised by dividing the 
Renilla luciferase signal by control Firefly luciferase levels. Fold repression in each 
genotype of neurons was calculated by dividing the normalised reporter gene activity 
in cells transfected with non-methylated plasmid by normalised activity of cells with 
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methylated plasmid. Average fold repression was calculated from five independent 
biological replicates of this experiment and the statistical significance of differences 
between wild-type and MeCP2-mutated cells was measured by unpaired two-sample 
Student’s t-test assuming equal variances. 
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 One of the strategies applied in order to decipher the function of a protein is 
to identify the proteins it interacts with. This has been done for MeCP2 using various 
approaches, techniques and conditions, however the reports do not agree with each 
other. The initial attempt to identify binding partners of MeCP2 was based on the 
finding that it is able to repress transcription. Investigation of interactions with 
plausible candidate co-repressors revealed that MeCP2 binds to Sin3A complex 
(Jones et al., 1998; Nan et al., 1998). The complex contains histone deacetylases 
HDAC1 and HDAC2, which can explain why MeCP2-mediated transcriptional 
repression was alleviated by treatment with TSA. The fact that the repression was 
only partially relieved by TSA suggested that MeCP2 is able to regulate transcription 
by a different mechanism (Yu et al., 2000), possibly involving histone 3 lysine 9 
methyltransferase (Fuks et al., 2003). A candidate protein driven search for other 
repressors binding to MeCP2 identified ample putative interactions: Ski, NCoR 
(Kokura et al., 2001); SMRT (Stancheva et al., 2003); CoREST, SUV39H1 (Lunyak 
et al., 2002); Brahma (Smarca2) (Harikrishnan et al., 2005, 2010); and cohesin 
subunits SMC1 and SMC3 (Kernohan et al., 2010). Also two transcription factors, 
TFIIB (Kaludov and Wolffe, 2000) and Sox2 (Szulwach et al., 2010) have been 
shown to bind to MeCP2 and possibly influence expression of other genes. Candidate 
approach revealed additional interactions of MeCP2 with proteins not directly 
involved in regulation of transcription: cyclin-dependent kinase-like 5 (CDKL5; 
Mari et al., 2005); DNA methyltransferase 1 (DNMT1; Kimura and Shiota, 2003); 
heterochromatin protein 1 (HP1; Agarwal et al., 2007); lamin B receptor (Guarda et 
al., 2009); and latency-associated nuclear antigen (LANA; Krithivas et al., 2004). 
However, the significance of these interactions in vivo has not been well established. 
 A different method of identifying proteins that possibly interact with MeCP2 
was applied by Forlani and co-workers. In order to bind each other, proteins must be 
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expressed at the same time and space. A bioinformatic search of published 
microarray data for proteins fulfilling these conditions with MeCP2, revealed 
potential candidates and the interaction with one of them, a transcriptional regulator 
yin yang 1 (YY1) was confirmed (Forlani et al., 2010). 
 Unbiased, non-candidate driven searches for proteins interacting with MeCP2 
have been performed only a few times. Young and co-workers over-expressed 
FLAG- and HA-tagged MeCP2 in HeLa cells and murine neuroblastoma cell line 
(Neuro2A) and subjected the co-immunoprecipitated material to mass spectrometry 
analysis (Young et al., 2005). Proteins were considered as specific binding partners 
of MeCP2 only when present in purifications with both tags from both cell lines. The 
authors did not publish the results of their search, but focused only on one identified 
protein, Y-box binding protein 1 (YB-1). Nevertheless, restricting the proteins 
interacting with mainly neuronal MeCP2 to the HeLa cell line raises a question about 
the physiological relevance of authors’ findings, especially when considered from the 
Rett syndrome point of view. 
 A more physiological approach was taken by the same laboratory when 
MeCP2 binding partners were co-immunoprecipitated with anti-MeCP2 antibody 
from wild-type mouse brains and compared to Mecp2-null control mice (Chahrour 
et al., 2008). Interestingly, none of the proteins reported before to bind to MeCP2 
were identified in this study. Notably low enrichment of MeCP2 by the antibody 
used could explain the small number of detected protein partners. Surprisingly, the 
first identified protein was a transcription factor CREB1, agreeing with authors’ 
hypothesis that MeCP2 is an activator of transcription. 
 A different attempt to identify proteins interacting with MeCP2 used the yeast 
two-hybrid screen method. Because full-length MeCP2 caused transcriptional 
repression in yeast, the N-terminal half of MeCP2 was used as a bait for human 
foetal brain library (Nan et al., 2007). The screen detected MeCP2 binding to 
α thalassemia/mental retardation syndrome X-linked protein (ATRX), a member of 
the chromatin remodelling protein family. The binding was confirmed by other 
methods (Nan et al., 2007) and by other laboratories (Kernohan et al., 2010). It was 
also reported to be disrupted by a mutation in MeCP2 that causes X-linked mental 
retardation in males, A140V. Additionally, the ATRX localisation to 
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heterochromatic foci was altered in the Mecp2 null cells (Nan et al., 2007). However, 
the Rett syndrome-causing mutations, even in the ATRX-interacting region did not 
affect the binding, putting in doubt the role of this interaction in RTT. 
 A yeast-two hybrid screen with the TRD domain of MeCP2 identified a 
homeodomain-interacting protein kinase 2 (HIPK2) that was shown to be able to 
phosphorylate MeCP2 (Bracaglia et al., 2009). However, the use of mouse embryo 
day 11 cDNA library in this study could mask other important interactions of 
MeCP2, given that it is expressed mainly in mature neurons. 
 MeCP2 has also been detected in screens for binding partners of other 
proteins. For example, it appeared on a list of interactors of PU.1 (Suzuki et al., 
2003) and formin-binding protein 11 (FBP11), a splicing factor containing the WW 
domain (Bedford et al., 1997). This allowed discovery of a WW-domain binding 
region on MeCP2 at its C-terminus, responsible for this interaction (Buschdorf and 
Strätling, 2004). Another splicing factor identified to bind to WW-binding region of 
MeCP2 was huntingtin-interacting protein C (HYPC). Both interactions were 
abolished by C-terminal truncation of MeCP2, suggesting a potential role in the Rett 
syndrome pathology (Buschdorf and Strätling, 2004). 
  
 Despite two decades of research, using different approaches and techniques, 
there is little consensus about what are the true interacting partners of MeCP2 
responsible for its function and its role in Rett syndrome pathology. Based on 
thorough biochemical analysis it has been reported that MeCP2 is in fact a monomer 
and does not stably associate with other proteins (Klose and Bird, 2004). However, 
that study used relatively high salt concentration to extract proteins from rat brain 
nuclei (400 mM NaCl) and could affect the weak interactions with partner proteins. 
 To date none of the published reports on interactions of MeCP2 described the 
effect of Rett syndrome mutations found frequently in the cluster at the end of TRD 
of MeCP2 (302-306). It is possible that these mutations disrupt general folding of the 
protein, affect its stability or prevent post-translational modifications that regulate its 
function. However, another possibility is that there are still some unidentified 
proteins interacting with MeCP2 and 302-306 mutations could disrupt their binding 
and in consequence cause RTT. Therefore, we decided to re-address the issue of 
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MeCP2 interacting partners, taking advantage of new molecular tools developed 
recently and perform an unbiased search for all of the proteins binding to the 
endogenous MeCP2 in mouse brains. 
 
 
3.2 Identification of MeCP2-interacting proteins by mass 
spectrometry 
 
 In order to identify proteins interacting with MeCP2 we used a knock-in 
reporter mouse model recently obtained in the laboratory, expressing MeCP2 tagged 
with GFP. The animals were generated by J. Guy and J. Selfridge by inserting a GFP 
tag at C-terminal end of the protein by homologous recombination of Mecp2 locus. 
As a result, the expression of MeCP2-GFP fusion protein is driven from the 
endogenous promoter of MeCP2 and levels of the protein should therefore be equal 
with the levels in wild-type mice. This notion was tested by extracting the nuclear 
proteins from brains of both animals and assessing the MeCP2 levels by Western 
blot. Wild-type MeCP2 and MeCP2-GFP were detected with comparable intensities 
demonstrating that the fused GFP tag does not affect the abundance of MeCP2 in the 
brain (Fig. 3.2A). There is, however, a risk that despite the equal levels of 
expression, the GFP tag can affect the function of a protein by altering its folding or 
disrupting its localisation due to increased size. The distribution of MeCP2-GFP has 
been assessed extensively by immunohistochemistry and confocal microscopy and 
was indistinguishable from the localisation of untagged MeCP2 (H. Cheval and 
J. Guy, personal communication; also see later chapters). The best indication that 
MeCP2-GFP is fully functional is that the transgenic mice are fertile, live till 
adulthood and their phenotypes appear to be indistinguishable from wild-type 
animals (J. Selfridge, unpublished). Moreover, an almost identical mouse model 
created by another group showed no detectable abnormalities and the expression 
profile and cellular localisation of MeCP2-GFP were alike the endogenous, untagged 
protein (Schmid et al., 2008). All of these observations prove that MeCP2-GFP 
mouse is a useful and valuable tool to study the function and characteristics of 
MeCP2 in vivo. 
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 In order to identify binding partners of MeCP2, the nuclear proteins were 
extracted from brains of wild-type and MeCP2-GFP mice under the physiological 
salt concentration (150 mM NaCl). Such an ionic strength is not able to liberate 
MeCP2 bound to chromatin (Meehan et al., 1992), therefore the extracts were treated 
with benzonase nuclease. Both extracts contained comparable amounts of proteins 
and their composition was similar as assessed by a silver stained SDS-PAGE gel 
(Fig. 3.2B, input lanes). Subsequently, the proteins were subjected to 
immunoprecipitation (IP) with an anti-GFP peptide derived from llama (Rothbauer 
et al., 2008). The advantage of using this short binding peptide to pull-down the 
GFP-tagged protein is its small size (~13 kDa), which does not influence the mass 
spectrometric identification of proteins. Therefore, the contaminations from 
immunoglobulin heavy and light chains found in a typical antibody 
immunoprecipitation are avoided. Successful pull-down of proteins bound to 
MeCP2-GFP and almost no proteins precipitated from wild-type controls were 
verified on a silver-stained gel (Fig. 3.2B, IP lanes).  
 
Figure 3.2. Immunoprecipitation of brain proteins from MeCP2-GFP mice. (A) Western 
blot showing comparable levels of MeCP2 in brain nuclei from wild-type (wt-Me2) and 
MeCP2-GFP knock-in mice (GFP-Me2). Histone H2B was used as a gel loading control. 
M – protein mass marker [kDa]. (B) Brain nuclear proteins were immunoprecipitated from 
wild-type mice or mice expressing MeCP2-GFP fusion protein with the anti-GFP peptide.  
in – 0.25% input, IP – 10% of immunoprecipitated material. The SDS-PAGE gel was 
silver-stained to visualise the proteins. 
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 The immunoprecipitated proteins were subjected to identification by mass 
spectrometry (performed by F. de Lima Alves and J. Rappsilber). In total, 261 
proteins were identified in both immunoprecipitations (all proteins are listed in 
Appendix Table 1). Amongst them 163 were unique for MeCP2-GFP IP, 63 were 
present in both purifications and 35 were found only in the wild-type brain IP. The 
high number of proteins identified in control IP is surprising, but mass spectrometry 
is such a sensitive method that even a small technical variation in IP efficiency or 
wash stringency could lead to a dramatic change in protein composition detected in 
each sample. Therefore, in order to produce a comprehensive list of plausible 
proteins interacting specifically with MeCP2 the results were compared to a 
biological replicate of the same experiment (performed by M. Lyst). Only the 
proteins represented by at least 2 peptides in both purifications from MeCP2-GFP 
brains, but not present in any of the wild-type MeCP2 control IPs, were considered 
as candidate specific interactors of MeCP2. Such a filtered list contains 40 proteins 
(Appendix Table 2). The top 25 of putative proteins associated with MeCP2 arranged 
by a number of identifying peptides are listed in the Table 3.2. 
 Surprisingly, the obtained list contains only two proteins that have been 
reported previously to interact with MeCP2, namely NCoR1 (Kokura et al., 2001) 
and SMRT (Stancheva et al., 2003). The other proteins suspected to be interacting 
partners of MeCP2 (see section 3.1) were not present in our purification. Sin3A, 
considered as one of the main co-repressors associated with MeCP2 and thought to 
be responsible for its function in suppressing transcription (Jones et al., 1998; Nan et 
al., 1998) was represented only by one peptide in my purification and therefore was 
excluded from the list (see Appendix). Mass spectrometry analysis of the biological 
replicate of this experiment detected 3 peptides of Sin3A, suggesting that this 
interaction is not the most prominent, when compared to the proteins from the top of 
the list. Other components of the Sin3A co-repressor complex were also detected by 
only few peptides (HDAC1) or were present in one of the wild-type control 
purifications (HDAC2). Although our mass spectrometry analysis was not 
quantitative and many factors could influence the number of recovered peptides 
(such as the efficiency of in-gel digestion, extraction, and peptide separation), the 
nature of the association of MeCP2 with Sin3A was reported before as weak and 
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unstable (Klose and Bird, 2004), what was additionally confirmed by 
immunoprecipitation from MeCP2-GFP brains followed by Western blot analysis 
(M. Lyst, personal communication).  
 
Table 3.2. Top 25 proteins identified in GFP immunoprecipitations from MeCP2-GFP 
brains. Proteins are arranged according to the number of identifying peptides in my 
experiment (Exp. #1). Column labelled ‘Exp. #2’ contains number of peptides assigned to 
each protein in the biological replicate of the experiment. Proteins highlighted in green 
belong to one co-repressor complex and were investigated further in the laboratory. 
Interactions of MeCP2 with proteins highlighted in yellow were confirmed and followed-up 
in this study. All of the proteins identified by mass spectrometry and a complete filtered list 









gene   Protein name 
52 57  Mecp2  Methyl-CpG-binding protein 2, Isoform B 
27 5  Ncor2  Nuclear receptor co-repressor 2 (SMRT) 
20 9  Ncor1  Nuclear receptor co-repressor 1 
17 13  Kpna4  Importin subunit α4 (KPNA4) 
16 12  Tbl1xr1  Transducin β-like 1 X-related protein 1 (TBLR1) 
12 15  Eif4a3  Eukaryotic initiation factor 4A-III 
11 7  Cdc5l  Cell division cycle 5-related protein 
11 19  Prpf19  Pre-mRNA-processing factor 19, Isoform 1 
10 7  Kpna3  Importin subunit α3 (KPNA3) 
8 3  Camk2a  Calcium/calmodulin-dependent protein kinase II α 
8 2  Ncoa5  Nuclear receptor coactivator 5 
8 2  Raly  RNA-binding protein Raly, Isoform 2 
7 10  Rbbp4  Retinoblastoma binding protein Rbbp4 
7 10  Tra2b  Transformer-2 protein homolog β, Isoform 1 
7 7  Sfrs7  Splicing factor, arginine/serine-rich 7, Isoform 2 
7 6  Snrnp70  U1 small nuclear ribonucleoprotein 70 kDa, Isoform 1 
7 5  Hdac3  Histone deacetylase 3 
7 5  Tbl1x  Transducin β-like 1 X-linked (TBL1) 
6 17  Smarcc2  SWI/SNF complex subunit Smarcc2, Isoform 2 (BAF170) 
5 2  Snw1  SNW domain-containing protein 1 
5 2  Wbp11  WW domain-binding protein 11 
4 9  Csnk2a1  Casein kinase II subunit α (CK2α) 
4 9  Wdr18  WD repeat-containing protein 18 
4 5  Magoh-rs1  Mago-nashi homolog 
4 5  Smu1  WD40 repeat-containing protein SMU1, Isoform 1 
4 4  Fyttd1  Forty-two-three domain-containing protein 1, Isoform 1 
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 Some of the newly identified proteins drew our attention. Interestingly, five 
out of top sixteen putative MeCP2-interacting partners (SMRT, NCoR1, TBLR1, 
TBL1 and HDAC3; marked green in Table 3.2) are members of NCoR/SMRT 
co-repressor complex. These interactions may have important consequences for the 
MeCP2 function as a transcriptional repressor and were investigated further (see 
Chapter 5). Two other mouse proteins at the top of the list, importin subunit α3 (also 
known as karyopherin α3; KPNA3) and importin subunit α4 (karyopherin α4; 
KPNA4) belong to the importin α family and interactions with them may explain 
how MeCP2 is transported to the nucleus (see Chapter 4). The final two candidate 
proteins picked for subsequent analysis, calcium/calmodulin-dependent protein 
kinase II α (CaMKIIα) and casein kinase 2α (CK2α) are protein kinases and could 
possibly regulate the function of MeCP2 through phosphorylation. 
 
3.3 Verification of mass spectrometry data by Western blotting 
 
 Mass spectrometry is a very sensitive technique and the results have to be 
interpreted cautiously to avoid false positives. Therefore, it is important to verify 
every interaction by means of other methods. To validate the selected subset of 
discovered binding partners of MeCP2, proteins were extracted from new MeCP2-
GFP mouse brain nuclei and immunoprecipitated with anti-GFP antibody, as 
previously. As a control, the brain nuclear extracts from mouse expressing H2B-GFP 
fusion protein were used (Jiang et al., 2008). Resulting IP samples and their 
corresponding inputs were analysed by Western blot, probing with antibodies raised 
against each of the tested putative MeCP2-interacting protein.  
 
3.3.1 Validation of interactions between MeCP2 and importins 
 
 In order to control the feasibility of the whole procedure the Western blot 
membranes were firstly incubated with anti-MeCP2 antibody. MeCP2 and its 
GFP-tagged version were detected in the inputs from brains of both genotypes 
confirming that they were expressed at comparable levels (Fig. 3.3.1A and B). The 
bands corresponding to MeCP2 were not detected in the immunoprecipitation lanes 
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of H2B-GFP mice, but as expected, they were present only in the IP lanes from the 
MeCP2-GFP samples (Fig. 3.3.1A and B). These results proved the successful 
immunoprecipitation of MeCP2-GFP with anti-GFP binding peptide and the validity 
of the method. 
 Probing the same Western blot membranes with antibodies raised against 
importins α detected KPNA3 and KPNA4 in the input lanes from both mice 
genotypes, but only in the MeCP2-GFP IP lanes, not in the H2B-GFP IP (Fig. 3.3.1C 
and D). The co-immunoprecipitation of KPNA3 and KPNA4 with MeCP2 suggests 
that the importins identified by mass spectrometry are indeed specific interacting 
partners of MeCP2. Both interactions seemed very strong as quantitative 
densitometric analysis of IP to input ratios revealed that approximately 40% of all 
KPNA3 was co-immunoprecipitated with MeCP2 (Fig. 3.3.1C). The binding of 
KPNA4 to MeCP2 was even stronger, reaching up to 93% of total protein 





Figure 3.3.1. Verification of MeCP2 interaction with importins. Brain nuclear proteins 
were immunoprecipitated with GFP binding peptide (GFP-IP) from mice expressing 
H2B-GFP or MeCP2-GFP fusion proteins and analysed by Western blot. Percentage 
numbers indicate the fraction of each sample loaded on the gel. The figure shows 
representative pictures of two independent experiments. (A and B) Detection of MeCP2 and 
MeCP2-GFP by anti-MeCP2 antibody. (C) Probing the same Western blot membrane as A 
for KPNA3. (D) Probing the same Western blot membrane as B for KPNA4.  
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3.3.2 Validation of interactions between MeCP2 and kinases 
 
 Other proteins supposedly binding to MeCP2 and selected for validation were 
CK2α and CaMKIIα protein kinases. To verify the data obtained with mass 
spectrometry, immunoprecipitations were performed as previously from new brain 
nuclear extracts of MeCP2-GFP and H2B-GFP mice. Subsequent Western blot 
analysis revealed that both kinases were co-immunoprecipitated only from 
MeCP2-GFP brains, confirming the interactions between MeCP2 and CK2α and 
CaMKIIα (Fig. 3.3.2A and B, respectively). Quantification of the proteins detected in 
the IP fractions and in the inputs showed that MeCP2 binding to kinases was much 
weaker than in the case of importins. Because of the low signal and high background 
from the antibodies used, the ratios could be only approximately estimated and 
~0.32% of all CK2α was bound by MeCP2 (Fig. 3.3.2A) and just ~0.22% of all 





Figure 3.3.2. Verification of interactions of MeCP2 with kinases. Brain nuclear proteins 
were immunoprecipitated with GFP binding peptide from mice expressing H2B-GFP or 
MeCP2-GFP fusion proteins and analysed by Western blot probing for (A) casein kinase 2α 
(CK2α) or (B) calcium/calmodulin-dependent protein kinase II α (CaMKIIα). These two 





3.3.3 Validation of other interactions of MeCP2 
 
 The interactions between MeCP2 and identified components of NCoR/SMRT 
co-repressor complex (NCoR1, SMRT, HDAC3 and TBLR1) were confirmed in a 
similar fashion in the laboratory (M. Lyst, personal communication). The interactions 
of MeCP2 with these proteins also appeared to be weaker than with importins. 
 Some other proteins identified by mass spectrometry (WBP11, MAP1B) were 
preliminarily tested for interaction with MeCP2, but could not be detected by 
Western blot analysis in the immunoprecipitates (data not shown). This may indicate 
either low sensitivity of the antibodies used or the false positive hits in the mass 
spectrometry analysis. 
 
3.4 Mapping the confirmed interactions on the MeCP2 sequence 
 
3.4.1 Generation of MeCP2 truncation mutants 
 
 The next step in analysis of interaction between two proteins is mapping the 
region of their binding. This can be achieved by expressing fragments of the tested 
proteins and assessing their binding. A series of FLAG-tagged truncation mutants of 
MeCP2, spanning its different regions and domains, was designed and produced. To 
allow the assessment of the potential influence of Rett syndrome mutations on the 
identified interactions, the MeCP2 constructs were designed with respect to the 
clusters of RTT mutations (Fig. 3.4.1-1). Each of the produced expression construct 
was verified by DNA sequencing. 
 
 The constructed MeCP2 fragments were then expressed in HeLa cells. 
Transfection efficiency was estimated by GFP signal in cells transfected with a 
plasmid expressing EGFP protein and was between 60% and 70% (Fig. 3.4.1-2; 
analysis of four independent transfections). Subsequent immunoprecipitations with 
anti-FLAG beads were followed by Western blot analysis to assess which fragments 
of MeCP2 bind the tested protein of interest. Each membrane was re-probed with 





Figure 3.4.1-1. Design and production of MeCP2 truncation mutants. The truncation 
mutants of MeCP2 were amplified by PCR from MeCP2_e2 human cDNA and cloned in 
frame into a vector expressing 3×FLAG tag. A schematic drawing of just a few of the 
produced constructs used in this study. The numbers correspond to amino acid positions in 
MeCP2_e2. Mutations causing Rett syndrome are depicted as vertical lines above MeCP2. 




Figure 3.4.1-2. HeLa cells transfection efficiency for immunoprecipitations. HeLa cells 
were transfected with EGFP-C1 plasmid and photographed live under the fluorescent 
microscope. Green fluorescent cells were counted and their number divided by the total 
number of cells counted using the phase contrast miscroscopy. Representative pictures of 
four independent transfections. Scale bar: 50 µm. 
MeCP2_e2 
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3.4.2 Mapping the interactions of MeCP2 with importins α and subunits 
of NCoR/SMRT co-repressor complex 
 
 Using the methodology described above the interactions between MeCP2 and 
importins α (KPNA3 and KPNA4) were extensively mapped to a specific region. 
The strategy, design of new MeCP2 truncations, results and further detailed analysis 
of the role of these interactions are described in the Chapter 4.  
 Identification of the region of MeCP2 interacting with the subunits of 
NCoR/SMRT co-repressor complex was performed in a similar fashion by M. Lyst 
and the obtained results and their consequences follow in the Chapter 5.  
 
3.4.3 Mapping the interaction of MeCP2 with casein kinase 2α 
 
 Casein kinase 2 is a promiscuous protein kinase expressed across a range of 
eukaryotic tissues and cells, including HeLa cell line (Edelman et al., 1987; Yu et al., 
1991). Therefore, binding of the endogenous protein to over-expressed fragments of 
MeCP2 could be tested. Immunoprecipitation of FLAG-tagged full length MeCP2 
and subsequent probing with anti-CK2α antibody confirmed that these proteins 
interact with each other in HeLa cells (Fig. 3.4.3, top). From two bands detected in 
all of the input fractions only the bottom one was immunoprecipitated. Our 
prediction is that the top band is a protein in the HeLa extract detected unspecifically 
by the antibody (it migrates at higher size than predicted size of CK2α) but is has not 
been tested. Surprisingly, analysis of interactions of truncated versions of MeCP2 
with the kinase revealed that each of the tested MeCP2 fragments bound CK2α. The 
strongest signal was detected in co-immunoprecipitations with full-length MeCP2 
and its non-overlapping fragments, 1-204 and 308-486 (Fig. 3.4.3, top). The other 
tested truncations of MeCP2 (143-309, 202-486 and 269-486) also weakly interacted 
with the kinase, suggesting that the whole length of MeCP2 can act as a CK2α 
binding surface. However, there was also a very weak CK2α band detected in a 
control IP lane, where immunoprecipitation was performed with the anti-FLAG 
beads in HeLa cells transfected with EGFP plasmid only (Fig. 3.4.3, top). This 
implies that at least some of the CK2α binding detected in all IP lanes may be due to 
the unspecific interactions with anti-FLAG beads.  
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Figure 3.4.3. MeCP2 interacts with CK2α at the whole length of the protein. HeLa cells 
were transfected with FLAG-MeCP2 truncation mutants or GFP-expressing plasmid 
(control). Inputs (in) and FLAG-immunoprecipitations (IP) were resolved on SDS-PAGE, 
Western blotted and probed for CK2α. Re-probing of the same membrane with anti-FLAG 
antibody. This experiment was performed once by honours student S. Young under my 
supervision. 
 
 All of the tested MeCP2 truncations were expressed and immunoprecipitated 
at similar levels, as assessed by re-probing the Western blot membrane with 
anti-FLAG antibody (Fig. 3.4.3, bottom; asterisks).  
 
3.4.4 Mapping the interaction of MeCP2 with CaMKIIα 
 
 Another kinase found in this study to interact with MeCP2 was 
calcium/calmodulin-dependent protein kinase II α. Western blot analysis revealed 
that it is not expressed in HeLa cells (data not shown). Therefore, to be able to 
perform the mapping analysis it had to be co-expressed with MeCP2 truncations. 
CamkIIα mouse gene was amplified from mouse brain cDNA, purified and cloned 
into a GFP-expressing plasmid to produce a fusion protein, which could be then 
easily tracked in cells. The N-terminus of CaMKIIα contains a conserved domain 
responsible for binding of kinase substrates, and we hypothesised that it could be a 
potential interaction surface for MeCP2. The C-terminus of CaMKIIα consists of a 
less conserved self-association domain (Hoelz et al., 2003; Chao et al., 2011). 
Therefore, to avoid the potential disruption of CaMKIIα binding surface, the GFP tag 
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was placed at the C-terminus of the protein, where the fused protein was less likely 
to affect the interaction with MeCP2. 
 The co-expression of CaMKIIα-GFP and full length FLAG-MeCP2 in HeLa 
cells, subsequent FLAG-immunoprecipitations and Western blot analysis revealed 
that these two recombinant proteins bind to each other (Fig. 3.4.4A). Interestingly, a 
band migrating higher than the predicted molecular weight of CaMKIIα-GFP was 
detected in the input fractions and was strongly enriched in the FLAG-MeCP2 IP 
(Fig. 3.4.4A). It is possible that this band is a post-translationally modified version of 
CaMKIIα and it is preferred by MeCP2, however the character of this band has not 
been determined. The interaction was also detected between CaMKIIα-GFP and 
MeCP2 1-204 fragment, and, to a lower extent, with the 143-309 fragment. The N-
terminal truncations of MeCP2 (269-486 and 308-486) did not co-immunoprecipitate 
CaMKIIα. The FLAG-IP procedure in control cells, expressing CaMKIIα-GFP, but 





Figure 3.4.4. MeCP2 interacts with over-expressed CaMKIIα at 143-204. HeLa cells 
were co-transfected with plasmids expressing CaMKIIα-GFP and FLAG-MeCP2 truncation 
mutants or only CaMKIIα-GFP (control). (A) Inputs (in) and FLAG-immunoprecipitations 
(IP) were resolved on SDS-PAGE gel, Western blotted and probed for CaMKIIα. These 
experiments were performed twice with help of honours student S. Young under my 
supervision. (B) Mapping of the MeCP2-CaMKIIα interaction on the MeCP2 sequence with 
a minimal interacting region marked with blue dashed box. 
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 Summarizing, it seems that CaMKIIα interacts with the N-terminal part of 
MeCP2, within a minimal region mapped between amino acids 143-204, and 
probably some additional binding sites between 1-143 (Fig. 3.4.4B). Interestingly, 
this region overlaps with the MBD, a known hotspot for Rett syndrome causing 
mutations. The effect of these mutations on the ability of MeCP2 to interact with 
CaMKIIα should be tested in the future to reveal if there is any correlation between 






 Immunoprecipitation of MeCP2 from mouse brains and identification of 
co-immunoprecipitated proteins by mass spectrometry performed by us in this study 
provided a new list of potential protein partners of MeCP2. Out of 40 identified 
proteins, only two of them have been reported previously. The reason for the 
discrepancies between ours and published results may lie in the technical approach 
taken by each study. Some of the previously performed purifications of MeCP2 used 
high salt concentrations (300-400 mM NaCl) what could be too stringent for most of 
the interactions (Lunyak et al., 2002; Klose and Bird, 2004; Agarwal et al., 2007; 
Gonzales et al., 2012). Other studies suffered from weak affinity of anti-MeCP2 
antibody (Chahrour et al., 2008). Thanks to the recently developed new molecular 
tools we were able to perform efficient co-immunoprecipitations under the 
physiological salt conditions. We were aware that lower stringency of protein 
extraction and washes is burdened with a risk of retaining some weak unspecific 
interactions, which could be detected by sensitive mass spectrometry. However, 
analysis of two independent protein purifications allowed us to form a relatively 
short list of plausible MeCP2 interactors. Eight out of nine proteins chosen for 
verification by Western blotting confirmed the mass spectrometry results. Other 
evidence for the appropriateness of our approach is that some of the repeatedly 
confirmed interactions of MeCP2 present in our purifications are abolished at 
300 mM NaCl (M. Lyst, personal communication).  
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 The fact that some of the interactions reported before were not found under 
our conditions may indicate that they are not the major partners of MeCP2 and were 
detected only because of the candidate approach or as artefacts. An example of 
Sin3A is the best illustration of the former. As MeCP2 was reported to be able to 
repress transcription a quest for finding the repressor interacting with it was taken by 
many laboratories. Sin3A, an HDAC-containing co-repressor complex was one of 
the plausible candidates and indeed it was co-immunoprecipitated with MeCP2 
(Jones et al., 1998; Nan et al., 1998). Although the biochemical analysis showed that 
this interaction is weak and not stable (Klose and Bird, 2004) it was considered to be 
the repressor responsible for the main function MeCP2. Also in our study the binding 
of Sin3A and the subunits of the co-repressor, HDAC1 and HDAC2 to MeCP2 was 
weak (based on number of identifying peptides as well as Western blot analysis 
performed by M. Lyst). However, we have identified most of the components of 
another co-repressor complex, NCoR/SMRT. The abundance of identified peptides 
of each of the protein of the complex in our both co-immunoprecipitations was much 
higher than for Sin3A complex. Moreover, the candidate approach studies also 
revealed the interactions between MeCP2 and NCoR1 and SMRT (Kokura et al., 
2001; Stancheva et al., 2003). As the function of both Sin3A and NCoR/SMRT 
complexes in terms of transcriptional repression is similar, our data raises possibility 
that NCoR/SMRT can be the major co-repressor binding to MeCP2 and contributing 
to the transcriptional repression function of MeCP2 more than Sin3A. This notion 
has been addressed and is described in Chapter 5. 
 Interestingly, one of the core components of NCoR/SMRT co-repressor 
complex, G protein pathway suppressor 2 (GPS2), was not identified in any of our 
mass spectrometry screens. In addition, Western blot analysis failed to detect GPS2 
in GFP immunoprecipitations from mouse brains expressing MeCP2-GFP (M. Lyst, 
personal communication). It has been shown that GPS2 interacts with both TBL1 and 
SMRT (Oberoi et al., 2011), therefore it is possible that MeCP2 is competing for its 
binding sites and these proteins are mutually exclusive in the complex. Another 
possibility is that due to its small size (36.6 kDa) GPS2 was missed in mass 
spectrometry identification and the antibodies used for Western blot were not 
sensitive enough to detect the indirect interaction. This issue remains unanswered at 
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the moment, but should be addressed in the future with additional antibodies or in 
vitro binding assays. 
 Another explanation for the discrepancies between the published interactions 
of MeCP2 and the data obtained in our purifications may be that some of the 
interactions may be activity-dependent. Since the phosphorylation of MeCP2 has 
been shown to be regulated by neuronal activity (Zhou et al., 2006; Tao et al., 2009), 
it is possible that some of the interactions with MeCP2 may be disrupted and others 
transiently present only upon neuronal activation. The preference of some of the 
candidate protein partners of MeCP2 to bind it when phosphorylated was recently 
reported (Gonzales et al., 2012). The unbiased investigation of the composition of 
proteins co-immunoprecipitating with MeCP2 upon seizure induction in mice would 
be an interesting set of experiments shedding more light onto this issue. 
 
 Amongst the proteins identified by us as interacting with MeCP2 there are 
also other candidates of potential interest. For example, retinoblastoma binding 
protein 4 (RBBP4 also known as RbAp48) is a histone binding protein that can bring 
histone substrates to the complexes involved in chromatin remodelling or histone 
deacetylation (Nicolas et al., 2000). It has been found to be associated with NuRD 
and Sin3 co-repressor complexes (Sun et al., 2007), as well as with nucleosome 
remodelling factor complex (NURF; Barak et al., 2003). Another protein implicated 
in chromatin remodelling and putatively interacting with MeCP2 is chromodomain 
helicase DNA binding protein 4 (CHD4). It was additionally suggested to be 
involved in histone deacetylation (Schmidt and Schreiber, 1999). A different protein 
putatively binding to MeCP2 and being a part of SWI/SNF chromatin remodelling 
complex is a member 2 of subfamily C of SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin (SMARCC2, also known as BAF170). A protein 
belonging to the same complex (SMARCA2, also known as Brahma) has been 
identified to bind to MeCP2 before (Harikrishnan et al., 2005, 2010). Although it was 
not detected in our present purifications and the validity of its interaction with 
MeCP2 was questioned previously (Harikrishnan et al., 2006; Hu et al., 2006), the 
fact that yet another component of the complex seems to be co-immunoprecipitated 
with MeCP2 suggests that this elusive interaction, may in fact be real. The 
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importance of these findings remains to be determined. All of the proteins mentioned 
above can contribute to the role of MeCP2 as transcriptional repressor, and the 
character and significance of the interactions between them should be investigated in 
the future. 
 
 We have also confirmed and investigated further the interactions of MeCP2 
with importin α family proteins, KPNA3 and KPNA4. The quantification of detected 
binding revealed that these interactions are very strong, with 40% of KPNA3 and 
more than 90% of KPNA4 molecules bound by MeCP2 in brains. These values seem 
to be unbelievable high and possibly do not reflect the strength of a real in vivo 
interaction, but may at least partially be due to the high affinity of importins to the 
exposed NLS of MeCP2 in the homogenised nuclei. However, even if the real 
interactions are weaker than presented here, they are still much stronger than of the 
other analysed interactions, suggesting their significance. The functionality, 
consequences and the relationship between MeCP2 and KPNA3 and KPNA4 are 
described in Chapter 4. 
 
 The interactions of MeCP2 with subunits α of two serine/threonine protein 
kinases identified by mass spectrometry were confirmed by us using another method 
and mapped on the MeCP2 sequence. Both CK2 and CaMKII are abundant in 
neurons and have been implicated in regulation of synaptic plasticity, neurite 
extension and memory formation (Lieberman and Mody, 1999; Yamauchi, 2005; 
Lucchesi et al., 2011).  
 According to the preliminary data CK2α binds to the whole length of MeCP2. 
It is possible that CK2 has multiple binding sites on MeCP2, similar to the reported 
interaction of MeCP2 with for example for Sin3A (Nan et al., 1998). Another 
explanation is that the detected interaction is indirect and mediated by other proteins 
binding to different regions of MeCP2. Given a broad range of protein substrates of 
CK2 (Pinna, 2002; Meggio and Pinna, 2003) it is a hypothesis, that should be 
formally tested. The role of CaMKII in activity-dependent phosphorylation of serine 
421 of MeCP2 has been reported before (Zhou et al., 2006), but it was later 
suggested that it is rather mediated by another kinase, CaMKIV (Tao et al., 2009). 
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Notably, the interaction between MeCP2 and these proteins in vivo has never been 
demonstrated and it could be that they act indirectly in a cascade of kinases. Two 
kinases reported to interact with MeCP2 and mediate its phosphorylation, CDKL5 
(Mari et al., 2005) and HIPK2 (Bracaglia et al., 2009) have not been detected in our 
purifications. However, our discovery brings CaMKII kinase back in the spotlight as 
a potential regulator of MeCP2 function. The identified region of interaction (143-
204, with possible additional binding sites in the N-terminus of MeCP2) contains 
threonine 148 and serine 149, identified as phosphorylated residues of MeCP2 (Tao 
et al., 2009; Gonzales et al., 2012). It is also in proximity to other reported sites of 
MeCP2 phosphorylation: serines 80, 164 and 229. Although the most studied 
phosphorylated serine 421 lies further away from the putative CaMKII binding 
region, the very complex supramolecular organisation of the kinase, consisting of 14 
subunits, may allow it to interact in a distance from the docking site (Hoelz et al., 
2003). Interestingly, the putative CaMKII interacting region overlaps with the MBD 
domain, where numerous Rett syndrome causing mutations are found, including the 
most frequent, T158M. The effect of these mutations on the ability of MeCP2 to bind 
the kinase should be investigated and may give some evidence on the aetiology of 
RTT. 
 
 One of the alleged functions suggested for MeCP2 is transcriptional 
activation (Yasui et al., 2007; Chahrour et al., 2008; Ben-Shachar et al., 2009). The 
putative protein postulated to be involved in this process, a transcription factor 
CREB1, has not been identified in our co-immunoprecipitations. However, the mass 
spectrometry list of MeCP2 interactors contains other proteins that may potentially 
act as activators of transcription. SNW domain-containing protein 1 (SNW1) is able 
to activate vitamin D receptor and retinoic acid receptor (Baudino et al., 1998; Kang 
et al., 2010). Nuclear receptor co-activator 5 (NCoA5) also known as co-activator 
independent of AF-2 function (CIA) binds and activates estrogen receptors and some 
orphan nuclear receptors (Sauvé et al., 2001). Interestingly, both proteins can also act 
as transcriptional repressors (Sauvé et al., 2001; Leong et al., 2004). Therefore, the 
role of the interaction of MeCP2 with these proteins and their involvement in the 
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reputed MeCP2 function as transcriptional activation is difficult to predict without 
further studies. 
 
 A number of proteins identified by us seem to be involved in regulation of 
pre-mRNA splicing. MeCP2 has been shown to affect the splicing profiles of various 
genes (Young et al., 2005). Although the protein YB-1 suggested in that study to 
mediate the role of MeCP2 in splicing was not detected in our purifications, it could 
be that the other binding partners of MeCP2 can serve the same purpose. The 
proteins involved in splicing and reported to interact with the putative WW-domain 
binding region on MeCP2 (FBP11 and HYPC; Bedford et al., 1997; Buschdorf and 
Strätling, 2004) were also absent from our list. However, we identified several 
possible candidates, such as two subunits of transformer-2 protein homolog, 
α (TRA2A) and β (TRA2B). Both proteins are factors promoting alternative splicing 
(Tacke et al., 1998; Sakashita et al., 2004). Another protein identified by us with a 
potential function in mRNA splicing is WW domain-binding protein 11 (WBP11), 
also known as splicing factor that interacts with PQBP-1 and PP1 (SIPP1) (Llorian et 
al., 2004; Tapia et al., 2010). Although the preliminary test by Western blotting did 
not confirm its interaction with MeCP2, it has to be confirmed with additional 
antibodies. Also, an intron-binding protein aquarius (Aqr); eukaryotic initiation 
factor 4A-III (Eif4a3); Pinnin (Pnn); isoform 1 of the pre-mRNA-processing factor 
19 (Prpf19) and isoform 2 of RNA-binding protein Raly were on the list of MeCP2 
interacting proteins and are implicated to be involved in splicing. The information 
about all of the proteins mentioned above were retrieved from the GeneCards 
database (www.genecards.org; Rebhan et al., 1997, 1998).  
 
 The results presented in this chapter provide a solid foundation for future 
research. The already confirmed interactions should be followed and investigated 
further. One of the first steps to additionally validate the importance of the detected 
interactions should be immunoprecipitation from wild-type brains performed with an 
anti-MeCP2 antibody in order to pull-down the endogenous MeCP2. If the 
investigated protein partner is co-immunoprecipitated in such experiment, regardless 
of the GFP-tag on MeCP2, it would reinforce the significance of the binding. Further 
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evidence would come from reciprocal IP experiments, when the immunoprecipitation 
with antibody against the tested protein should co-precipitate MeCP2 if the 
interaction is genuine. However, these types of experiments depend largely on the 
efficiency and specificity of used antibodies and on the abundance of tested proteins. 
One way to circumvent these problems is to over-express the tagged versions of 
investigated proteins and use specific antibodies raised against the tag. Given that the 
CamkIIα gene has already been successfully cloned by us as a GFP-fusion protein, 
the reverse IP (with anti-GFP antibody and probing for MeCP2 in the pull-down) can 
be carried out in the near future. 
 It is also important to remember that the detected interactions with proteins 
that are a part of larger complexes can be indirect. To find out which proteins are 
bound directly to MeCP2, the in vitro binding assays with purified recombinant 
components of the complex should be performed. 
 
 The whole list of new protein partners of MeCP2 can be studied further in 
detail in order to assign new functions or new proteins involved in the already 
postulated roles of MeCP2. To identify which of them are important for Rett 
syndrome each interaction should be tested for its disruption by RTT causing 
mutations in MeCP2. 
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 The eukaryotic nucleus is separated from the cytoplasm by means of a 
nuclear envelope. This tight lipid structure is inlaid with nuclear pore complexes, 
which allow small water-soluble molecules to diffuse freely in and out of the 
nucleus. It is generally considered that proteins larger than 9 nm diameter 
(corresponding to a molecular weight of 45-60 kDa) cannot passively cross the 
nuclear membrane (Paine et al., 1975; Nigg, 1997; Weis, 2003). However, there are 
reports showing that, depending on the protein, even macromolecules of size up to 
110 kDa can diffuse to the nucleus (Wang and Brattain, 2007). Nonetheless, to 
facilitate fast and reliable nuclear import of large proteins, sometimes against the 
concentration gradient, active transport systems have evolved. Canonical facilitated 
nuclear import relies on the presence of nuclear localisation signal (NLS) on the 
cargo protein. A specialized class of proteins called importins α is able to recognise 
and bind to these sequences. Upon binding to the NLS, importin α forms a 
heterodimer with importin β, which docks the whole complex to the nuclear pore and 
translocates to the nucleus (reviewed in: Lange et al., 2007). Inside the nucleus the 
complex is disassembled upon binding of RanGTP, Nup50 and CAS (cellular 
apoptosis susceptibility protein), cargo protein is released and importins with CAS 
and RanGTP are recycled back to the cytoplasm (Kutay et al., 1997; Lindsay et al., 
2002). GTP hydrolysis in Ran, induced by binding of Ran-BP and Ran-GAP in the 
cytoplasm liberates importins for another round of transport (Bischoff and Görlich, 
1997). 
 Importins α and β belong to a karyopherin protein family. The nomenclature 
of importins is quite confusing; for example the equivalent of mouse importin α3 is 
called importin α4 in humans and vice versa (reviewed in: Goldfarb et al., 2004). 
Therefore, throughout this dissertation, the unambiguous symbols KPNA3 and 
KPNA4 will be used to describe specific importins α. 
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 There are also other, alternative nucleocytoplasmic transport systems, which 
do not depend on importins nor a classical NLS. For example, calmodulin-mediated 
nuclear import, regulated by calcium levels in the cells, is responsible for 
SRY/SOX-9 delivery to the nucleus (Pruschy et al., 1994; Argentaro et al., 2003). 
Proteins without a classical NLS can also translocate to the nucleoplasm by binding 
to other proteins with a target sequence (so-called piggy-back mechanism) or by 
interacting directly with nucleoporins in the nuclear pore complexes (reviewed in: 
Wagstaff and Jans, 2009). 
 The interaction between MeCP2 and KPNA3 and KPNA4 identified by us is 
interesting not only because it can explain how MeCP2 is transported to the nucleus, 
but also for the reason that importins are believed to play a role in many important 
cell functions. For instance they can influence mitosis, nuclear envelope formation 
and animal development (Mason et al., 2003). In neurons importin-mediated 
transport is crucial for proper axon guidance, connections and plasticity (Otis et al., 
2006). All these processes, when disrupted, can potentially lie in the basis of Rett 
syndrome. Moreover, recent report showed that KPNA2 (another member of 
importin α family) can also regulate nuclear size in Xenopus (Levy and Heald, 2010). 
It is established that neuronal nuclei in the brains of mouse model of Rett syndrome 
are significantly smaller than their wild-type counterparts (Chen et al., 2001; Yazdani 
et al., 2012; S. Cobb, personal communication). Therefore, we hypothesised that the 
strong interaction between MeCP2 and importins α could be crucial for neuronal 
function and development and may be connected to the nuclear size phenotype. 
I decided to investigate closely a possible relationship between these proteins and 
Rett syndrome. The detailed mapping of the importin interaction sites on MeCP2 was 
followed by studies of the influence of Mecp2 knock-out on the distribution and 
abundance of importins in mouse brains. 
 
4.2 Mapping the MeCP2-importins interactions 
 
 As mentioned above, importins α are known to bind to nuclear localisation 
signals (NLS). These are characterised by a stretch of basic amino acids (aa) and can 
be either monopartite (7 aa) or bipartite (17 aa), where basic aa are separated by a 
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linker (Robbins et al., 1991). To identify the potential binding sites on MeCP2, its 
sequence was analysed bioinformatically using PSORT II algorithm (Nakai and 
Horton, 1999). It revealed ten putative NLS sequences (7 monopartite and 3 bipartite, 
Fig. 4.2.1) that could be bound by importins. 
 
Figure 4.2.1 Prediction of Nuclear Localisation Signals in MeCP2 sequence. PSORTII 
algorithm was employed to predict monopartite and bipartite NLSs in MeCP2_e2 human 
sequence. 
 
 To test which of the predicted nuclear localisation signals bind importins α, 
a series of MeCP2 truncation mutants spanning different NLS sequences was used to 
map the interactions. Both KPNA3 and KPNA4 could be detected by Western blot 
after over-expression of full length FLAG-MeCP2 in HeLa cells followed by FLAG 
immunoprecipitation, confirming the interaction and the feasibility of the method 
(Fig. 4.2.2). The detailed binding analysis showed that MeCP2 truncations 
containing NLS2 interact with both importins (such as fragments 202-486 and 1-273; 
Fig. 4.2.2A and black bars in Fig. 4.2.2B). Truncations missing or disrupting NLS2 
(for example 269-486, 1-262) failed to bind tested importins (Fig. 4.2.2A and white 
bars in Fig. 4.2.2B). Therefore, another MeCP2 mutant missing only that sequence 





Figure 4.2.2. Mapping of MeCP2-importins interactions.  (A) Western blot showing 
interactions with KPNA3 and KPNA4 with full-length and some of the tested MeCP2 
truncations. in – input, IP – immunoprecipitation. Re-probing the membrane with anti-FLAG 
antibody confirmed equal expression and immunoprecipitation of MeCP2 truncations. Asterisks 
between inputs and IPs mark the specific band for each of them. (B) A cartoon summarising the 
interactions with all of the tested MeCP2 truncations. Black bars represent fragments bound by 
tested importins (+); white colour indicates lack of the binding (–) and grey bar stands for 
intermediate binding in one of two biological replicates of the experiment (±). ND – binding of 




A very weak KPNA4 band in the ∆NLS IP was not observed in two repeats of this 
experiment. These results refined mapping of the interactions to a 253-269 region of 
MeCP2 (Fig. 4.2.2B). All of the MeCP2 truncation mutants were expressed and 
immunoprecipitated at comparable levels as assessed by re-probing the Western blot 
membrane with anti-FLAG antibody (Fig. 4.2.2A, asterisks). 
4.3 Role of importins in nuclear transport of MeCP2 
 
 The NLS confirmed to interact with importins α is the same sequence 
reported previously to be a functional NLS of MeCP2 (Nan et al., 1996). MeCP2 
fragments missing this NLS (1-261, 1-178) were localised mostly in the cytoplasm, 
with some ‘leakage’ detected to the nucleus. However, this study was performed 
using large fusion of MeCP2 fragments with β-galactosidase, which is known to 
form a homotetramer of total weight exceeding 1.8 MDa (Jacobson et al., 1994) 
whose size could affect the localisation of the tested constructs. Others have reported 
that there must be another functional NLS in MeCP2, because MeCP2 [168X] fused 
with GFP was detected in the nucleus (Kumar et al., 2008), although it does not have 
any of the predicted NLS sequences. In light of our data that MeCP2 interacts with 
importins only at NLS2 I decided to test myself the localisation of full-length MeCP2 
and its mutant truncated at the position 255 (MeCP2 [255X]), hence lacking the 
NLS2. NIH-3T3 mouse fibroblast cells were transfected with plasmids expressing 
wild-type or mutant MeCP2 fused with GFP under the CMV promoter. The cells 
were fixed, immunofluorescently stained for MeCP2 and observed under the 
confocal microscope. In 54 out of 55 tested cells full-length protein was localised in 
the nucleus in the characteristic DAPI bright foci (Fig. 4.3A), which are known to be 
regions of methylated pericentromeric heterochromatin (Miller et al., 1974). On the 
contrary, in 56% of 69 examined cells transfected with GFP-MeCP2 [255X] mutant, 
the protein was detected in the nucleus as well as in the cytoplasm. This was more 
prominent with the red antibody signal than in the GFP channel (Fig. 4.3B). 
However, in 44% of cells the localisation of truncated MeCP2 was identical with full 
length protein, being detected solely in the nucleus (Fig. 4.3C). As imaging of cells 
fixed with paraformaldehyde sometimes can lead to artefacts (Schmiedeberg et al., 
2009), the cells transfected in the same way were also observed live under the 
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fluorescence microscope. The wild-type protein localised again in the nucleus in the 
characteristic bright foci. Localisation of GFP-MeCP2 [255X] was even more similar 
to full length protein with approximately 54% cells with green GFP signal solely in 
the nucleus and less than a half of cells with detectable MeCP2 in the cytoplasm 
(data not shown). These experiments confirmed previous observations that MeCP2 is 
able to localise in the nucleus even without the NLS2, although its distribution is 
slightly impaired. The possible reasons for it, proposed ways to test them and 
potential consequences are discussed later. 
 
Figure 4.3. MeCP2-GFP localises in the nucleus even when truncated at position 255. 
NIH-3T3 cells were transfected with wild-type GFP-MeCP2 or GFP-MeCP2 [255X] and 
images were taken under the confocal microscope. (A) Full length MeCP2 exhibited only the 
nuclear localisation. (B) In 56% of cells transfected with truncated MeCP2 it localised in the 
cytoplasm as well as in the nucleus. (C) In 44% of cells MeCP2 [255X] was observed only 
in the nucleus, similarly to full length protein. The DNA constructs were gifts from 
L. Schmiedeberg. Scale bar: 20 µm. 
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4.4 Effect of MeCP2 knock-out on importins distribution 
 
4.4.1 Analysis of importins distribution in Mecp2-GFP+/- brain 
 
 Importins α are known to shuttle between cytoplasm and nucleus while 
transporting their cargo. The strong interaction between them and MeCP2 in the 
nucleus (40% of total KPNA3 and ~93% of KPNA4 are bound by MeCP2; 
Chapter 3.3) led us to the idea that importins can be retained in the nucleus in 
wild-type neurons and that the release of this retention in Mecp2 knock-out brains 
may lead to defects that contribute to Rett syndrome. To test this hypothesis I looked 
at the distribution of importins α in wild-type neurons and in cells lacking MeCP2. 
The direct comparison was possible by immunohistochemistry in the brain slices of a 
female heterozygous mouse Mecp2-GFP
+/-
. In these animals one allele of MeCP2 
has a fusion GFP protein knocked-in under the endogenous Mecp2 promoter and the 
Mecp2 gene on the other allele is deleted. MeCP2-GFP is expressed in only half of 
the neurons, which are mixed with the Mecp2 knock-out neurons in the brain due to 
random X chromosome inactivation. The presence of MeCP2 can be visualized by 
the endogenous GFP signal and the superimposed picture of immunofluorescent 
staining of protein of interest should show if lack of MeCP2 has any influence on the 
localisation of the tested protein. To confirm the feasibility of the method the brain 
slices were first immunostained with antibody raised against MeCP2. Confocal 
microscopy scans were carried out in the CA1 region of the hippocampus and in the 
dentate gyrus, which are both known to be enriched in neurons (Buckmaster and 
Schwartzkroin, 1995). Green signal from MeCP2-GFP fusion protein was detected in 
approximately 50% of the nuclei, which were visualised by staining with DAPI 
(Fig. 4.4.1-1). Co-staining with anti-MeCP2 antibody gave a very similar picture and 
the great overlap between red and green signals allowed me to consider each green 
signal in the subsequent experiments as MeCP2 positive (Fig 4.4.1-1). Brain slices 
containing the hippocampus were stained with two different antibodies raised against 
KPNA4. Although the quality of staining was not as good as in the case of MeCP2, 
the importin distribution has been preliminarily assessed. Analysis of 60 nuclei on 3 
brain slices suggested that the localisation of KPNA4 was not affected by the 
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presence or lack of MeCP2 (Fig. 4.4.1-2). KPNA4 seemed to be nuclear and not 
concentrated in the heterochromatic foci, regardless of the presence or absence of 
MeCP2. 
 Immunofluorescent staining with antibody raised against KPNA3 was 
performed in a similar fashion, however the low signal/noise ratio made the analysis 





Figure 4.4.1-1. Distribution of MeCP2-GFP in Mecp2-GFP
+/-
 heterozygous female 
mouse brain. Brain slices from Mecp2-GFP
+/-
 female mouse were immunostained with anti-
MeCP2 antibody and DAPI. Confocal miscroscopy showed the presence of MeCP2 in only 
half of the neurons in characteristic DAPI-bright heterochromatic foci. The GFP signal of 
MeCP2-GFP fusion protein overlapped completely with the antibody staining. Scale 





Figure 4.4.1-2. Distribution of importins in Mecp2-GFP+/- heterozygous female mouse 
brain. Brain slices from Mecp2-GFP+/- female mouse were immunostained with 
anti-KPNA4 antibody and DAPI. Confocal miscroscopy showed the presence of MeCP2 in 
only half of the neurons, and no difference in the distribution of KPNA4 between them. The 
insets are 3-fold magnifications of areas marked with white rectangles. Scale bar: 20 µm. 
 
 
4.4.2 Importins distribution in biochemically fractionationated brains  
 
 Another method to test the distribution of proteins between the nucleus and 
cytoplasm is biochemical fractionation. The brains from wild-type and MeCP2 
knock-out mice were homogenized and proteins divided into cytoplasmic and 
nuclear fractions. Probing the Western blot membrane with antibodies against control 
proteins showed their predicted distribution: GAPDH was solely in the cytoplasm, 
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whereas histone H2B in the nuclear fraction (Fig. 4.4.2). Additionally, as expected, 
MeCP2 was present only in the nuclei of wild-type brains and could not be detected 
in the samples from Mecp2-null animals. Both KPNA3 and KPNA4 proteins were 
detected mainly in the nuclear fraction and their distribution was not affected by the 





Figure 4.4.2. Lack of MeCP2 does not influence importins distribution. Protein extracts 
from biochemically fractionated wild-type (wt) and Mecp2 knock-out (KO) mouse brains 
were separated by SDS-PAGE, Western blotted and probed with antibodies marked on the 
right. cyt – cytoplasmic fraction, nuc – nuclear fraction. Representative of three independent 
experiments.  
 
4.4.3 The effect of Mecp2 knock-out on mRNA levels of importins 
 
 Although lack of MeCP2 had no influence on importin distribution between 
cytoplasm and nucleus, we observed a weak trend towards lower levels of KPNA3 
and KPNA4 proteins in Mecp2 knock-out brains when compared to wild-type 
(Fig. 4.4.2 and data not shown). That led us to an alternative hypothesis that could 
link MeCP2-importins interactions to the Rett syndrome. In wild-type neurons the 
interaction with MeCP2 causes sequestration of the pool of importins α in the 
nucleus and leads to their increased production. In Mecp2 knock-out brain this 
 97
hypothetical feedback mechanism is not active and in consequence importins are 
present at lower levels what may cause some of the Rett syndrome phenotypes. The 
abundance of the protein may be regulated at both transcriptional and translational 
levels, as well as being affected by the stability of the protein. Therefore, a 
comprehensive analysis of the influence of Mecp2 knock-out on levels of both 
KPNA3 and KPNA4 was performed. The quantification of mRNA molecules of 
importins relative to Gapdh and assessed by RT-qPCR showed no significant effect 
of MeCP2 on their transcription (Fig. 4.4.3). Kpna6 mRNA was used as a control 
and its expression should not depend on the presence of MeCP2 as it was not 
detected to interact with it. Indeed the mRNA level of Kpna6 also stayed unchanged 
upon deletion of MeCP2 (Fig. 4.4.3). 
 

































Figure 4.4.3. Knock-out of Mecp2 does not influence the mRNA levels of importins α in 
the brain. qPCR analysis was performed on cDNAs from brains from two wild-type (wt) 
and two Mecp2 knock-out (KO) mice (gift from Pete Skene). Error bars represent standard 
deviations calculated from tryplicated PCR wells. 
 
4.4.4 The effect of Mecp2 knock-out on protein levels of importins 
 
 The protein levels of importins were tested by quantitative Western blotting 
and normalized to levels of the neuronal marker NeuN. As expected, MeCP2 was 
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absent in the knock-out brains. No obvious difference in the KPNA3 and KPNA4 
levels was detected between wild-type and Mecp2 knock-out brains. The equal 
loading of the gels was additionally confirmed by even levels of total histone H3 








































Figure 4.4.4. Knock-out of Mecp2 does not influence the protein levels of importins α in 
the brain. Brains from two wild-type (wt 1 and wt 2) and two Mecp2 knock-out (KO 1 and 
KO 2) mice were homogenized, proteins extracted and separated by SDS-PAGE in three 
concentrations increasing two-fold. (A) Western blot membranes were probed with 
antibodies against MeCP2, KPNA3 and KPNA4, neuronal marker NeuN and histone H3. (B) 
Densitometric analysis revealed no significant difference in protein levels of importins 
between MeCP2 wild-type and knockout brains. Representative blot of three independent 






 In Chapter 3 we detected interactions between MeCP2 and mouse importins α 
KPNA3 and KPNA4 by mass spectrometry and validated them by Western blotting. 
Here we confirmed these interactions in HeLa cells, proving that they are not species, 
nor cell-type specific. Detailed mapping restricted both interactions to a short 
sequence between positions 253-269 of MeCP2, which corresponds to the previously 
identified functional NLS (Nan et al., 1996). The results presented here indicate for 
the first time that MeCP2 is transported to the nucleus via a canonical, active, 
importin-mediated pathway.  
 The fact that only one of the ten putative nuclear localisation signals in 
MeCP2 is interacting with identified importins α was not surprising. The algorithm 
used for identifying potential NLS sequences is only predictive and therefore not 
always accurate (Nakai and Horton, 1999). Moreover, isoforms of importin α subunit 
exhibit some sequence specificity (Köhler et al., 1999; Quensel et al., 2004) and do 
not bind to any NLS-like sequence. 
 MeCP2 is quite often depicted in the literature as possessing two NLS 
sequences (Bienvenu and Chelly, 2006; Singh et al., 2008; Marchetto et al., 2010; 
Gadalla et al., 2011), although deletion analysis revealed that MeCP2 localises 
purely in the nucleus of mammalian cells only when contains NLS2 (Nan et al., 
1996). The argument for existence of another functional NLS at 173-193 region of 
MeCP2 comes from low resolution immunofluorescent experiments performed in 
Drosophila melanogaster SL2 cells (Kudo, 1998). Also Kumar and colleagues 
postulated that there is another NLS in MeCP2 since GFP-tagged MeCP2 [168X] 
truncation mutant can still localise in the nucleus (Kumar et al., 2008). Furthermore, 
in my experiments GFP-MeCP2 [255X] mutant devoid of NLS2 was detected in the 
nucleus. However, the biochemical data disagree with this notion as the other 
putative NLS sequences do not bind the tested importins and no other proteins that 
could be involved in the active transport were detected by mass spectrometry.  
 A possible explanation for the MeCP2 localisation puzzle could be that, 
although it is almost as big as the limit for free diffusion through the nuclear pores 
(60 kDa), due to its unusual elongated shape (Klose and Bird, 2004) it can get to the 
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nucleus by a passive mechanism. Once it is there its high affinity to methylated DNA 
due to the MBD domain sequesters it from the free-floating pool of MeCP2 and more 
molecules can diffuse to the nucleus. There is already one piece of evidence 
supporting this hypothesis. The localisation of short N-terminal fragment of MeCP2 
(1-108) lacking NLS2 and also devoid of MBD was solely cytoplasmic (Nan et al., 
1996). This free-diffusion theory would explain why the MeCP2 fragments fused to 
large β-galactosidase were localised mostly in the cytoplasm when lacking NLS2 
(Nan et al., 1996), but much smaller fusion proteins GFP-MeCP2 [168X] (Kumar 
et al., 2008) and GFP-MeCP2 [255X] (this study) were detected more visibly in the 
nucleus. However, to convincingly test this hypothesis a series of MeCP2 constructs 
without NLS2 and mutated in the MBD domain, but retaining other parts of protein 
should be tested. A prediction of this model is that MeCP2-∆NLS2 with disrupted 
ability to bind to methylated DNA will not localise in the nucleus, although this 
needs to be formally assessed in the future. Additionally, the localisation of MeCP2 
mutants non-interacting with importins α can be tested in cells treated with 
5-azacytidine or in cells with mutated Dnmt genes. The disruption of methylation 
machinery in such cells should result in lack of MeCP2 binding sites in the genome 
and therefore MeCP2 should not be retained in the nucleus without its functional 
NLS2. 
 Another possibility is that in the immunofluorescence experiments, 
expression of MeCP2 is driven by a strong CMV promoter resulting in 
non-physiological over-expression of MeCP2 and in consequence incorrect 
localisation. The fact that full-length MeCP2 was never observed in the cytoplasm 
and that in some cells GFP-MeCP2 [255X] was detected only in the nucleus 
suggests, however, that over-expression is not a problem. Further interpretational 
difficulties may come from the fact that tested MeCP2 truncation mutants were 
designed by introducing a premature stop codon in the full-length MeCP2 sequence 
by site-directed mutagenesis (Kumar et al., 2008; Schmiedeberg et al., 2009). If the 
artificially inserted stop codon occasionally is read-through by the translational 
machinery, it will produce a full-length protein localising in the nucleus as wild-type. 
That would give the wrong impression that truncated MeCP2 without NLS2 
sequence is transported to the nucleus. Therefore, generation and testing truncated 
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gene constructs knocked-in under the endogenous promoter of MeCP2 would give 
more accurate answers about their localisation 
 
 The identified classical active transport system of MeCP2 may seem to be 
unnecessary and redundant when the protein can localise in the nucleus without it. 
However, an active import to the nucleus is faster and more reliable than free 
diffusion. In order to investigate the importance of importin mediated transport of 
MeCP2 it would be interesting to test how the knock-down of importin α subunits 
affect the MeCP2 localisation and function, for example transcriptional repression of 
reporter genes. This approach however may be difficult to interpret as disrupting the 
general nuclear import system can influence many other processes.  
 
 Conservation of fragments of protein sequence during the course of evolution 
suggests their functional importance. The positively charged amino acids in the 
253-269 NLS2 region of MeCP2 are conserved from zebrafish to humans, implying 
their evolutionary advantage (Fig. 4.5; lysines and arginines are marked in red 
colour). Although the amino acids in the linker region of this bipartite NLS are 
different amongst the species, the length of the fragment is unchanged, plausibly 
preserving its function. On the contrary, NLS1 is shorter and NLS3 is longer in fish 
compared to other classes of animal kingdoms, suggesting that these sequences may 
be not functional (Fig. 4.5).  
 
 Interestingly, there are no registered Rett syndrome-causing mutations in the 
NLS2 region in the RettBASE database. This may be due to the fact that NLS 
sequence is quite redundant and a change of a single amino acid due to a missense 
mutation will not disrupt its function (Kosugi et al., 2009). Another possibility is that 
the database of mutations causing Rett syndrome is not complete or the mutations 
present in the human population have not saturated all of the possible sites for 
causing the disease. It is also possible that the RTT mutations on other sites of the 
protein affect its folding and in consequence the interaction with importins. This is 
easy to imagine in the case of the P225R and P322L mutations, where proline 
residues are substituted with more flexible amino acids that detrimentally affect the 
 102 
tertiary structure of MeCP2. The effect of the most common RTT missense 
mutations on the binding of importins should be analysed in the future. 
 
 
Figure 4.5. Alignment of nuclear localisation signals of MeCP2 from different animals. 
The sequences of putative bipartite NLS sequences of MeCP2 from human (Homo sapiens), 
chimpanzee (Pan troglodytes), dog (Canis lupus familiaris), opossum (Monodelphis 
domestica), mouse (Mus musculus), rat (Rattus norvegicus), frog (Xenopus laevis) and 
zebrafish (Danio rerio) were aligned using Jalview software (Waterhouse et al., 2009). 
 
 
 Considering the strength of interactions between MeCP2 and importins α we 
hypothesised that they may have other consequences than just nuclear transport and 
that these functions may be related to Rett syndrome. Investigation of the effects of 
Mecp2 knock-out on KPNA3 and KPNA4, however, did not reveal any disturbance 
of their localisation. Also, the hypothesis that the retention of importins in the 
nucleus by MeCP2 leads to their increased expression turned out not to be true. Total 
levels of KPNA3 and KPNA4 mRNA and protein were not changed in the brains of 
Mecp2 knock-out mice. These findings do not mean that the relationship between 
these proteins has no physiological consequences, but in light of the presented 
evidence it seems unlikely to be a significant contributor to the Rett syndrome. 
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 Although not of crucial significance for Rett syndrome, these findings 
advance our understanding of the functional domains of MeCP2. Researchers 
involved in studies on MeCP2 could benefit from resolving the confusion regarding 
the number and position of functional nuclear localisation signals. Additionally, the 
rapid development of sequencing techniques, their falling cost and increasing 
accessibility, will undoubtedly lead to a better coverage of the mutations and 
polymorphisms in the human population that lead to disease. If the mutations in the 
identified fragment of MeCP2 ever appear to be linked to any disorder, the 
knowledge of proteins interacting there and their role should help in developing new 
potential drugs and therapies. 
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Chapter 5: Transcriptional repression 





 Mass spectrometric analysis of MeCP2 interacting partners revealed binding 
of 5 subunits of the NCoR/SMRT co-repressor complex. This multi-subunit, 
megadalton complex contains either NCoR1 or SMRT in its core, and HDAC3, 
TBL1, TBLR1 and GPS2 associated with them via multiple interactions (Li et al., 
2000; Zhang et al., 2002; Oberoi et al., 2011). It was discovered as a complex 
responsible for repression of transcription from unliganded nuclear receptors (Chen 
and Evans, 1995; Hörlein et al., 1995). However, this complex is also able to repress 
transcription by association with proteins other than receptors (reviewed in: 
Karagianni & Wong, 2007). The crucial role of the NCOR/SMRT complex in the 
development was shown by embryonic lethality of mouse knock-outs of its 
components: Ncor, Smrt and Hdac3 (Jepsen et al., 2000, 2007, 2008; Bhaskara et al., 
2008). 
 The interaction of MeCP2 with NCoR/SMRT co-repressor complex in mouse 
brain was validated by Western blot. Subsequently, the interaction was mapped on 
MeCP2 by co-immunoprecipitations of FLAG-tagged MeCP2 fragments (M. Lyst, 
personal communication). The complex was shown to bind to a region at the end of 
the TRD domain of MeCP2, between amino acids 269-309 (Fig. 5.1). Interestingly, a 
part of that region is a hotspot for missense mutations causing Rett syndrome. The 
influence of these mutations on binding of the complex was tested in the laboratory 
by co-immunoprecipitations. All RTT point mutations in that region: P302R, K304E, 
K305R and R306C, abolished the interaction (M. Lyst, personal communication). 
These results suggested that binding of NCoR/SMRT co-repressor complex may be 
crucial for the correct function of MeCP2, which is missing in RTT. As discussed 
above, NCoR/SMRT complex is involved in repression of transcription. Therefore, 
we decided to test if the mutations abolishing MeCP2-NCoR/SMRT interactions 






Figure 5.1. Mapping of MeCP2-NCoR/SMRT complex interactions. Summary of 
experiments performed by M. Lyst. Black bars represent fragments binding to the complex, 
grey colour indicates intermediate binding and white bars stand for lack of the binding. The 
mutations causing Rett syndrome are depicted as vertical lines above MeCP2. 
 
 
5.2 Transcriptional repression by MeCP2 in vitro 
 
 Wild-type MeCP2 has been previously shown to repress transcription of 
reporter genes through its TRD domain (Nan et al., 1997, 1998). Investigation of the 
effects of different RTT mutations in MeCP2 on its transcriptional properties showed 
that nonsense mutants devoid of the NCoR/SMRT-interacting region (such as 255X 
and 270X) failed to exhibit repression activity (Yusufzai and Wolffe, 2000). 
Interestingly, MeCP2 with missense mutation R306C was reported to repress 
transcription as well as wild-type protein (Yusufzai and Wolffe, 2000; Drewell et al., 
2002). In the light of the fact that this mutation abolishes MeCP2 association with a 
co-repressor complex we decided to revisit this observation. We addressed this issue 
by utilizing a system in mammalian cell lines where a reporter gene, Firefly 
luciferase, bearing five GAL4 binding sites was co-expressed with MeCP2 
C-terminal fragment fused to GAL4 DNA binding domain (Fig. 5.2.1). A plasmid 
carrying Renilla luciferase gene was co-transfected as a control in order to be able to 





Figure 5.2.1. DNA constructs used in transcriptional repression assays. The reporter 
Firefly luciferase gene contained five GAL4 Upstream Activating Sequences (UAS) 
upstream of the thymidine kinase promoter (TK). Effector constructs were either N-terminal 
or C-terminal halves of MeCP2 fused to GAL4 DNA binding domain under the control of 
cytomegalovirus promoter (CMV). Point mutations were introduced in the TRD. As a 
transfection control Renilla luciferase was co-transfected with the other constructs. 
 
 The initial experiments performed in HeLa cells using equal amounts of 
reporter and effector plasmids showed that both C-terminal wild-type MeCP2 and its 
mutated version R306C are able to efficiently repress transcription. This repression 
was alleviated by treating cells with trichostatin A (TSA), a histone deacetylase 
inhibitor, demonstrating that the repression was mediated by HDACs (Fig. 5.2.2). 
Interestingly, the effect of TSA on MeCP2 [R306C] was much stronger than on 
wild-type MeCP2. That brought us to the idea that MeCP2 [R306C] may indeed be 
impaired in its capacity to repress transcription compared to the wild-type protein, 
but that this fact could be masked by its over-expression. If the system was indeed 
saturated with the large excess of effector protein in relation to its binding sites on 
the less abundant reporter gene, then even the residual repression activity of the 
R306C mutant could be enough to reduce its transcription. The impairment of 
repressive machinery of the cells by TSA treatment, however, would reduce the rate 
of transcriptional repression to sub-saturating levels and reveal the poorer 
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performance of MeCP2 [R306C] than wild-type MeCP2 in repressing the reporter 
gene. To test the saturation hypothesis, the amount of the effector DNA construct 
was titrated down to a minimal amount needed for repression by the wild-type 
protein. Consistent with initial experiments, at the highest concentration of 1 µg/ml 
of MeCP2-coding plasmid there was no difference between wild-type and R306C in 
their repression activity (Fig. 5.2.3, navy blue bars). However, 100-fold dilution of 
the effector plasmid revealed a clear difference between them. Wild-type C-terminus 
of MeCP2 was able to repress transcription of the luciferase reporter 6-fold when 
compared to luciferase activity in cells transfected with GFP instead of MeCP2, 
whereas the R306C mutant behaved like no-MeCP2 control (Fig. 5.2.3, light blue 
bars). Further 100-fold dilution of the effector plasmids resulted in no repression 
activity exhibited by both wild-type and mutated C-terminal fragment of MeCP2 
(Fig. 5.2.3, turquoise bars). From this point 10 ng/ml of MeCP2 plasmid was used in 
all further experiments. 
 
 









































Figure 5.2.2. Over-expressed C-terminal part of MeCP2 can repress transcription of a 
reporter gene regardless of its R306C mutation. 1 µg of plasmid coding wild-type 
C-terminus of MeCP2 (wt) or its mutated version R306C were co-transfected with reporter 
Firefly luciferase gene and a control Renilla luciferase gene. The activities of enzymes were 
measured and normalised. Fold repression was calculated by dividing the obtained values by 
the luciferase activity in control cells transfected with GFP plasmid instead of MeCP2 
(no MeCP2). The error bars represent propagated standard deviations of 4 technical 
replicates of each transfection. 
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Figure 5.2.3. Reducing the amount of transfected MeCP2 construct revealed the failure 
in repression activity of R306C mutant. 1 µg, 10 ng or 0.1 ng of each MeCP2-coding 
plasmids were co-transfected with reporter Firefly luciferase gene and a control Renilla 
luciferase gene. The enzyme activities were measured and normalised. Fold repression was 
calculated as in Figure 5.2.2. The error bars represent propagated standard deviations of 3 
technical replicates of each transfection. 
 
 Having found the optimal conditions to assess the repressor activity of 
MeCP2, different RTT missense mutations were tested. Each experiment was 
normalised to luciferase activity in cells transfected with GFP coding plasmid instead 
of MeCP2. Repeatedly, wild-type C-terminus of MeCP2 was an effective repressor, 
whereas R306C as well as other RTT mutants in the NCoR/SMRT-interacting region 
(P302R, K304E and K305E) failed to repress transcription (Fig. 5.2.4). The 
N-terminal half of MeCP2 was also tested as a control and, as expected, showed no 
repression. The differences between fold repression by wild-type C-terminal part of 
MeCP2 and each of the tested mutants were statistically significant (unpaired 
two-sample Student’s t-test assuming unequal variances; p < 0.05). Furthermore, the 
repressive ability of the C-terminal fragment of MeCP2 mutated outside of the 
269-309 region was assessed. P225R repressed transcription as well as the wild-type 
protein, which agrees with the observation that it is able to bind the NCoR/SMRT 
co-repressor complex. Cell treatment with TSA alleviated the repression and had no 
effect on the already non-repressing mutants (Fig. 5.2.4). These experiments were 




Figure 5.2.4. MeCP2 missense mutations in the NCoR/SMRT-interacting region fail to 
repress transcription in NIH-3T3 cells. 10 ng of plasmid coding each of the tested MeCP2 
mutant was co-transfected with luciferase genes and measured and normalised as in 
Figure 5.2.3. wt – wild-type, ctrl – control cells transfected with GFP plasmid instead of 
MeCP2. The error bars represent standard errors of the means of 2-6 independent biological 
experiments. Asterisks above the bars represent the p value of two-tailed t-test when 
compared to wild-type C-terminal half of MeCP2. * - p<0.05, ** - p<0.01, *** - p<0.001. 




 Additional DNA constructs with mutated GAL4-MeCP2 were designed in 
order to investigate the effects of further mutations in the NCoR/SMRT-interacting 
region on transcriptional repression mediated by MeCP2. New tested mutants 
included two less common mutations causing Rett syndrome (K305E, R306H) and 
three mutants with amino acid changes not reported as giving rise to RTT (L301P, 
I303T, K307E). Another tested mutation outside of the RTT cluster, A279V, was 
reported only once as causative to the syndrome in Korean patients and without 
testing the genotype of the parents of the patients (Chae et al., 2004). Analysis of 
binding of all these mutants to NCoR/SMRT complex by co-immunoprecipitations 
revealed a lack of interaction in case of mutations between positions 301-306, 
intermediate binding to K307E and wild-type-like binding to A279V (M. Lyst, 
personal communication). The luciferase repression assay correlated well with the 
binding data, showing lack of repression by MeCP2 mutated between 301-306, 
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wild-type-like repression by A279V and intermediate repression by K307E mutant 
(Fig. 5.2.5). This set of experiments was performed in HeLa cells and normalised to 
cells transfected with the N-terminal part of MeCP2, therefore these results could not 
be directly combined with the similar experiments performed in NIH-3T3 cells 
(Fig. 5.2.4). However, the facts that the observed phenomenon is not only 
mouse-specific but also true in a human cell line and that the fold repression values 




Figure 5.2.5. MeCP2 missense mutations in the NCoR/SMRT-interacting region fail to 
repress transcription in HeLa cells. HeLa cells were transfected as in Figure 5.2.4. Fold 
repression was calculated by dividing the obtained values by the luciferase activity in cells 
transfected with N-terminal half of MeCP2. The error bars represent propagated standard 
deviations of two technical repeats. 
 
 
 An important factor that has to be taken into account when comparing the 
effects of mutations in MeCP2 on its ability to repress reporter gene transcription is 
the expression level of each mutant. Since the amount of MeCP2 effector plasmid 
used in each luciferase experiment was very low it proved difficult to detect 
expressed proteins by conventional methods. Even the ultra-sensitive Western blot 
performed from HeLa cells transfected with the amount of MeCP2-coding plasmid 
used in the luciferase assays (10 ng) was barely able to detect the expressed protein 
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using the antibody against GAL4 DNA binding domain (GAL4-DBD; Fig. 5.2.6A) 
or against MeCP2 (data not shown). However, amongst the unspecific bands, in all 
lanes apart from a control cells lane (not transfected with effector plasmid) there was 
a visible band corresponding to predicted size of each of the fragments of MeCP2 
(Fig. 5.2.6A). The levels of both wild-type N- and C-termini of MeCP2, as well as 
R306C, were comparable. The proteins were equally loaded on the gel as assessed by 
the intensity of an unspecific band at 70 kDa (an asterisk in Fig. 5.2.6A). The effect 
of TSA on histone acetylation levels was tested on the same Western blot and, as 
expected, revealed hyper-acetylation of histone H3 upon cell treatment with TSA in a 
dose-dependent manner (Fig. 5.2.6A). Each group of three bands corresponding to 
acetylated histones H3 in cells subjected to different treatments could also be used as 
a confirmation of even loading of the proteins on the gel. 
 To confirm the comparable expression of GAL4-MeCP2 constructs, Western 
blots were also performed on samples from NIH-3T3 cells transfected with 10-fold 
higher amounts of the plasmids than in the reporter gene assays. Such approach 
allowed easier detection of the effector proteins when probed with the antibody 
against the GAL4 DNA binding domain. N-terminal half of MeCP2, as well as 
wild-type, R306C and K304E mutants of the C-terminal half showed comparable 
expression when normalised to the levels of histone H3 (Fig. 5.2.6B).  
 These results do not definitely prove that all of the MeCP2 mutants used in 
the luciferase assays are expressed equally and ideally more of them should be tested 
in the future. However, the facts that R306C is expressed on the same level as 
wild-type, and that P225R and A279V mutants are able to repress transcription 
suggest that the other mutants could also be expressed at comparable levels. In 
summary, the results of reporter gene assays showing the failure of transcriptional 
repression by MeCP2 [R306C] and other mutants disrupting the interaction with 







Figure 5.2.6. Equal expression of used MeCP2 mutants.  (A) Ultra-sensitive Western blot 
showing the expression of 10 ng of MeCP2 DNA constructs in HeLa cells and the effect of 
TSA on the acetylation levels of histone H3. (B) Western blot showing the expression of 
100 ng of MeCP2 DNA constructs in NIH-3T3 cells. An asterisk indicates the unspecific 







5.3 Neuronal differentiation system 
 
 MeCP2 is a neuronal protein and therefore plays a role in the Rett syndrome 
primarily in neurons. To study the effect of RTT mutations on its properties in a 
more physiologically relevant system than HeLa or NIH-3T3 cell cultures, it would 
be the best to generate neurons with mutated MeCP2. As embryonic stem cells 
(ESCs) are easier to genetically alter than mature neurons, a series of ES cell lines 
harbouring different mutations in MeCP2 have been generated in the laboratory with 
a plan to produce knock-in mice (J. Guy, C. Merusi, J. Selfridge). The MeCP2-GFP 
knock-in ES cell line (MeCP2-GFP [WT]) has already been successfully used in 
making a mouse. The T158M and R306C mutations were introduced in the same 
locus in order to study the two most common RTT mutations disrupting two 
characterized domains of MeCP2 (MBD and TRD, respectively). The stem cells can 
be differentiated into neurons using protocol established by Bibel and co-workers 
(Bibel et al., 2004; Fig. 5.3.1). ESCs are first grown for 4 days on non-adhesive 
plates without leukaemia inhibitory factor (LIF) to produce embryoid bodies (EB) 
and for a further 4 days in medium containing retinoic acid (RA) to drive their 
differentiation into neuronal progenitors. Subsequently, the cells are harvested and 
seeded on laminin-coated dishes and grown in a neuronal medium. After 5-6 days in 
culture the cells express MeCP2 and are considered as mature and relatively pure 
neurons, as can be assessed by Tuj1 (neuron-specific class III beta-tubulin) staining 
(Fig. 5.3.1). Another neuronal marker used for detecting neurons is neuronal nuclear 
antigen (NeuN). Counting the ratio of NeuN positive cells over all healthy nuclei 
(excluding the clearly apoptotic cells) in 5 different neuronal differentiations 
confirmed the high purity of each culture (> 80% neurons). Staining for a glial 
fibrillary acidic protein (GFAP), an astrocyte cells marker, corroborated the notion 




Figure 5.3.1. ES cells differentiation into neurons. The procedure of stem cells 





Figure 5.3.2. Purity of ES cells-derived neurons. Confocal images of neurons derived 
from MeCP2-GFP ES cells, stained for a neuronal marker NeuN and astrocyte marker 
GFAP. Scale bar: 50 µm  
 
 
 Neurons derived from ES cells have been used to test the influence of 
mutations in MeCP2 on its properties. One of the features of wild-type MeCP2 is its 
localisation in the DAPI-birght foci, consisting of methylated pericentromeric 
heterochromatin. The neurons produced from 3 different genotypes of ES cells  
(MeCP2-GFP [WT], MeCP2-GFP [T158M], MeCP2-GFP [R306C]) were fixed and 
images were collected under the confocal microscope. As expected, the signal from 
wild-type MeCP2-GFP overlapped with DAPI bright spots (Fig. 5.3.3A). The R306C 
mutant was also localised to heterochromatin (Fig. 5.3.3B). Conversely, the GFP 
signal in cells expressing MeCP2-GFP [T158M] mutant was more diffuse and not 
concentrated in the usual sites of MeCP2 (Fig. 5.3.3C). This observation confirms 
that a mutation in the methyl-CpG-binding domain of MeCP2 disrupts its localisation 
on chromatin, and this defect might underlie Rett syndrome caused by the cluster of 
mutations in MBD.  
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Figure 5.3.3. Neurons derived from ES cells harbouring different mutations in MeCP2 
exhibit altered localisation of MeCP2. Confocal microscopy of ES cells differentiated into 
neurons. DAPI, GFP signal and immunocytochemistry for neuronal marker MAP2 in: 
(A) MeCP2-GFP [WT], (B) MeCP2-GFP [R306C], (C) MeCP2-GFP [T158M]. Scale bar: 
20 µm. 
 
 Immunocytochemistry performed using antibodies recognising the neuronal 
marker, microtubule-associated protein 2 (MAP2), demonstrated that the observed 
cells were mature neurons (Fig. 5.3.3). 
 Neurons obtained from ES cells in the same way were used to test the 
interactions between the endogenous MeCP2 and NCoR/SMRT complex. The effect 
of mutations in MBD and TRD domains was opposite to their influence on MeCP2 
binding to chromatin. GFP immunoprecipitations showed that MeCP2-GFP [T158M] 
was able to bind the components of the co-repressor complex as well as 
MeCP2-GFP [WT], whereas the R306C mutation abolished the interaction in 
neurons (M. Lyst, personal communication). These results corroborate the data 
obtained in HeLa cells over-expressing MeCP2 mutants, but in a more 
physiologically relevant system of neuronal cultures with MeCP2 mutations 





 To summarize, our discoveries made in neurons derived from ES cells 
allowed us to form a hypothesis that MeCP2 can function as a ‘bridge’ between 
methylated chromatin and the NCoR/SMRT complex. Disruption of any of its 
domains by RTT mutations affects either its proper localisation on chromatin 
(T158M mutation in MBD) or the interaction with a co-repressor complex (R306C 
mutation in TRD). The functional consequence of the failure of bringing the 
co-repressor complex to MeCP2 binding sites in chromatin is not yet known. 
Therefore, we employed the neuronal differentiation system again, to test the 
influence of the Rett syndrome-causing mutations on the transcriptional repression 
and compare the results with Mecp2 knock-out neurons.  
5.4 Transcriptional repression in ES cell-derived neurons 
 
 In order to test the hypothesis that MeCP2 functionally links methylated 
chromatin and NCoR/SMRT co-repressor complex we sought for a system to assess 
the methylation-dependent transcriptional repression. As there are no convincing 
genomic targets of MeCP2 identified thus far, we decided to use the methylated 
reporter assay. It utilises a methylated luciferase gene and relies upon the ability of 
methyl-CpG binding proteins (MBD) to bind to the methyl groups on DNA. To 
assess the transcriptional repression function of the tested MBD protein, the 
luciferase activity recovered from methylated plasmid is then compared with activity 
recovered from an unmethylated version of the gene. This system has been used in 
the laboratory previously to assess the methylation-dependent transcriptional 
repression in cell lines co-transfected with Mecp2, Mbd2 or Mbd3 genes (Guy et al., 
2001; Hendrich et al., 2001). However, it has never been done in the neurons 
expressing endogenous, mutated versions of MeCP2. 
 As a first step in the methylated reporter assay the plasmids with the 
luciferase reporter gene had to be methylated. Preliminary experiments showed very 
low transfection efficiency of mature neurons and hence low luciferase signals from 
a plasmid bearing Firefly luciferase. Therefore, I decided to methylate the Renilla 
luciferase gene, as it generally gives more luminescent signal and its expression 
therefore is easier to detect (data not shown). The plasmid coding less active Firefly 



















Figure 5.4.1. DNA constructs used in methylated reporter assays. (A) Schematic diagram 
of the DNA constructs used in methylated reporter assays. (B) The density of CpG 
dinucleotides on a reporter gene sequence and predicted sizes (in base pairs) of largest 
fragments given by digestion with HinP1I and MspI/HpaII restriction endonucleases. 
(C) Confirmation of methylation of SV40-Renilla plasmid by digestion with methylation 
sensitive restriction enzymes. Agarose gel stained with ethidium bromide. M+ - plasmid 
methylated in vitro, M– - plasmid ‘mock’ methylated, processed in the same way as M+, but 






 To assess the effectiveness of in vitro methylation with SssI CpG 
methyltransferase, the processed plasmid was digested by methylation sensitive 
restriction enzymes and resolved on agarose gel. Both HinP1I and HpaII enzymes 
failed to cut the methylated plasmid, while they efficiently digested the unmethylated 
plasmid to the fragments of predicted size (Fig. 5.4.1B and C). To test if methylation 
and purification processes did not inhibit the restriction enzymatic reaction per se, 
both plasmids were incubated with MspI endonuclease, an isoschizomer of HpaII, 
insensitive to DNA methylation. In this case both methylated and unmethylated 
plasmids were efficiently digested. These experiments allowed me to conclude that 
the effector plasmid was completely methylated at the CpG dinucleotides and 
therefore could be used in the methylation repression studies. 
 
 In order to establish the best method of transfecting mature neurons 
I performed preliminary experiments testing various gene delivery protocols. 
A plasmid bearing the mCherry gene was introduced into ES cell-derived neurons 
using two dilutions of five different transfection agents (JetPEI; X-tremeGENE 9; 
X-tremeGENE HP; Lipofectamine Plus; and calcium phosphate; see Chapter 2 for 
details). Live cell imaging revealed that, although very low, the highest transfection 
efficiency was obtained with the X-tremeGENE 9 reagent (data not shown) and this 
was therefore used in all subsequent experiments. Staining of fixed cells with DAPI 
allowed calculation of transfection efficiency under the confocal microscope and it 
was between 2-3% (Fig. 5.4.2). As the lipid-based gene delivery methods are most 
efficient against the dividing cells we feared that the transfected cells, although 
expressing MeCP2-GFP (Fig. 5.4.2), were not neurons. However, co-staining the 
cells with anti-MAP2 antibody revealed that approximately 20% of transfected cells 
were neuronal (Fig. 5.4.3). The other transfected cells could be immature neurons, 






Figure 5.4.2. Transfection efficiency of ES cell-derived neurons. Representative images 
of ES cell-derived neurons transfected with a methylated reporter gene and co-transfected 









Figure 5.4.3. Transfection of neurons. Imunocytochemistry with anti MAP2 antibody 
revealed that some of the cells successfully transfected with plasmid coding mCherry protein 
were neurons. Scale bar: 50 µm.  
 
 
 Five genotypes of neurons, two expressing wild-type MeCP2 (wild-type ES 
cells and MeCP2-GFP [WT] cell line) and three with alterations in the Mecp2 gene 
(knock-out, MeCP2-GFP [T158M] and MeCP2-GFP [R306C]) were then produced. 
Cells were transfected with luciferase plasmids and the effect of MeCP2 on reporter 
gene expression was assessed by luminometry. Fold repression was calculated as a 
ratio of normalised luminescence in cells transfected with unmethylated reporter 
gene over the normalised luminescence in cells transfected with methylated plasmid. 
The means were calculated from the values obtained in five independent biological 
replicate experiments. Overall, there were no significant differences between fold 
repression of methylated reporter genes in the five tested neuronal genotypes (Fig. 
5.4.4). The methylated gene was expressed on average 7.6-fold lower level than its 
unmethylated counterpart, regardless of the MeCP2 presence or mutation. A weak 
trend towards higher repression of luciferase gene in cells expressing wild-type 
MeCP2 than in Mecp2 knock-out cells could be observed, but it was not statistically 
significant (unpaired two-sample Student’s t-test assuming equal variances; 






























Figure 5.4.4. Mutations in MeCP2 do not influence the repression of methylated 
reporter gene in ES cell-derived neurons. Combined fold repression of methylated 
reporter gene over its unmethylated counterpart in neurons derived from ES cells expressing 
different types of MeCP2 or with Mecp2 gene knocked out (KO). Average of five biological 
replicate experiments. Error bars represent standard errors of the means.  
 
 
5.5 Lower protein levels of mutated MeCP2 in ES cell-derived 
neurons 
 
 As the methylated reporter assay used here depends on endogenous proteins, 
we hypothesised that the negligible effect of MeCP2 on methylated reporter gene 
expression may be due to the fact that the neurons used in these experiments were 
not mature enough and were therefore expressing inadequate levels of MeCP2. 
Although the confocal microscopy analysis revealed green signal in the neuronal 
cultures of cells with GFP-tagged MeCP2 knock-in, it was not quantitative and it was 
difficult to compare the MeCP2 levels between the cell genotypes. To investigate the 
amounts of MeCP2, protein extracts from ES cell-derived neurons were analysed by 
Western blot. MeCP2 was detected in all but Mecp2 knock-out neurons. Two 
wild-type versions of the protein (endogenous MeCP2 in wild-type ES cells and the 
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knocked-in MeCP2-GFP fusion protein) were expressed at similar levels (Fig. 5.5A). 
Interestingly, in neurons harbouring two different missense mutations in Mecp2 
(T158M and R306C) the protein levels were lower than in wild-types by 
densitometric analysis (Fig. 5.5B). Similar phenomenon of lower levels of 
endogenously expressed mutated MeCP2 was recently observed in the Mecp2
T158A/y
 





Figure 5.5 Expression of MeCP2 mutants in the ES cell-derived neurons.  
(A) Representative Western blot of protein extracts from ES cell-derived neurons probed 
with anti-MeCP2 antibody and anti-H3 as a loading control. (B) Densitometric analysis of 




5.6 Immunohistochemistry of HDAC3 and MeCP2 
  
 The functional interaction between MeCP2 and the NCoR/SMRT complex 
suggests that the complex may be targeted to chromatin at the MeCP2 binding sites. 
The very high abundance of MeCP2 molecules in neurons, reaching almost the 
number of nucleosomes, results in coating whole chromosomes while tracking the 
methylated CpG dinucleotides (Skene et al., 2010). Microscopy images of mouse 
neurons expressing MeCP2-GFP fusion proteins show that it localises in the DAPI 
bright spots consisting of highly methylated pericentromeric heterochromatin. We 
hypothesised that the components of NCoR/SMRT complex should also localise in 
the spots occupied by MeCP2, and that this localisation should be disrupted upon 
MeCP2 deletion. In order to test this hypothesis I used a brain from a heterozygous 
Mecp2-GFP
+/-
 female mouse for immunohistochemistry, as described in 
Chapter 4.4.1. As expected, only half of the neurons were MeCP2 positive and the 
GFP signal from MeCP2 fusion was clearly co-localised with the DAPI bright spots 
(Fig. 5.6A and B). The immunofluorescent staining with anti-HDAC3 antibody gave 
a strong signal in the nuclei, but it seemed to be excluded, rather than enriched, from 
the heterochromatic foci. The HDAC3 distribution appeared not to be different 
between MeCP2 positive and knock-out neurons (Fig. 5.6A, insets). This observation 
was true in four pictures from two different brain slices, with ~50 neuronal nuclei 
analyzed on each. The obtained fluorescent signal was not due to unspecific binding 
of the secondary antibody as the control staining omitting primary antibody gave no 
signal at all (Fig. 5.6B). Immunofluorescent staining with antibodies against other 
components of NCoR/SMRT complex was either very weak or gave high 
background and was therefore impossible to interpret (data not shown). These are 
only preliminary results and they do not disprove the formulated hypothesis until 
they are systematically repeated with the antibodies with checked specificity or with 













Figure 5.6. HDAC3 does not co-localise with MeCP2 in mouse neurons. Confocal 
microscopy of Mecp2-GFP+/- heterozygous female mouse brain. (A) Immunohistochemistry 
for HDAC3. Insets are a 3x magnification of a region marked with white square. 
Representative images of 2 brain slices (B) Staining control with secondary antibodies only, 







 In this chapter I showed that the identified interaction between MeCP2 and 
NCoR/SMRT co-repressor complex is probably crucial for MeCP2 function as a 
transcriptional repressor and the disruption of this function likely plays a role in Rett 
syndrome. The NCoR/SMRT complex binds to a fragment of MeCP2 containing 
residues commonly mutated in RTT, including the second most frequent missense 
mutation, R306C (RettBASE). The identified NCoR/SMRT-interacting region on 
MeCP2 is quite wide (40 aminoacids between positions 269-309) and needs to be 
defined more precisely in the future. The fact that A279V mutant binds the complex 
and is able to repress transcription suggests that the minimal region of interaction 
may be shorter. Also, the biotinylated peptide comprising of 285-319 amino acids 
was sufficient to interact with the co-repressor complex in the in vitro binding studies 
(J. Nowak, personal communication).  
 The single amino acid substitutions in the identified region that cause Rett 
syndrome prevent binding of the complex and also lead to the impairment of 
transcriptional repression by MeCP2. The results presented in this chapter are the 
first example of a functional consequence of a disease-causing missense mutation in 
the TRD of MeCP2. Two previous reports claimed that MeCP2 [R306C] mutant can 
repress transcription as efficiently as the wild-type protein (Yusufzai and Wolffe, 
2000; Drewell et al., 2002). Our contrasting results are most probably due to the use 
of saturating amounts of MeCP2 by other laboratories. It also suggests that this 
mutant possesses some residual repression activity, possibly due to residual binding 
of NCoR/SMRT complex. Although we could not detect it by 
co-immunoprecipitations from both HeLa cells and ES cell-derived neurons 
expressing MeCP2 [R306C], there is one report demonstrating weak binding of 
SMRT to this mutant (Stancheva et al., 2003). Another possibility is that the residual 
repression activity of MeCP2 [R306C] is mediated by Sin3A complex, which binds 
to a different region of TRD (Nan et al., 1998) and the RTT mutations in the 302-306 
cluster do not affect it. The interaction of MeCP2 with Sin3A, though, is more than 
10-fold weaker than the interaction with NCoR/SMRT (M. Lyst, personal 
communication). It suggests that although real, the interaction of MeCP2 with Sin3A 
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is not the major one and its disruption is not responsible for RTT. The evidence that 
RTT mutations in 302-306 cluster abolish binding of NCoR/SMRT co-repressors and 
cause significant impairment of the repression properties (at least in cell culture 
systems) is much stronger and should change the way we look at MeCP2. 
 We of course bear in mind that our discovery was made in a very artificial 
system, where MeCP2 is fused to the GAL4 DNA binding domain, which targets it 
directly to the reporter gene. To fully appreciate the importance of our findings it 
would be helpful to be able to examine a mouse bearing the R306C mutation in 
MeCP2. The prediction is that such mouse should recapitulate the entire spectrum of 
Rett syndrome phenotypes making it invaluable tool to study the pathology of the 
disease. To ultimately confirm that the interaction between MeCP2 and 
NCoR/SMRT lies in the basis of the disease, a system that allows rescuing the 
abolished interaction is also needed. For example suppressor mutation on 
NCoR/SMRT or GFP-binding domain fused to NCoR to enforce the interaction with 
MeCP2-GFP [R306C]. If such a mouse has the Rett phenotype rescued, then it may 
be worth screening for drugs that permit the co-repressor binding to the mutated 
MeCP2. 
 Regrettably the R306C mouse is not available yet, therefore we tried to 
dissect the molecular function of MeCP2 by means of other methods. The embryonic 
stem cell differentiation system appealed as a good way of obtaining pure neuronal 
cultures with various mutations in MeCP2 due to the ease of introducing mutations in 
ES cells. Indeed, the procedure of neuron production was successful and showed that 
wild-type MeCP2-GFP expressed from endogenous locus localised correctly to 
heterochromatin. The localisation of MeCP2-GFP [R306C] was indistinguishable 
from the wild-type protein, but the MeCP2-GFP [T158M] distribution on chromatin 
was more diffuse. This mutation was previously shown to disrupt the MeCP2 
structure and in consequence its interaction with methylated DNA in the in vitro 
binding assays (Yusufzai and Wolffe, 2000; Ghosh et al., 2008; Ho et al., 2008). 
Also the over-expression of the MeCP2 [T158M] in cell cultures proved its faulty 
localisation to heterochromatin when compared to wild-type protein (Kudo et al., 
2003; Schmiedeberg et al., 2009). This is the first time when the MeCP2 [T158M] 
mutant expressed from endogenous locus in neurons is shown to have a binding 
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defect. It supports the data from Zhou laboratory, where MeCP2 [T158A] mouse also 
exhibited mislocalisation of MeCP2 (Goffin et al., 2012).  
 All of the mentioned localisation studies were performed using fixed cells or 
brain sections. However, when T158M and other MeCP2 mutants in MBD were 
over-expressed in NIH-3T3 cells, live cells imaging showed their normal localisation 
(Schmiedeberg et al., 2009). Also the neurons produced from MeCP2-GFP [T158M] 
ES cells showed MeCP2 enriched in heterochromatic foci to some extent when 
observed in live cells (data not shown). Nevertheless, as the cell fixation procedure 
does not disrupt the localisation of wild-type MeCP2, it is still safe to say that 
MeCP2 [T158M] has some binding defect. It may be due to the altered binding 
dynamics (Kumar et al., 2008) and should be investigated in further details once the 
MeCP2-GFP [T158M] mouse is available. 
 The subsequent experiments that followed the ES cells differentiation into 
neurons failed to find the functional consequences of RTT mutations in Mecp2. 
Luciferase reporter assays performed in neurons harbouring different mutations of 
MeCP2 did not show any significant differences in transcriptional repression of the 
methylated reporter gene between wild-type MeCP2, mutants and knock-out. One of 
the possible interpretations is that the primary function of endogenous MeCP2 is not 
the transcriptional repression, which was observed previously mostly in the cultured 
cells transfected with engineered MeCP2 constructs. However there are also other, 
technical, explanations. The luciferase signal in cells transfected with methylated 
plasmid was always lower than in case of a plasmid free of methylation (~7.6 fold). 
This may be due to the presence of other methyl-CpG binding proteins in neurons, 
higher compaction of the chromatinised methylated plasmid, or the simple occlusion 
of transcription factors by the methyl groups on CpG dinucleotides. All of these 
factors could mask the effects of mutations in MeCP2 on the reporter gene 
expression and contribute to the fact that there were no significant differences 
identified. It is also possible that the amounts of plasmid coding the reporter 
luciferase and its ratio to the control plasmids were not chosen optimally. If the 
number of molecules of reporter gene DNA was in a large excess over the amount of 
available MeCP2 molecules, then the effect of mutations in the protein would be 
undetectable as the majority of luciferase signal would come from the excess of its 
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gene unbound by MeCP2. Unfortunately, due to the nature of these experiments and 
very time-consuming process of neuron production, the testing of many various 
plasmid ratios and a systematic optimization of the assay was impossible in the 
available time. 
 Although MeCP2 was detected in the ES cell-derived neurons it is possible 
that the Western blot analysis revealed average levels of MeCP2 in the population of 
cells. If the subset of cells that were transfected contained smaller amounts of 
MeCP2, it could partially explain why the methylated reporter assay in these cells 
failed to show any differences between the MeCP2 genotypes. Methylated plasmid 
has to compete for MeCP2 binding with the whole genome. The components of 
NCoR/SMRT co-repressor complex could also not be expressed at the same levels in 
the transfected ES cell-derived neurons as in the mature brain and therefore, being a 
limiting resource, masking the effects of mutations in MeCP2.  
 If these experiments were to be continued the priority would be to ensure that 
the neurons used are mature and express uniformly large amounts of the tested 
proteins. This could be achieved by keeping them in culture for longer periods of 
time, however the preliminary studies showed that there is an increased risk of cell 
death during prolonged in vitro tissue culture.  
 Improvement of the transfection efficiency is also essential, as it would allow 
scaling down the whole procedure and in consequence enable the proper 
optimization of used DNA ratios. The usual method of gene delivery into non-
dividing cells is viral transduction, but unfortunately it cannot be used in this case 
where the plasmid is methylated since the methylation marks would be removed 
during the viral life cycle. Instead of inefficient chemical-based methods of neuron 
transfection, maybe cells could be electroporated. The standard procedure that 
involves cell trypsinisation was utilized to transfect luciferase constructs into 
primordial neural stem cells and achieved ~30% transfection efficiency, which was 
enough to detect luciferase activity in used assays (Muotri et al., 2010). However, 
this approach cannot be used in the ES cells differentiation system for testing the 
effects of endogenous MeCP2, because transfection at the progenitor stage would be 
too early to reach neuronal maturity and trypsinisation of cultured neurons at later 
stages would destroy the neuronal network and connections. However, there are in 
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situ electroporators available that can deliver DNA to the adherent cells. Purchase 
and use of such equipment should be considered in the future. 
 The lower levels of MeCP2-GFP [T158M] and MeCP2-GFP [R306C] 
mutants than the wild-type versions of the protein could be an effect of impaired 
neuronal maturation when MeCP2 is mutated. Against this hypothesis is the fact that 
neurons of all genotypes express neuronal markers NeuN and MAP2. Another 
possibility could be faster degradation of mutated proteins. This would stand in line 
with recent discovery that in a mouse model harbouring a MeCP2 [T158A] mutation 
the MeCP2 protein stability is decreased (Goffin et al., 2012). In the same 
publication fibroblast cultures derived from RTT patient with T158M mutation also 
showed reduced level of MeCP2 when compared to an age-matched female control. 
If this phenomenon is also true for R306C, and perhaps other mutations, it could 
make a contribution to the molecular basis of Rett syndrome. Mutated proteins can 
be misfolded, recognized by the protein degradation machinery and destined for 
proteolysis. This hypothesis would explain why missense mutations outside of the 
functional domains of MeCP2, as well as nonsense mutations in the C-terminus can 
cause Rett syndrome. This mechanism can be especially true in case of P255R and 
P322L mutations, where proline residue has been substituted with a structurally 
distinct amino acid. As proline has a very rigid conformation (Fasman, 1989) it is 
possible to imagine how its substitution can affect proper protein folding. At present, 
however, there is no evidence relating to these hypotheses. 
 To our surprise immunohistochemistry of one of the components of 
NCoR/SMRT complex, HDAC3, did not show the co-localisation with MeCP2 in 
MeCP2-GFP
+/-
 brain slices. Differences in HDAC3 distribution in neurons 
expressing and lacking MeCP2 have also not been detected. These results may be 
explained by technical constrains of the immunohistochemistry procedure itself. 
MeCP2 localises in the heterochromatin and such environment might not be 
permissive for the anti-HDAC3 antibody. Use of other antibodies or one of the 
antigen retrieval methods could improve the staining and give different results. It is 
also possible that the interaction between MeCP2 and NCoR/SMRT complexes is 
very transient and dynamic. The fast turnover would be enough to repress 
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transcription wherever MeCP2 is bound, but it is not sufficient to detect the 
co-localisation in a snap-shot of fixed cells. As the number of MeCP2 molecules in 
neurons is reaching the number of nucleosomes (Skene et al., 2010) the abundance of 
components of NCoR/SMRT complex is probably much lower. The complex has 
other functions independent of MeCP2 and its own binding sites could be occupied 
by it and remain unchanged regardless of MeCP2 status. Therefore, the lack of 
expected results in these experiments does not rule out the importance of the 
interaction. The same limitations may apply to other techniques used or planned to 
be used to investigate the interaction further, such as chromatin immunoprecipitation. 
ChIP of HDAC3 or other components of NCoR/SMRT complexes followed by high-
throughput sequencing could tell us how many MeCP2 binding sites are also 
occupied by the repressor complex. Unfortunately, preliminary results suggest that 
cell fixation with paraformaldehyde disrupts the MeCP2 interaction with 
NCoR/SMRT complex, as assessed by immunoprecipitations followed by Western 
blotting (M. Lyst, personal communication). The 269-309 region of MeCP2 
identified as a binding surface for NCoR/SMRT complex contains 8 lysine residues 
in close proximity (Fig. 5.7). These lysines may be cross-linked to each other instead 
of fixing the interaction between MeCP2 and proteins interacting in that region. This 
could also be the main reason why HDAC3 immunohistochemistry of fixed cells 
showed no co-localisation with MeCP2 and even the exclusion from MeCP2-dense 






Figure 5.7. Lysine residues in the C-terminal end of TRD domain. 269-309 fragment of 






269 GRKPGSVVAAAAAEAKKKAVKESSIRSVHETVLPIKKRKTR 309 
 132 




 This study provides some new insights into the complex matter of the 
function of methyl-CpG binding protein MeCP2. More importantly, it extends the 
discoveries made in the laboratory regarding the role of MeCP2 in Rett syndrome. 
Our increased understanding of the molecular basis of this disorder gives hope for 
developing a successful therapy in the future. 
 
6.1 Novel interaction partners of MeCP2 
  
 Numerous studies using various approaches and techniques reported a 
plethora of proteins possibly interacting with MeCP2 and mediating one of its many 
putative functions. Due to inconsistencies between many of these reports, we decided 
to revisit the issue by taking advantage of recently developed molecular tools. Our 
physiological and unbiased search for interacting partners of MeCP2 in mouse brains 
revealed a list of candidate proteins of potential interest.  
 Amongst the proteins co-immunoprecipitated with MeCP2 we detected five 
out of six known core components the NCoR/SMRT co-repressor complex. Based on 
candidate-approach studies two of these proteins have been reported previously to 
interact with MeCP2 (NCoR and SMRT), but these discoveries were not followed up 
(Kokura et al., 2001; Stancheva et al., 2003). We additionally identified and 
confirmed novel interactions of MeCP2 with other proteins building the complex: 
TBL1, TBLR1 and HDAC3. This suggested strongly that the whole complex is 
bound by MeCP2. The functional consequence and significance of these interactions 
to the Rett syndrome were found in this study and are discussed later.  
 The other identified and validated interactions of MeCP2, with CK2α and 
CaMKIIα protein kinases, may explain the mechanism of post-translational 
modifications of MeCP2. Combining this data with the studies on binding of the 
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co-repressor complex may aid the future discoveries of how the function of MeCP2 
is dynamically regulated. 
 Two of the novel interactions detected in our search were with proteins 
belonging to the importin α family. The unusually strong binding of MeCP2 to both 
KPNA3 and KPNA4 suggested the significance of these interactions. However, 
I could not find any consequence of these interactions other than their role in the 
transport of MeCP2 to the nucleus. 
 There are also other proteins on our list that, if confirmed to be real binding 
partners of MeCP2, may help in explaining its molecular mechanism of action. 
However, in light of the gathered evidence for the importance of interaction between 
MeCP2 and NCoR/SMRT complex, the elucidation of the role of the other proteins 
does not seem like a priority at the moment.  
 
6.2 Only one NLS of MeCP2 is bound by importins α 
  
 After more than 20 year of research on MeCP2 it appears as a very complex 
protein with multiple interactions and roles in cells. The reports often contradict each 
other regarding the functional domains of the protein. This study should help at least 
in resolving the issue of number and position of functional nuclear localisation 
signals in MeCP2. The existence of at least 2 NLS sequences has been postulated 
from bioinformatic and localisation studies of MeCP2. However, our data clearly 
demonstrated that only one NLS (covering the region between 253-269 aa) is bound 
by importins α, suggesting that the other sequences are dispensable for the active 
transport of MeCP2 to the nucleus. More experiments are needed to explain the 
phenomenon of partial nuclear localisation of the truncation mutants of MeCP2 that 
are not able to interact with importins α. The hypothesis that MeCP2 is being 
retained in the nucleus due to its high affinity to methylated DNA will be tested in 
the near future. 
 Based on the evidence presented in Chapter 4 the function of MeCP2-
importins α interactions is probably only in the transport to the nucleus. The lack of 
MeCP2 did not affect importins localisation, expression or stability. The 
MeCP2-depleted cells exhibit significantly smaller nuclei, but this effect cannot be 
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attributed to the strong interaction between MeCP2 and KPNA3 and KPNA4. 
A possible link between lack of MeCP2 and nuclear size comes from the 
demonstration that neurons of Mecp2-null mice exhibit 2-fold increase of histone H1 
levels (Skene et al., 2010) and H1 was shown to compact chromatin and reduce the 
size of nuclei (Shen et al., 1995). Although the higher order structure of chromatin 
was more condensed in the presence of MeCP2 than histone H1 (Georgel et al., 
2003; Nikitina et al., 2007a) these studies were performed only in vitro, and their 
relevance in vivo is not known. It is also possible, that the smaller nuclei phenotype 
is not due to direct action of MeCP2, but is a secondary effect reflecting lack of the 
MeCP2 function elsewhere. A Rett nonsense mutant MeCP2 [294X] would be a 
good model to study the consequences of MeCP2 interaction with importins. Such a 
mutant does not interact with NCoR/SMRT co-repressor complex but still binds 
KPNA3 and KPNA4. If the nuclear size of cells expressing the endogenous MeCP2 
[294X] is smaller than of wild-type cells, it would demonstrate that the MeCP2 
interaction with importins is not ruling the size of nuclei, but it is an effect of 
disrupted transcriptional repression mediated by MeCP2-NCoR/SMRT interaction. 
ES cells harbouring this mutation in endogenous Mecp2 locus are being generated in 
the laboratory at the moment. 
 
6.3 NCoR/SMRT is the co-repressor complex responsible for 
transcriptional repression function of MeCP2, which is abolished 
by RTT mutations 
 
 The identification of the MeCP2 interaction with the NCoR/SMRT 
co-repressor complex and its subsequent mapping to the C-terminal region of 
transcriptional repression domain of MeCP2 indicated its possible function in 
repressing transcription. Moreover, the NCoR/SMRT-binding region on MeCP2 is 
coincident with a cluster of frequent missense mutations causing Rett syndrome. 
Further analysis showed that RTT mutations in this region indeed abolished the 
interaction. In this study I investigated the effect of the various mutations disrupting 
the MeCP2-NCoR/SMRT complex, on the transcriptional repression of reporter 
genes. I found that these MeCP2 mutants are not able to efficiently repress 
transcription. The repression by versions of MeCP2 that could interact with 
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NCoR/SMRT was dependent on histone deacetylase activity. Future studies should 
focus on testing a wider spectrum of mutations to better define the region responsible 
for NCoR/SMRT-mediated transcriptional repression. 
 The implications from these studies are important for understanding the 
pathology of Rett syndrome. It is the first time that the interaction of MeCP2 with 
another protein was shown to be abolished by the RTT-causing mutations. The 
disruption of this interaction affected the ability of engineered constructs of MeCP2 
to repress the transcription of reporter genes. The simplest conclusion is that the 
NCoR/SMRT-mediated transcriptional repression may be the major mechanism of 
function of MeCP2. 
 Although very probable from the gathered evidence, the link between other 
RTT mutations in the full-length protein and methylation-dependent transcriptional 
repression has not been shown directly in vivo. The ability of a wild-type MeCP2 to 
repress the methylated reporter gene was demonstrated previously (Guy et al., 2001) 
and surprisingly the R306C mutant was shown to be fully functional (Drewell et al., 
2002). This effect could be attributed to the over-expression of MeCP2 masking its 
impairment in repressing transcription, as we demonstrated that R306C exhibits 
some residual repression activity. Therefore, we tried to address this issue by testing 
the effect of RTT mutations in the endogenous Mecp2 gene expressed in the ES 
cell-derived neurons. Unfortunately, due to technical problems the experiments were 
inconclusive. Perhaps expressing MeCP2 constructs in the transfected cell line, 
although less physiologically relevant, would be an easier approach. The amounts of 
plasmids used will have to be carefully titrated in order to avoid the problem of 
masking the detrimental effect of mutations by saturation of the system with 
over-expressed proteins. In principle such a system would allow testing of the effects 
on methylation-dependent transcriptional repression of mutations throughout the 
whole length of MeCP2. 
 
6.4 Re-defining the functional domains of MeCP2 
 
 In this study I ruled out the existence of functional active NLS sequences 
other than the 253-269. Our recently obtained data regarding MeCP2 binding to 
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NCoR/SMRT complex and the necessity of this interaction to mediate transcriptional 
repression suggest that we should also change the way we look at the TRD of 
MeCP2. The transcriptional repression domain identified 15 years ago (Nan et al., 
1997) is probably not a single functional entity. The binding to NCoR/SMRT occurs 
only at the C-terminal end of the domain (residues 269-309). More detailed mapping 
of the interaction in the future should allow identification of even smaller minimal 
binding region. Why is the TRD domain so long then, and why are the amino acids 
207-269 necessary for proper transcriptional repression (Nan et al., 1997)? If the 
N-terminal region of TRD interacts with Sin3A it is possible that these two 
complexes collaborate with each other for the better repression effect. Supporting 
this idea is the fact that NCoR was reported to be able to interact with Sin3A in vitro 
and in vivo (Alland et al., 1997; Heinzel et al., 1997; Wang et al., 1998; Jones et al., 
2001). Against this hypothesis stands our data that the interaction of MeCP2 with 
NCoR/SMRT subunits is much stronger than with Sin3A complex. Additionally, the 
cluster of frequent mutations causing Rett syndrome disrupts the interaction with 
NCoR/SMRT, but not with Sin3A, and the mutations with opposite effect have not 
been identified. At the moment we do not have an explanation why the TRD of 
MeCP2 is much longer than the surface sufficient to bind to NCoR/SMRT. To 
address it, we would like to revisit the TRD-mapping studies, using more truncation 
mutants or the alanine substitutions scanning to re-define the minimal region 
sufficient for transcriptional repression. Also, more detailed mapping analysis of the 
interaction on both MeCP2 and NCoR subunits, followed by an attempt to crystalise 
fragments of the complex to obtain its structure will hopefully help solving this 
puzzle. A detailed description of the character of MeCP2-NCoR/SMRT interaction, 
supported by the crystal structure would be a great aid in the design or screening for 
new drugs and potential therapies for Rett syndrome. 
 
6.5 The levels of mutated MeCP2 in ES cell-derived neurons are 
lower than wild-type protein 
 
 Our efforts in obtaining new tools to study the effects of Rett syndrome 
mutations on MeCP2 function were successful only to some extent. Generation of 
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neurons derived from a series of ES cells harbouring various versions of Mecp2 gene 
allowed us to investigate the properties of endogenous MeCP2 in a more 
physiologically relevant environment than in transfected cell-line cultures. We 
confirmed that in this system the R306C RTT mutation in the NCoR/SMRT-binding 
region abolishes the interaction, but has no effect on MeCP2 localisation to the 
methylated foci on chromatin. Conversely, the T158M mutation in the MBD does 
not affect the binding of co-repressor complex but changes the ability of MeCP2 to 
bind to chromatin. Unfortunately, other experiments performed in the ES 
cell-derived neurons did not provide conclusive results, most probably due to the 
technical issues. Interestingly, I have observed that the protein levels of the mutated 
versions of MeCP2, T158M and R306C, are lower than the wild-type. It was also 
reported that another RTT mutation, T158A, has decreased stability in mouse (Goffin 
et al., 2012). If this effect is true for the other Rett syndrome mutations, it may be an 
additional contribution to the disease pathology and a potential target for future 
therapies. 
 
6.6 A model of MeCP2 function and the effect of RTT mutations 
 
 Based on the results presented in this study we propose a new model of 
MeCP2 function relevant to Rett syndrome. In the nucleus, MeCP2 can interact with 
methylated CpGs on DNA and NCoR/SMRT complex, serving as a ‘bridge’ between 
these two. The co-repressor complex targeted to methylated chromatin by MeCP2 
deacetylates histone tails, probably through its component HDAC3, and in 
consequence inhibits transcription (Fig. 6.6A). When MeCP2 is mutated in the MBD, 
such as in the case of T158M or other frequent mutations in the same cluster, it can 
no longer properly bind to the methylated DNA. Despite its intact interaction with 
MeCP2, the NCoR/SMRT co-repressor complex is not correctly delivered to its sites 
in the genome and transcription is not down-regulated. This is reflected by increased 
acetylation on histone tails (Fig. 6.6B). A mutation in the second RTT-related cluster 
of genetic alterations, such as R306C, affects the ability of MeCP2 to bind 
NCoR/SMRT. Proper localisation of MeCP2 to the methylated DNA is not sufficient 
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to prevent Rett syndrome, because the co-repressor is not correctly targeted to where 
it should perform its role (Fig. 6.6C). 
 
 Our model is not radically different from what was already considered as one 
of the functions of MeCP2. However, we think that the key player in the repression 
of transcription is not Sin3A but NCoR/SMRT co-repressor complex. The fact that 
interaction with it is disrupted by a cluster of mutations causing Rett syndrome and 
that the other cluster prevents MeCP2 from binding to methylated chromatin allows 
us to speculate that this function of MeCP2 is the only one underlying the pathology 
of RTT. The much less frequent RTT mutations outside of these two clusters may 
affect protein stability or folding, and this would again result in the lack of bridging 
methylated DNA and NCoR/SMRT. This hypothesis remains to be formally tested. 
The other reported interactions of MeCP2, and based on them various putative 
functions, may be true in in vitro assays and in some cases even in vivo, but the 
important issue is how relevant to the Rett syndrome they are. Prior to this study this 
question was never properly addressed. 
 The NCoR/SMRT co-repressor complex contains the histone deacetylase 
HDAC3. Therefore, the functional consequence of MeCP2 ‘bridging’ methylated 
chromatin and the complex should also manifest in a difference in histone acetylation 
when MeCP2 is mutated or missing. The global hyperacetylation of histones in 
MeCP2 knock-out brains was observed only when neurons were purified away from 
glial cells (Skene et al., 2010). The effect of mutations in MeCP2 on global and local 
acetylation of histones should be tested in the future when MeCP2 [T158M] and 
MeCP2 [R306C] mice are available. Fluorescence-activated cell sorting of neuronal 
nuclei followed by Western blot analysis with anti-acetyl H3 antibodies, as well as 
ChIP assays for acetylated H3 and MeCP2 should reveal if disrupting just one side of 




Figure 6.6. A model of MeCP2 function based on the research in this study. The black 
line depicts DNA wrapped on purple nucleosomes. Black lollipops represent methylated 
CpGs. Yellow circles labelled ‘Ac’ are acetylated histone tails. An asterisk in MBD or TRD 
represents a mutation in MeCP2. (A) In a wild-type cells MeCP2 binds to methylated CpGs 
and represses transcription by recruiting NCoR/SMRT complexes deacetylating histone tails. 
(B) When mutated in MBD, MeCP2-NCoR/SMRT can no longer bind to chromatin and 
repress transcription, resulting in acetylated histone tails. (C) MeCP2 mutated in TRD can 
bind to methyl-CpG, but fails to recruit NCoR/SMRT and the transcription is not repressed. 
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 Importantly, the targets of MeCP2-NCoR/SMRT-mediated repression are not 
known. As the genes regulated by MeCP2 have not been convincingly identified, it is 
possible that MeCP2 affects global transcription, maybe from non-coding regions. 
The genome-wide search for the consequences of lack of MeCP2 on the transcription 
is on-going at the moment.  
 It is also possible that the function of MeCP2-NCoR/SMRT interaction is not 
related to histone deacetylation, but affects other proteins. Acetylation has been 
shown to regulate localisation, DNA-binding and stability of various proteins 
(reviewed in: Kouzarides, 2000). HDACs are also able to deacetylate non-histone 
substrates and influence their function, for example HDAC3-mediated deacetylation 
of NFκB subunit causes its export from the nucleus (Chen et al., 2001a). The 
comparison of the acetylated proteins in Mecp2 wild-type and knock-out brains could 
provide an insight on this hypothesis.  
 
 The simple model of MeCP2 function proposed by us offers hope for 
developing new strategies to try to cure at least some of the Rett syndrome patients. 
A screen for molecules capable of overriding the R306C mutation by allowing 
NCoR/SMRT to bind to mutated MeCP2 is one approach that could to be taken. 
Another possibility is to search for NCoR/SMRT mutants that could interact with 
altered MeCP2. Perhaps the manipulation of the components of NCoR/SMRT would 
be an easier target for potential gene therapy than MeCP2. I believe that this study 
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Appendix Table 1. All proteins identified by mass spectrometry in GFP 
immunoprecipitations from MeCP2-GFP and wild-type mouse brains. The proteins 
were GFP immunoprecipitated from MeCP2-GFP (Me2-GFP) and wild-type (Wt) mouse 
brains and subjected to mass spectrometry identification. All of the identified proteins are 
listed in an alphabetical order with their IPI database accession number and the number of 
peptides that identified each protein. If the protein was present only in a MeCP2-GFP 
purification it is marked with light blue, if present only in wild-type brain then it is marked 






number Protein description Wt 
Me2-
GFP 
IPI00229328 1110037F02Rik hypothetical protein LOC66185   2 
IPI00131674 2210010C04Rik trypsinogen 7 1 1 
IPI00121045 A2bp1 Isoform 1 of Fox-1 homolog A 5 2 
IPI00121136 Acin1 Apoptotic chromatin condensation inducer Isoform 1   6 
IPI00221528 Actbl2 Beta-actin-like protein 2 2   
IPI00114593 Actc1 Actin, alpha cardiac muscle 1   1 
IPI00649132 Adad1 adenosine deaminase domain containing 1   1 
IPI00672180 Adnp activity-dependent neurop   1 
IPI00127766 Akap8l A-kinase anchor protein 8-like   7 
IPI00114350 Angpt1 Angiopoietin-1   1 
IPI00330263 Aqr Intron-binding protein aquarius   3 
IPI00230009 Arglu1 Isoform 2 of Arginine and glutamate-rich protein 1 2 2 
IPI00409462 Bat1a Spliceosome RNA helicase Bat1 2   
IPI00420725 Camk2a calcium/calmodulin-dependent protein kinase II alpha   8 
IPI00875723 Camk2b 68 kDa protein   4 
IPI00124695 Camk2g CamK protein kinase type II gamma chain Isoform 1   2 
IPI00123755 Cbx5 Chromobox protein homolog 5 1   
IPI00153134 Ccnk Cyclin-K   1 
IPI00284444 Cdc5l Cell division cycle 5-related protein   11 
IPI00318428 Cenpv Isoform 1 of Centromere protein V   2 
IPI00396802 Chd4 Chromodomain-helicase-DNA-binding protein 4   3 
IPI00608001 Chd5 chromodomain helicase DNA binding protein 5 isoform 2   1 
IPI00229604 Cherp SR-related CTD associated factor 6   16 
IPI00313899 Cpne9 Copine-9 2   
IPI00314302 Cpsf2 Cleavage and polyadenylation specificity factor sub.2 1 1 
IPI00421085 Cpsf6 Cleavage and polyadenylation specificity factor sub.6 1   
IPI00132376 Crnkl1 Crooked neck-like protein 1   1 
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IPI00120162 Csnk2a1 Casein kinase II subunit alpha   4 
IPI00622716 Ctnnbl1 Beta-catenin-like protein 1   3 
IPI00129146 Cugbp2 Isoform 5 of CUG-BP- and ETR-3-like factor 2   1 
IPI00648836 D11Bwg0517e hexaribonucleotide binding protein 3 isoform 3 3   
IPI00894965 D11Bwg0517e Isoform 2 of Fox-1 homolog C   8 
IPI00133708 D1Pas1 Putative ATP-dependent RNA helicase Pl10 1 1 
IPI00396797 Ddx17 Isoform 1 of Probable ATP-dependent RNA helicase  3 11 
IPI00652987 Ddx21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21   5 
IPI00330406 Ddx23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23   1 
IPI00468896 Ddx46 Isoform 1 of Probable ATP-dependent RNA helicase  2   
IPI00648763 Ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 1 1 
IPI00420363 Ddx5 Probable ATP-dependent RNA helicase DDX5 11 21 
IPI00117771 Ddx50 ATP-dependent RNA helicase DDX50   1 
IPI00130102 Des Desmin 1   
IPI00128818 Dhx15 Putative pre-mRNA-splicing factor ATP-dep. RNA helicase  1 11 
IPI00265358 Dhx38 Putative uncharacterized protein   1 
IPI00339468 Dhx9 Isoform 2 of ATP-dependent RNA helicase A 7 49 
IPI00113635 Dkc1 H/ACA ribonucleoprotein complex subunit 4   1 
IPI00307837 Eef1a1 Elongation factor 1-alpha 1 5   
IPI00119667 Eef1a2 Elongation factor 1-alpha 2   2 
IPI00469260 Eftud2 116 kDa U5 small nuclear ribonucleoprotein component 1 22 
IPI00126716 Eif4a3 Eukaryotic initiation factor 4A-III   12 
IPI00466032 Elavl1 ELAV embryonic lethal, abnormal vision, Drosophila-like 1 4 8 
IPI00410779 Elavl2 ELAV-like 2 isoform 1 2   
IPI00122451 Elavl3 Isoform HuC-L of ELAV-like protein 3   4 
IPI00222990 Elavl3 Isoform HuC-S of ELAV-like protein 3 1   
IPI00466120 Elavl4 Elavl4 protein   10 
IPI00119581 Fbl;LOC100044829 rRNA 2’-O-methyltransferase fibrillarin 2 1 
IPI00330634 Fbll1 rRNA/tRNA 2’-O-methyltransferase fibrillarin-like protein 1   2 
IPI00118205 Fhl2 Four and a half LIM domains protein 2 2   
IPI00120174 Friend of PRMT1 protein   2 
IPI00117063 Fus RNA-binding protein FUS 1 1 
IPI00462979 Fyttd1 Forty-two-three domain-containing protein 1, Isoform 1   4 
IPI00918335 Gcfc1, GC-rich sequence DNA-binding factor 1   1 
IPI00116535 Gm10120 similar to Sm D2 isoform 1   1 
IPI00607069 Gm10257 hypothetical protein isoform 1   6 
IPI00274175 Gm5121 similar to ribosomal protein S8 isoform 1   1 
IPI00395100 Gm5409 Try10-like trypsinogen 3   
IPI00621335 Gm847 similar to hCG1643239 1   
IPI00752798 Gm9294 predicted gene 9294   1 
IPI00153400 H2afj Histone H2A.J 1 5 
IPI00230264 H2afx Histone H2A.x   1 
IPI00137852 H2afy Isoform 1 of Core histone macro-H2A.1 2 8 
IPI00652934 H2afy2 Core histone macro-H2A.2   2 
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IPI00331734 H2afz Histone H2A.Z   3 
IPI00114232 Hdac1 Histone deacetylase 1   2 
IPI00137668 Hdac2 Histone deacetylase 2   6 
IPI00135456 Hdac3 histone deacetylase 3   7 
IPI00228616 Hist1h1a Histone H1.1   1 
IPI00223713 Hist1h1c Histone H1.2   4 
IPI00111957 Hist1h2ba Histone H2B type 1-A 1   
IPI00272033 Hist2h2ac;Hist2h2ab Histone H2A type 2-C   2 
IPI00229539 Hist3h2bb histone cluster 3, H2bb   1 
IPI00114642 Histone H2B type 1-F/J/L   7 
IPI00230730 Histone H3.2 1 1 
IPI00109813 Hnrnpa0 heterogeneous nuclear ribonucleoprotein A0 5 4 
IPI00553777 Hnrnpa1 Putative uncharacterized protein 3 10 
IPI00828488 Hnrnpa2b1 Heterogeneous nuclear ribonucleoproteins A2/B1  4 28 
IPI00269661 Hnrnpa3 Heterogeneous nuclear ribonucleoprotein A3, iso. 1 10 22 
IPI00117288 Hnrnpab Heterogeneous nuclear ribonucleoprotein A/B   1 
IPI00223443 Hnrnpc Heterogeneous nuclear ribonucleoproteins C1/C2, iso C1   19 
IPI00130343 Hnrnpc Putative uncharacterized protein 5 1 
IPI00330958 Hnrnpd Heterogeneous nuclear ribonucleoprotein D0, iso. 1   10 
IPI00230086 Hnrnpd Heterogeneous nuclear ribonucleoprotein D0, iso. 2  7   
IPI00226073 Hnrnpf Isoform 1 of Heterogeneous nuclear ribonucleoprotein F 1 4 
IPI00133916 Hnrnph1 Heterogeneous nuclear ribonucleoprotein H 11 15 
IPI00108143 Hnrnph2, Heterogeneous nuclear ribonucleoprotein H2 7 7 
IPI00816884 Hnrnph3 heterogeneous nuclear ribonucleoprotein H3   6 
IPI00223253 Hnrnpk Isoform 1 of Heterogeneous nuclear ribonucleoprotein K 3 9 
IPI00620362 Hnrnpl Heterogeneous nuclear ribonucleoprotein L 7 16 
IPI00653643 Hnrnpl Putative uncharacterized protein   2 
IPI00132443 Hnrnpm Heterogeneous nuclear ribonucleoprotein M, iso. 1 12 39 
IPI00128441 Hnrnpr Putative uncharacterized protein 4 5 
IPI00458583 Hnrnpu Heterogeneous nuclear ribonucleoprotein U 39 43 
IPI00755892 Hnrpdl heterogeneous nuclear ribonucleoprotein D-like   7 
IPI00129417 Hnrpdl Heterogeneous nuclear ribonucleoprotein D-like 3   
IPI00121760 Hnrpll Heterogeneous nuclear ribonucleoprotein L-like, iso. 1   2 
IPI00323357 Hspa8 Heat shock cognate 71 kDa protei 11 21 
IPI00127947 Ik IK cytokine   2 
IPI00318550 Ilf2 Interleukin enhancer-binding factor 2 5 10 
IPI00130591 Ilf3 Isoform 3 of Interleukin enhancer-binding factor 3 1 12 
IPI00458765 Khdrbs1 KH domain-containing, RNA-binding, signal transd.ass.1 2 1 
IPI00314520 Khdrbs3 KH domain-containing, RNA-binding, signal trans. ass. 3   6 
IPI00462934 Khsrp Far upstream element-binding protein 2 1   
IPI00230429 Kpna3 Importin subunit alpha-3   10 
IPI00129792 Kpna4 Importin subunit alpha-4   17 
IPI00139301 Krt5 Keratin, type II cytoskeletal 5 4   
IPI00346834 Krt76 Keratin, type II cytoskeletal 2 oral   1 
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IPI00122418 Luc7l3 Isoform 2 of Luc7-like protein 3 1   
IPI00132692 Magoh-rs1 mago-nashi homolog   4 
IPI00453826 Matr3 Matrin-3 9 73 
IPI00115240 Mbp Isoform 1 of Myelin basic protein 1   
IPI00223377 Mbp Isoform 4 of Myelin basic protein   3 
IPI00131063 Mecp2 Isoform A of Methyl-CpG-binding protein 2 1   
IPI00775806 Mecp2 Isoform B of Methyl-CpG-binding protein 2   52 
IPI00228590 Mfap1a;Mfap1b Microfibrillar-associated protein 1   1 
IPI00116372 Mlf2 Myeloid leukemia factor 2   6 
IPI00651807 Mll2 myeloid/lymphoid or mixed-lineage leukemia 2   3 
IPI00624969 Mta1 Mta1 protein   3 
IPI00125745 Mta3 Isoform 1 of Metastasis-associated protein MTA3   1 
IPI00408909 Mtap1a Isoform 1 of Microtubule-associated protein 1A   6 
IPI00896700 Mtap1b microtubule-associated protein 1B (MAP1B)   69 
IPI00154084 Myef2 Isoform 2 of Myelin expression factor 2 6 24 
IPI00458056 Ncbp1 Nuclear cap-binding protein subunit 1   1 
IPI00317794 Ncl Nucleolin   2 
IPI00313525 Ncoa5 Nuclear receptor coactivator 5   8 
IPI00551272 Ncor1 nuclear receptor co-repressor 1   20 
IPI00123871 Ncor2 nuclear receptor co-repressor 2   27 
IPI00554928 Nefl Neurofilament light polypeptide 5   
IPI00320016 Nono Non-POU domain-containing octamer-binding prot., iso1 3   
IPI00463468 Nop58 Nucleolar protein 58 1   
IPI00119059 Nr2f1 COUP transcription factor 1   1 
IPI00263048 Numa1 nuclear mitotic apparatus protein 1   1 
IPI00136169 Pabpn1 Isoform 1 of Polyadenylate-binding protein 2   1 
IPI00127707 Pcbp2 Isoform 1 of Poly(rC)-binding protein 2   1 
IPI00321597 Pelp1 Proline-, glutamic acid- and leucine-rich protein 1   3 
IPI00133491 Phf5a PHD finger-like domain-containing protein 5A   3 
IPI00331172 Plrg1 Pleiotropic regulator 1   1 
IPI00317891 Pnn Pinin   3 
IPI00320034 Polr2b DNA-directed RNA polymerase II subunit RPB2   1 
IPI00130185 Ppp1ca Ser/thr-protein phosphatase PP1-alpha catalytic subunit   1 
IPI00123862 Ppp1cc Ser/thr-protein phosphatase PP1-γ catalytic subunit 1   
IPI00117687 Pre-mRNA branch site protein p14   1 
IPI00123445 Prkaa2 5'-AMP-activated protein kinase catalytic subunit alpha-2   1 
IPI00480507 Prpf19 Isoform 1 of Pre-mRNA-processing factor 19   11 
IPI00222760 Prpf19 Isoform 2 of Pre-mRNA-processing factor 19 2   
IPI00226155 Prpf38a Isoform 1 of Pre-mRNA-splicing factor 38A   2 
IPI00458908 Prpf4 U4/U6 small nuclear ribonucleoprotein Prp4   2 
IPI00320690 Prpf4b Serine/threonine-protein kinase PRP4 homolog   2 
IPI00130409 Prpf6 Isoform 1 of Pre-mRNA-processing factor 6   4 
IPI00121596 Prpf8 Pre-mRNA-processing-splicing factor 8 1 50 
IPI00115257 Psip1 Isoform 1 of PC4 and SFRS1-interacting protein 2   
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IPI00321266 Pspc1 Isoform 1 of Paraspeckle component 1 2   
IPI00751759 Ptbp2 Isoform 1 of Polypyrimidine tract-binding protein 2   4 
IPI00127174 Puf60 Isoform 2 of Poly(U)-binding-splicing factor PUF60 10 2 
IPI00849047 Similar to heterogeneous nuclear ribonucleoprotein U-like 2 31 39 
IPI00130147 Raly Isoform 2 of RNA-binding protein Raly   8 
IPI00310432 Ralyl Isoform 1 of RNA-binding Raly-like protein   5 
IPI00122696 Rbbp4 Histone-binding protein RBBP4   7 
IPI00122698 Rbbp7 Histone-binding protein RBBP7   1 
IPI00116031 Rbm10 Isoform 1 of RNA-binding protein 10   3 
IPI00471450 Rbm12b2 RNA binding motif protein 12 B2   1 
IPI00404707 Rbm14 Isoform 1 of RNA-binding protein 14 6 14 
IPI00170394 Rbm17 Splicing factor 45   7 
IPI00221951 Rbm22 Pre-mRNA-splicing factor RBM22   2 
IPI00421119 Rbm25 Isoform 1 of RNA-binding protein 25   2 
IPI00127763 Rbm39 Isoform 1 of RNA-binding protein 39 12 8 
IPI00177224 Rbm4b RNA-binding protein 4B   1 
IPI00130160 Rbm5 Isoform 1 of RNA-binding protein 5   1 
IPI00279153 Rbm6 Rbm6 protein   1 
IPI00223425 Rbm9 Isoform 1 of RNA-binding protein 9   1 
IPI00124979 Rbmx RNA binding motif protein, X-linked   2 
IPI00663587 Rbmxrt RNA binding motif protein, X chromosome retrogene   20 
IPI00122227 Rnps1 RNA/DNA-binding protein   3 
IPI00221840 Rod1 Isoform 1 of Regulator of differentiation 1   1 
IPI00133985 Ruvbl1 RuvB-like 1 1 2 
IPI00123557 Ruvbl2 RuvB-like 2 1 1 
IPI00944159 Safb scaffold attachment factor B   40 
IPI00857736 Safb2 Scaffold attachment factor B2   9 
IPI00458854 Sart3 Squamous cell carcinoma antigen recognized by T-cells 3   1 
IPI00313539 Scai Isoform 1 of Protein SCAI 2 1 
IPI00408796 Sf3a1 Splicing factor 3 subunit 1 2 14 
IPI00380281 Sf3a2 splicing factor 3a, subunit 2   4 
IPI00137848 Sf3a3 Splicing factor 3A subunit 3 1 10 
IPI00623284 Sf3b1 Splicing factor 3B subunit 1 2 41 
IPI00349401 Sf3b2 splicing factor 3b, subunit 2 1 16 
IPI00122011 Sf3b3 Isoform 1 of Splicing factor 3B subunit 3 4 26 
IPI00154082 Sf3b4 Splicing factor 3B subunit 4   1 
IPI00420807 Sfrs1;LOC100048559 Splicing factor, arginine/serine-rich 1, iso. 1 2 11 
IPI00468994 Sfrs11 splicing factor, arginine/serine-rich 11 isoform 1 2 1 
IPI00117232 Sfrs13a Isoform 3 of Splicing factor, arginine/serine-rich 13A   2 
IPI00405760 Sfrs14 Putative splicing factor, arginine/serine-rich 14 17 66 
IPI00121135 Sfrs2 Splicing factor, arginine/serine-rich 2   1 
IPI00129323 Sfrs3 Isoform Long of Splicing factor, arginine/serine-rich 3 3 3 
IPI00607076 Sfrs4 splicing factor, arginine/serine-rich 4   1 
IPI00314709 Sfrs5 Splicing factor, arginine/serine-rich 5   2 
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IPI00310880 Sfrs6 arginine/serine-rich splicing factor 6   5 
IPI00153743 Sfrs7 Isoform 2 of Splicing factor, arginine/serine-rich 7   7 
IPI00117932 Sin3a Isoform 1 of Paired amphipathic helix protein Sin3a   1 
IPI00229571 Sltm Isoform 1 of SAFB-like transcription modulator   21 
IPI00314654 Smarca1 Probable global transcription activator SNF2L1, iso. 2   1 
IPI00381019 Smarcc2 Isoform 2 of SWI/SNF complex subunit SMARCC2   6 
IPI00331342 Smu1 Isoform 1 of WD40 repeat-containing protein SMU1   4 
IPI00420329 Snrnp200 Small nuclear ribonucleoprotein 200 2 43 
IPI00461621 Snrnp40 U5 small nuclear ribonucleoprotein 40 kDa protein   7 
IPI00625105 Snrnp70 Isoform 1 of U1 small nuclear ribonucleoprotein 70 kDa   7 
IPI00170008 Snrpa1 U2 small nuclear ribonucleoprotein A’ 11 12 
IPI00114052 Snrpb Small nuclear ribonucleoprotein-associated protein B   3 
IPI00322749 Snrpd1 Small nuclear ribonucleoprotein Sm D1 1 3 
IPI00119224 Snrpd3 Small nuclear ribonucleoprotein Sm D3   3 
IPI00133955 Snrpe Small nuclear ribonucleoprotein E   1 
IPI00317298 Snw1 SNW domain-containing protein 1   5 
IPI00134457 Son Isoform 1 of Protein SON   1 
IPI00118438 Srrm1 Isoform 2 of Serine/arginine repetitive matrix protein 1   1 
IPI00225062 Srrm2 Isoform 3 of Serine/arginine repetitive matrix protein 2   12 
IPI00134300 Ssb Lupus La protein homolog   1 
IPI00120344 Supt16h FACT complex subunit SPT16   1 
IPI00406117 Syncrip Heterogeneous nuclear ribonucleoprotein Q, isoform 1   2 
IPI00127982 Sytl4 Isoform 1 of Synaptotagmin-like protein 4   1 
IPI00121758 Tardbp TAR DNA-binding protein 43   3 
IPI00223056 Tbl1x F-box-like/WD repeat-containing protein TBL1X   7 
IPI00308283 Tbl1xr1 F-box-like/WD repeat-containing protein TBL1XR1   16 
IPI00458057 Tex10 Tex10 protein   1 
IPI00112101 Tfip11 Tuftelin-interacting protein 11   1 
IPI00556768 Thrap3 Thyroid hormone receptor-associated protein 3   1 
IPI00377298 Tra2a transformer-2 alpha   3 
IPI00139259 Tra2b Isoform 1 of Transformer-2 protein homolog beta   7 
IPI00312128 Trim28 Isoform 1 of Transcription intermediary factor 1-beta 7 13 
IPI00229801 Trp53bp1 transformation related protein 53 binding protein 1   32 
IPI00110753 Tuba1a Tubulin alpha-1A chain   2 
IPI00117348 Tuba1b Tubulin alpha-1B chain 4   
IPI00109061 Tubb2b Tubulin beta-2B chain 4 1 
IPI00411097 U2 snRNP-associated SURP motif-containing protein isoform 2   18 
IPI00318548 U2af1 Splicing factor U2AF 35 kDa subunit 3 5 
IPI00221628 U2af1l4 Splicing factor U2AF 26 kDa subunit 1   
IPI00113746 U2af2 Splicing factor U2AF 65 kDa subunit 8 7 
IPI00138892 Uba52, Ubiquitin-60S ribosomal protein L40 1 3 
IPI00329998 Uncharacterised 11 kDa protein 6 9 
IPI00474144 Uncharacterised 42 kDa protein 3   
IPI00123333 Wbp11 WW domain-binding protein 11   5 
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IPI00136252 Wdr18 WD repeat-containing protein 18   4 
IPI00139957 Wdr5 WD repeat-containing protein 5   1 
IPI00120744 Xab2 Pre-mRNA-splicing factor SYF1   2 
IPI00653196 Yap1, Putative uncharacterized protein   1 
IPI00621973 Ylpm1 YLP motif containing 1   9 
IPI00464155 Zbtb4 zinc finger and BTB domain containing 4 1   
IPI00121264 Zfml Isoform 4 of Zinc finger protein 638   2 
IPI00314507 Zfp326 Isoform 1 of Zinc finger protein 326 2 17 
IPI00330097 Zfp871 zinc finger protein 871   1 
IPI00918528 Zfr Protein   1 
IPI00131810 Zfr Zinc finger RNA-binding protein 1   




Appendix Table 2. All proteins identified as specific interaction partners of MeCP2. 
The list of proteins identified by mass spectrometry in GFP immunoprecipitations from 
MeCP2-GFP and wild-type mouse brains (Exp. #1; Appendix Table 1) was compared to a 
similar list from a biological replicate of the experiment (Exp. #2; M. Lyst). A protein was 
considered as a specific interaction partner of MeCP2 only if it was represented by at least 2 
peptides in both purifications from MeCP2-GFP brains and no peptides were present in both 








Protein    
symbol  Protein name 
52 57  Mecp2  Isoform B of Methyl-CpG-binding protein 2 
27 5  Ncor2  Nuclear receptor co-repressor 2 
20 9  Ncor1  Nuclear receptor co-repressor 1 
17 13  Kpna4  Importin subunit alpha-4 
16 12  Tbl1xr1  F-box-like/WD repeat-containing protein TBL1XR1 
12 15  Eif4a3  Eukaryotic initiation factor 4A-III 
11 19  Prpf19  Pre-mRNA-processing factor 19, Isoform 1 
11 7  Cdc5l  Cell division cycle 5-related protein 
10 7  Kpna3  Importin subunit alpha-3 
8 3  Camk2a  Calcium/calmodulin-dependent protein kinase II alpha 
8 2  Ncoa5  Nuclear receptor coactivator 5 
8 2  Raly  RNA-binding protein Raly, Isoform 2 
7 10  Rbbp4  Histone-binding protein RBBP4 
7 10  Tra2b  Transformer-2 protein homolog beta, Isoform 1 
7 7  Sfrs7  Splicing factor, arginine/serine-rich 7, Isoform 2 
7 6  Snrnp70  U1 small nuclear ribonucleoprotein 70 kDa, Isoform 1 
7 5  Hdac3  Histone deacetylase 3 
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7 5  Tbl1x  F-box-like/WD repeat-containing protein TBL1X 
6 17  Smarcc2  SWI/SNF complex subunit SMARCC2, Isoform 2  
5 2  Snw1  SNW domain-containing protein 1 
5 2  Wbp11  WW domain-binding protein 11 
4 9  Csnk2a1  Casein kinase II subunit alpha 
4 9  Wdr18  WD repeat-containing protein 18 
4 5  Magoh-rs1  Mago-nashi homolog 
4 5  Smu1  WD40 repeat-containing protein SMU1, Isoform 1 
4 4  Fyttd1  Forty-two-three domain-containing protein 1, iso. 1 
3 58  Chd4  Chromodomain-helicase-DNA-binding protein 4 
3 27  Mta1  Metastasis-associated protein Mta1 
3 12  Pelp1  Proline-, glutamic acid- and leucine-rich protein 1 
3 7  Pnn  Pinin 
3 5  Tra2a  Transformer-2 alpha 
3 3  Aqr  Intron-binding protein aquarius 
3 3  H2afz  Histone H2A.Z 
3 3  Rnps1  RNA/DNA-binding protein 
2 8  Hist2h2ac  Histone H2A type 2-C 
2 6  H2afy2  Core histone macro-H2A.2 
2 5  Hdac1  Histone deacetylase 1 
2 5  Sfrs5  Splicing factor, arginine/serine-rich 5 
2 4  Tuba1a  Tubulin alpha-1A chain 
2 2  Ik  IK cytokine 
 
